## SUNDAY | OCTOBER 09, 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Room 1</th>
<th>Room 2</th>
<th>Room 3</th>
<th>Room 4</th>
<th>Room 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45–10:15</td>
<td>PD 00</td>
<td>PD 02</td>
<td>PD 03</td>
<td>WS 00</td>
<td>WS 01</td>
</tr>
<tr>
<td>Governance for Health</td>
<td>Medical Education</td>
<td>Global Health Security</td>
<td>Press Conference</td>
<td>Chronic Kidney Disease in Sri Lanka</td>
<td>Noncommunicable Diseases</td>
</tr>
<tr>
<td>10:30–12:00</td>
<td>PD 01</td>
<td>WS 01</td>
<td>WS 02</td>
<td>WS 03</td>
<td>WS 04</td>
</tr>
<tr>
<td>Noncommunicable Diseases</td>
<td>M8 Alliance: Charité</td>
<td>M8 Alliance: Charité</td>
<td>M8 Alliance: Charité</td>
<td>M8 Alliance: University of São Paulo</td>
<td>Neglected Tropical Diseases</td>
</tr>
<tr>
<td>M8 Alliance: Charité</td>
<td>M8 Alliance: Charité</td>
<td>M8 Alliance: Charité</td>
<td>M8 Alliance: Charité</td>
<td>M8 Alliance: University of São Paulo</td>
<td>M8 Alliance: University of São Paulo</td>
</tr>
<tr>
<td>13:00–14:30</td>
<td>PD 02</td>
<td>WS 05</td>
<td>WS 06</td>
<td>WS 07</td>
<td>WS 08</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Aging &amp; Primary Care</td>
<td>The Science of Addiction</td>
<td>From Archeology and Genomes to Evolutionary Medicine</td>
<td>Conflict and Health</td>
<td>Global Health Security</td>
</tr>
<tr>
<td>Sabin Vaccine Institute</td>
<td>M8 Alliance: Charité</td>
<td>M8 Alliance: Charité</td>
<td>Humboldt Forum Berlin</td>
<td>British Medical Journal Case Reports</td>
<td>Munich Security Conference Foundation</td>
</tr>
<tr>
<td>Sanofi</td>
<td>M8 Alliance: Coimbra Health</td>
<td>M8 Alliance: Charité</td>
<td>World Health Summit</td>
<td>International Committee of the Red Cross</td>
<td>National Academy of Medicine</td>
</tr>
<tr>
<td>15:00–16:30</td>
<td>PD 03</td>
<td>WS 09</td>
<td>WS 10</td>
<td>WS 11</td>
<td></td>
</tr>
<tr>
<td>Munich Security Conference Foundation</td>
<td>M8 Alliance: Charité</td>
<td>World Health Organization</td>
<td>M8 Alliance: National University of Singapore</td>
<td>F. Hoffmann-La Roche Ltd.</td>
<td></td>
</tr>
<tr>
<td>National Academy of Medicine</td>
<td>M8 Alliance: Charité</td>
<td>VAMED AG</td>
<td>VAMED AG</td>
<td>M8 Alliance: Charité</td>
<td></td>
</tr>
<tr>
<td>17:00–18:30</td>
<td>KEY 01</td>
<td>WS 10</td>
<td>WS 11</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opening Ceremony</td>
<td>M8 Alliance</td>
<td>Patient Safety</td>
<td>Personalized Healthcare Vision in Oncology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M8 Alliance</td>
<td>M8 Alliance: Charité</td>
<td>M8 Alliance: National University of Singapore</td>
<td>M8 Alliance: Charité</td>
<td></td>
<td></td>
</tr>
<tr>
<td>German Federal Foreign Office</td>
<td>German Federal Ministry of Health</td>
<td>World Health Organization</td>
<td>German Federal Foreign Office</td>
<td></td>
<td></td>
</tr>
<tr>
<td>German Federal Ministry of Health</td>
<td>World Health Organization</td>
<td>VAMED AG</td>
<td>Munich Security Conference Foundation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30–21:30</td>
<td>Welcome Reception</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## MONDAY | OCTOBER 10, 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Session</th>
</tr>
</thead>
</table>
| 09:00 – 10:30 | PD 04 | Universal Health Coverage  
German Healthcare Partnership  
MB Alliance: The Graduate Institute Geneva  
Rabin Martin |
| 09:00 – 10:30 | WS 12 | Improving Processes for Access to Medicines  
European Federation of Pharmaceutical Industries and Associations  
Sanofi |
| 09:00 – 10:30 | WS 13 | Coalition for Epidemic Preparedness Innovations  
Coalition for Epidemic Preparedness Innovations  
Government of Norway  
Department of Biotechnology, Government of India |
| 09:00 – 10:30 | WS 14 | Tuberculosis and Migration  
Koch-Metschnikow-Forum e.V.  
Friends of the Global Fund |
| 09:00 – 10:30 | WS 15 | Migration, Cultures and Health  
All European Academies  
World Health Summit |
| 11:00 – 12:30 | KEY 02 | Migration and Refugee Health  
International Committee of the Red Cross  
International Organization for Migration  
MB Alliance: Johns Hopkins Bloomberg School of Public Health |
| 14:00 – 15:30 | PD 05 | Planetary Health  
Leopoldina  
MB Alliance: London School of Hygiene & Tropical Medicine |
| 14:00 – 15:30 | WS 16 | Global Mental Health  
Max Planck Institute for Psychiatry  
University Hospital Tübingen |
| 14:00 – 15:30 | WS 17 | One Health  
MB Alliance: InterAcademy Partnership for Health  
One Health Platform |
| 14:00 – 15:30 | WS 18 | Fostering Open Science in Global Health  
Centre Virchow-Villermé for Public Health |
| 14:00 – 15:30 | WS 19 | Next Generation Medical Logistics  
KfW Development Bank |
| 16:00 – 18:00 | KEY 03 | Technological Innovation for Health  
MB Alliance: Clinical Research Institute Montreal  
Royal Philips NV |
| 16:00 – 18:30 | PD 05a | The Contribution of Biologic Medicines to Public Health  
F. Hoffmann-La Roche Ltd.  
World Health Summit |
| 19:00 – 23:00 | WHS Night | Allianz Forum, Pariser Platz 6, 10117 Berlin  
Allianz Deutschland AG  
MB Alliance |

**Coffee Break (30 min)**

**Lunch Break (90 min)  
WHS Startup Track Pitch Competition (Europa-Foyer/Main Hall)**

**Coffee Break (30 min)**

**WHS Night | Page 104**
<table>
<thead>
<tr>
<th>Time</th>
<th>Room 1</th>
<th>Room 2</th>
<th>Room 3</th>
<th>Room 4</th>
<th>Room 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 – 10:30</td>
<td>PD 06</td>
<td>WS 20</td>
<td>WS 21</td>
<td>WS 22</td>
<td>WS 23</td>
</tr>
<tr>
<td></td>
<td>Value in Healthcare</td>
<td>Better Leadership: Improved Healthcare</td>
<td>Strengthening Health Systems for Education and Training</td>
<td>Polio Eradication</td>
<td>Cardiovascular Diseases</td>
</tr>
<tr>
<td></td>
<td>The Boston Consulting Group</td>
<td>European School of Management and Technology</td>
<td>Association of Research-Based Pharmaceutical Companies (vfa)</td>
<td>MB Alliance: The Graduate Institute Geneva</td>
<td>MB Alliance: Charité</td>
</tr>
<tr>
<td></td>
<td>World Economic Forum</td>
<td>InterAcademy Partnership for Health</td>
<td>Joint Conference Church and Development</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>MB Alliance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Young Physician Leaders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 – 12:30</td>
<td>KEY 04</td>
<td>WS 24</td>
<td>WS 25</td>
<td>WS 26</td>
<td>WS 27</td>
</tr>
<tr>
<td></td>
<td>Translational Research</td>
<td>Strategic Priorities in R&amp;D for Global Health</td>
<td>Data Warehouse Systems as a Basis for Precision Medicine</td>
<td>Gender Responsive Governance</td>
<td>Implementing the Health-Related SDGs</td>
</tr>
<tr>
<td></td>
<td>Berlin Institute of Health</td>
<td>European Commission and the Horizon 2020 Scientific Panel for Health</td>
<td>German Centers for Health Research (DZG)</td>
<td>Women in Global Health USAID</td>
<td>MB Alliance: The Graduate Institute Geneva</td>
</tr>
<tr>
<td></td>
<td>MB Alliance:</td>
<td></td>
<td></td>
<td></td>
<td>Think Tank Initiative Canada</td>
</tr>
<tr>
<td></td>
<td>Monash University</td>
<td>National University of Singapore</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Coffee Break (30 min)

Lunch Break (90 min)

16:00 – 18:00 | KEY 05 | WS 28  | WS 29  | WS 30  | WS 31  |
|              | Women, Empowerment and Health: Equity and Agency | Action: SDG – All for Health Equity | World Health Organization | |
|              | MB Alliance: |         |         |         | |
|              | Clinical Research Institute Montreal | National University of Singapore |         |         | |
|              | The Graduate Institute Geneva | University Hospital Geneva |         |         | |
|              | University of Geneva | University of Montreal |         |         | |
# TABLE OF CONTENTS

Program Overview  4  
Welcome Messages  8  
WHS Participants & Key Facts  18  
Central Topics 2016  19  
WHS Vision, Mission, Goals  20  
WHS Presidents  22  
WHS Scientific Committee & Ambassadors  23  
WHS Council  24  
M8 Alliance  27  
WHS Startup Track  34  
New Voices in Global Health  36  
WHS Night  38  
WHS Community & Social Media  39  
Summit Program, Sunday, October 09, 2016  41  
Summit Program, Monday, October 10, 2016  77  
Summit Program, Tuesday, October 11, 2016  107  
Summit Venue  136  
Accommodation  138  
City of Berlin  140  
Federal Foreign Office  142  
General Information  146  
Media Information  150  
Contacts  151  
Keynote Speakers and Chairs  152  
Speaker Index with Pictures  163  
Speaker List  176  
Supporting Institutions  178  
Summit Partners  180
The individual desire for health and wellbeing is something we all share. With this in mind, one of the aims of the 2030 Agenda for Sustainable Development is to encourage people across the globe to live lives that are as healthy as possible at every stage of their existence. We committed ourselves to this goal last year within the framework of the United Nations. Now we have to implement this ambitious objective. That involves fighting epidemics and poverty related diseases and also extends to improving prevention and treatment of complaints of modern civilisation such as diabetes and cardiovascular disorders.

Germany plays a very active role in global health policy. To bring about further progress, we must strengthen healthcare systems worldwide and reform the global healthcare structure. We sharpened the focus on both these issues during Germany’s G7 Presidency. We intend to build on this when our country assumes the G20 Presidency at the end of this year.

Whether we are talking about institutional factors or other global health issues such as a joint approach to tackling antimicrobial resistance, we can only be effective in overcoming the challenges they present if scientists, policymakers and society work together side by side. This is why dialogue forums such as the World Health Summit are particularly important. As the patron of the Summit, I would like to welcome all participants to Berlin. This message comes with my hope that you will enjoy a fruitful exchange of new insights. I would like to thank you most sincerely for your remarkable commitment to advancing healthcare throughout the world.

Angela Merkel


Angela Merkel
Bundeskanzlerin der Bundesrepublik Deutschland
The themes discussed during this eighth World Health Summit are both ambitious and strategic. They also reflect the deep changes we are seeing in the world. The terms of globality and universality are now, more than ever, associated with health: quality care for all, accessible to all; international preventive measures; renewed support for health as a driver of development, growth and stability; and an ambitious research policy, which is a source of progress. These are principles to which France is committed, and which it supports in international bodies. France thus obtained, during the last G7, that reflection will take place at international level on access to expensive medicines. This Summit is a forum for discussion and dialogue, bringing together men and women “of good will”. That means it is a place of peace.

I wish you all excellent meetings.

François Hollande
President of the French Republic
It is impossible to talk about health issues in the past year in Europe without reflecting on the refugee crisis, and the challenges and opportunities that it has presented for Europe. Over one million children, women and men arrived at our shores and borders last year.

The European Union had a common responsibility to ensure that these persons, many of them physically and mentally exhausted, were offered care and support, including through the provision of healthcare when required. Their journeys were punishing, and we cannot imagine the impossible choice they had to make between staying in their countries in extreme danger and the unenviable alternative of risking their lives at the hands of people smugglers. Europe’s number one task was to offer these people a humane reception in Europe, which the Commission helped to achieve by the setting up of hotspots in Greece and Italy, and through financial and practical assistance to our Member States under our emergency asylum funding and through the EU’s Civil Protection Mechanism.

Our next priority is to ensure the effective integration of those that are granted international protection. For some that will mean receiving access to our health services. At the same time, the people who arrive in Europe must be given the opportunity to pay their way, through access to the labour market. And there is an obvious counterbalance to the demands they make of our healthcare system with the contributions that they can make to it. I hear of many medical professionals coming to Europe seeking to rebuild their lives; doctors and nurses, pharmacists and researchers, carers and therapists. In the next year I hope to hear heart-warming stories of their integration into our national health services, care homes, research institutes and universities and the valuable contribution they are making.

And one reason to welcome these new arrivals is the reason I gave you in my message for last year’s World Health Summit – Europe’s population is getting older, which makes it increasingly difficult to provide for our healthcare needs. I know that you will again address the healthcare challenges of an aging population at this year’s Summit. Setting strategic research priorities will be of fundamental importance, and I am pleased that the European Commission continues to make an important contribution through our Horizon 2020 funding program.

Another area where we are making an important contribution is eHealth. More and more people are taking steps to monitor their own health and lifestyles
12 WELCOME MESSAGE JEAN-CLAUDE JUNCKER

through wearable devices and smartphones. These form an excellent contribution to prevent and monitor diseases. Through the Connecting Europe Facility, we are contributing to building Europe’s digital health infrastructure. So far, 20 of our Member States have applied for funding to connect their systems and exchange health data and patient information or to offer e-prescriptions and reduce the administrative burden on our care systems.

Let me conclude by mentioning the healthcare industry, which is one of the major drivers of jobs, growth and innovation in Europe. We need a successful economy to sustain our European social model, and you are an intrinsic part of this with the many thousands of jobs you create and sustain. The world is getting older, and the world is in need of health technology to sustain us as we go through a major demographic change. Europe must lead the way in looking after its own citizens, and it must generate a competitive advantage in the global market for healthcare services and products.

I wish you a fruitful Summit, and another year of success.

Jean-Claude Juncker
President of the European Commission
This year’s meeting finds us face-to-face with a challenge of unprecedented scale: for the first time ever, more than 60 million people are fleeing war, terror and persecution. The effects have been profound. Europe, seen for decades as a model for cooperation and friendship, is diverging from its blueprint. Social norms and contracts are dissolving under the weight of mistrust and short-term interests. In many countries, health systems are struggling hard with the duty of providing care for those in need.

Experience shows that there is only one way to confront these paramount issues: we have to build up trust again and intensify international cooperation. Last year’s G7 summit emphasized these issues and the German government ties its G20 Presidency at the end of 2016 to sharpening this focus and working on reforming the global healthcare structure, as Chancellor Angela Merkel expresses in her Welcome Message. This strong political will is being accompanied by the internationally endorsed Sustainable Development Goals (SDG) and highly promising developments in translational research that cross the boundaries between science and medicine, as well as increasing accessibility of data and powerful new tools.

This spirit of cooperation permeated the WHS Geneva Meeting in April 2016, held on the occasion of the Geneva Health Forum’s (GHF) sixth edition and 10 year anniversary. It emphasized the continuous commitment of the Swiss government and the GHF organizers to global health and peace, thus providing a sterling example of partnership and friendship and sounding a clear call for collaboration of all health-related sectors.

To continue this call, the World Health Summit 2016 will draw more international experts from academia, politics, the private sector, and civil society than ever before. Their deliberations will focus on topics including:
• Migration and Refugee Health: From Care to Policy

• Technological Innovation for Health: Improving Healthcare Delivery

• Women, Empowerment and Health: Equality and Agency

• Translational Research: Advancing Innovative Treatment

• Infectious Diseases: Lessons Learned from Ebola to Zika

• Sustainable Development Goals: Transforming the Health Agenda

Supported by the M8 Alliance of Academic Health Centers, Universities, and National Academies, this meeting will serve as an example of the way trust and cooperation can improve lives worldwide.

What better goal could we collectively contribute than the hope for longer, healthier lives that can be lived out in peace? Please join us as we work toward this goal.

Antoine Flahault  
WHS President

Detlev Ganten  
WHS President
Since its foundation in 2009, the mission of the World Health Summit (WHS) has always been ambitious and unique: to translate cutting edge research and best practice patient care into an international agenda that will ultimately lead to improved worldwide health and a higher quality of life for all. As scientists and representatives of Berlin institutions working in precisely these areas of health, we could not agree more with this strategic goal. However, to ensure the success of this endeavor, strong national and international political support is essential. Already during its 2015 meeting, the G7 stressed the importance of global health. Chancellor Angela Merkel has subsequently confirmed that this approach will continue at the G20 level under her presidency. We applaud this determination and are delighted to observe that over the course of the last eight years, the WHS has become the ideal forum to develop topics that will shape this political agenda. Indeed, the WHS has been instrumental in bringing together experts in health-related sectors across the world who have now assumed an advisory role for political decision makers in times of crisis.

The Berlin Institute of Health (BIH) significantly enhances the cooperative health-care environment that reaches far beyond Berlin. The young institute (since 2013) brings together the excellent patient care of the Charité – Universitätsmedizin Berlin and the pioneering basic research of the Max Delbrück Center for Molecular Medicine in the Helmholtz Association. The BIH merges existing research units of the MDC and the Charité whilst augmenting the research space with world-class faculty and cutting-edge platforms. This has resulted in the creation of a unique ecosystem for excellent research and innovation which in turn facilitates the swift translation of research results into concrete benefits for our patients and the global population at large.

The World Health Summit has been instrumental in creating and maintaining the impact of this approach. It is built on the strong foundation of the M8 Alliance of Academic Health Centers, Universities and National Academies, a global network of leading academic institutions. Each year in October, the combined expertise of the WHS partners convenes in Berlin where WHS participants (experts
from the fields of academia, politics, the private sector, and civil society) are invited to tackle current and impending health issues. The WHS has thus become the foremost strategic forum for addressing questions relating to global health.

On behalf of the Berlin Institute of Health, the Charité – Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association, we welcome you to this year’s WHS, its sessions and its social events. To find sustainable answers to the challenges ahead we need reliable, resourceful, creative partners. This meeting provides the perfect platform to forge new alliances and nourish truly innovative healthcare solutions.

Karl Max Einhäupl
Chief Executive Officer
Charité – Universitätsmedizin Berlin

Axel Radlach Pries
Dean
Charité – Universitätsmedizin Berlin

Erwin Böttinger
Chief Executive Officer
Berlin Institute of Health (BIH)

Martin Lohse
Chair of the Board and Scientific Director
Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
PARTICIPANTS AND KEY FACTS

Participants Profile
The World Health Summit brings together more than 1,500 decision makers and representatives of all health-related fields from more than 80 countries to address the most pressing issues that medicine and healthcare systems will face over the next decade and beyond.

KEY FACTS
DATE: October 09–11, 2016
VENUE: German Federal Foreign Office
Werderscher Markt 1, 10117 Berlin
Entrance: Unterwasserstraße 10

The World Health Summit will be taking place at the Federal Foreign Office. Please be advised that due to security reasons, all delegates will be subject to a security check including a passport identification confirmation.

Please be aware: You will not be able to enter the Summit venue, if you are not able to present your passport or ID-card. Unfortunately, this procedure may produce a slight delay for entrance into the building. We therefore kindly ask you to refrain from bringing your luggage to the Summit venue, as this will slow down the security check process.

Who will attend the WHS 2016?
• Top-level researchers and members of the scientific community
• High-profile political decision-makers
• Executives and representatives from the healthcare system
• Leaders of the health-related industry and technology sector
• Representatives of civil society and foundations
• Students and young professionals from all health-related fields
Migration and Refugee Health: From Care to Policy
The current wave of migration – the biggest since the end of World War II – is putting issues of migrant health at the top of government agendas. Basic care is no longer enough. We now need new concepts for adapting health policy strategies that take into account transformative processes, both in migrant countries of origin and in the nations to which they emigrate.

Technological Innovation for Health: Improving Healthcare Delivery
Successful healthcare quality and delivery depends on effective medical devices – the tools for prevention, diagnosis, treatment and rehabilitation. Technological innovations in the field are helping reduce inefficiencies in healthcare delivery, while at the same time streamlining access, reducing costs, improving quality and making medicine more personalized and precise.

Women, Empowerment and Health: Equality and Agency
It’s grown strikingly clear that empowering women is a crucial component in achieving sustainable health and development objectives. Attaining greater equality for girls when it comes to health, nutrition and education is the first step towards ensuring that women will later be able to realize their full potential as equal partners in development.

Translational Research: Advancing Innovative Treatment
Translational research is advancing innovation, making it even more attractive for further investment and development. A central aspect of this process is the effective translation of knowledge, mechanisms and techniques generated by advances in fundamental scientific research, turning them into novel approaches for prevention, diagnosis and treatment.

Infectious Diseases: Lessons Learned from Ebola to Zika
In the wake of the Ebola epidemic in Africa, the WHO has now declared another global public health emergency based on clustered conditions thought to be caused by the Zika virus. Several key lessons from the Ebola response can already be applied to this new threat. Chief among them is that public health teams must ensure that prevention/treatment methods are accepted by people at risk of contracting the disease. Broader societal concerns also have to be addressed more effectively.

Sustainable Development Goals: Transforming the Health Agenda
The Sustainable Development Goals (SDGs) address social, economic and environmental challenges that can only be solved through integrated approaches. All of these aspects also have an impact on health, so they are critical contributors to the changes that will have to occur in pursuing global well-being.
The World Health Summit (WHS) is the annual conference of the M8 Alliance of Academic Health Centers, Universities and National Academies. Through the InterAcademy Partnership (IAP) for Health, it is organized in collaboration with national academies of science in more than 67 countries.

**VISION**

The vision behind the World Health Summit is to improve health all over the planet, catalyzing that process through collaboration and open dialogue, and steering tomorrow’s agenda to improve research, education, healthcare, and policy outcomes.

**MISSION**

The WHS mission is to bring together researchers, physicians, key government officials, and representatives from industry – as well as from NGOs and healthcare systems all over the world – to address the most pressing issues facing every facet of healthcare and medicine in the upcoming decade and beyond.

**GOALS**

- To bring together all stakeholders at the level of equals
- To establish a unique and sustainable high-level forum and network
- To help define the future of medicine, research and healthcare
- To find answers to major health challenges – both today and tomorrow
- To make global recommendations and set health agendas worldwide
PRESIDENTS

ANTOINE FLAHAULT
Director
Institute of Global Health,
University of Geneva,
Switzerland

DETLEV GANTEN
Honorary Chairman of the Board
Charité Foundation,
Germany

HÉLÈNE BOISJOLY
Incoming International President
Dean
Faculty of Medicine,
University of Montreal,
Canada

FORMER PRESIDENTS

2015
SHUNICHI FUKUHARA
Dean
School of Public Health,
Kyoto University,
Japan

2014
JOSÉ OTÁVIO AULER JR.
Dean
University of São Paulo Medical School,
Brazil

2013
JOHN EU LI WONG
Chief Executive Officer
National University Health System,
Singapore

2012
MICHAEL J. KLAG
Dean
Johns Hopkins Bloomberg School of Public Health,
USA

2011
STEVE WESSELINGH
Dean
Monash University,
Melbourne,
Australia

2010
STEVEN K. SMITH
Pro Rector (Health)
Imperial College London,
United Kingdom

2009
AXEL KAHN
President
Paris Descartes University,
France
The WHS Scientific Committee consists of the M8 Alliance Executive Committee (see page 29) and these members of the WHS Council:

**WHS SCIENTIFIC COMMITTEE**

- **RIFAT ATUN**
  Director, Global Health Systems Cluster
  Harvard T.H. Chan School of Public Health

- **DAVID DE KRETSER**
  Professor (Reproductive Endocrinology)
  Monash University

- **BÄRBEL-MARIA KURTH**
  Director, Epidemiology and Health Monitoring
  Robert Koch Institute (RKI)

- **KLAUS LINDPAINTNER**
  VP and Global Head Human Genetics and Computational Biomedicine, Pfizer Inc.

- **EDUARDO PISANI**
  Executive Director
  International Federation of Pharmaceutical Manufacturers & Associations

- **ERICH R. REINHARDT**
  Chairman
  Medical Valley EMN e.V.

- **HEINZ RIEDERER**
  Managing Director
  iNG innovation. Nachhaltigkeit. Gesundheit

- **GÜNTER STOCK**
  President, ALLEA
  All European Academies

**WHS AMBASSADORS**

- **MANFRED DIETEL**
  Director, Institute of Pathology
  Charité - Universitätsmedizin Berlin

- **ECKART VON HIRSCHHAUSEN**
  Medical Doctor and Cabaret Germany

- **REINHARD SCHÄFERS**
  (former) Ambassador
  Federal Republic of Germany

- **RAINER SAUERBORN**
  Director
  Institute of Public Health, Heidelberg University

- **CHARLES YANKAH**
  Chairman of the Board
  Afrika Kulturinstitut e.V., Berlin
## COUNCIL

<table>
<thead>
<tr>
<th>Name</th>
<th>Title and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ALA ALWAN</strong></td>
<td>Regional Director, Eastern Mediterranean World Health Organization</td>
</tr>
<tr>
<td><strong>RIFAT ATUN</strong></td>
<td>Director, Global Health Systems Cluster</td>
</tr>
<tr>
<td><strong>GERD BINNIG</strong></td>
<td>Director, Definiens AG</td>
</tr>
<tr>
<td><strong>ZULFIQAR BHUTTA</strong></td>
<td>Chair, Global Child Health University of Toronto</td>
</tr>
<tr>
<td><strong>ERWIN BÖTTINGER</strong></td>
<td>Chief Executive Officer, Berlin Institute of Health</td>
</tr>
<tr>
<td><strong>JAMES CHAU</strong></td>
<td>Anchorman, CCTV News, UNAIDS Goodwill Ambassador</td>
</tr>
<tr>
<td><strong>PIERRE CORVOL</strong></td>
<td>Professor (Experimental Medicine), Collège de France</td>
</tr>
<tr>
<td><strong>THOMAS CUENI</strong></td>
<td>Secretary General, Interpharma</td>
</tr>
<tr>
<td><strong>MANFRED DIETEL</strong></td>
<td>Director, Institute of Pathology, Charité – Universitätsmedizin Berlin</td>
</tr>
<tr>
<td><strong>GUDRUN DOLL-TEPPER</strong></td>
<td>Vice-President Education, German Olympic Sports Confederation</td>
</tr>
<tr>
<td><strong>GEORG DUDA</strong></td>
<td>Director, Julius Wolff Institut, Charité – Universitätsmedizin Berlin</td>
</tr>
<tr>
<td><strong>KLAUS DUGI</strong></td>
<td>Corporate Sen. Vice-President Medicine, Boehringer Ingelheim</td>
</tr>
<tr>
<td><strong>THOMAS ESCHENHAGEN</strong></td>
<td>Director, German Centers for Health Research (DZG)</td>
</tr>
<tr>
<td><strong>TIMOTHY G. EVANS</strong></td>
<td>Director, Health Nutrition &amp; Population, The World Bank</td>
</tr>
<tr>
<td><strong>ARMIN FIDLER</strong></td>
<td>President, European Health Management Association</td>
</tr>
<tr>
<td><strong>TEDROS GHEBREYESUS</strong></td>
<td>Minister of Foreign Affairs, Federal Democratic Republic of Ethiopia</td>
</tr>
<tr>
<td><strong>JÖRG HACKER</strong></td>
<td>President, German Academy of Sciences, Leopoldina</td>
</tr>
<tr>
<td><strong>ANDY HAINES</strong></td>
<td>Professor (Public Health), London School of Hygiene &amp; Tropical Medicine</td>
</tr>
<tr>
<td><strong>ZSUZSANNA JAKAB</strong></td>
<td>Regional Director, Europe World Health Organization</td>
</tr>
<tr>
<td><strong>STEFAN KAUFMANN</strong></td>
<td>Director, Max Planck Institute for Infection Biology</td>
</tr>
<tr>
<td><strong>ILONA KICKBUSCH</strong></td>
<td>Director, Global Health Program, Graduate Institute Geneva</td>
</tr>
<tr>
<td><strong>DAVID DE KRETSER</strong></td>
<td>Professor (Reproductive Endocrinology), Monash University</td>
</tr>
<tr>
<td><strong>BÄRBEL-MARIA KURTH</strong></td>
<td>Director, Epidemiology and Health Monitoring, Robert Koch Institut (RKI)</td>
</tr>
<tr>
<td><strong>KLAUS LINDPAINTNER</strong></td>
<td>VP and Global Head, Pfizer Inc. Human Genetics and Computational Biomedicine</td>
</tr>
<tr>
<td><strong>PHILIPPE MEYER</strong></td>
<td>Professor Emeritus, French Academy of Sciences</td>
</tr>
<tr>
<td><strong>JOEL MENARD</strong></td>
<td>Professor, Faculty of Medicine, Paris Descartes</td>
</tr>
</tbody>
</table>
JÜRGEN MLYNEK  
Chairman of the Board of Trustees  
Falling Walls Foundation gGmbH  

TIKKI PANG  
Visiting Professor for Public Policy  
National University of Singapore  

ANDREAS PENK  
Head  
Pfizer Oncology Europe, Africa, and Middle East  

EDUARDO PISANI  
Executive Director  
International Federation of Pharmaceutical Manufacturers & Associations  

WOLFGANG PLSCHKE  
Member of the Board of Management  
Evotec AG  

MARTINA POETSCHKE-LANGER  
Director, Cancer Prevention  
German Cancer Research Center  

OLIVIER RAYNAUD  
Independent Advisor  

ERICH R. REINHARDT  
Chairman of the Board  
Medical Valley EMN e.V.  

HEINZ RIEDELER  
Managing Director  
iNG innovation.Nachhaltigkeit. Gesundheit  

MATHIAS SCHELLER*  
Chief Executive Officer  
Albertinen-Diakoniewerk  

HANS-J. SCHELLNHubER  
Director  
Potsdam Institute for Climate Change Research  

THOMAS SOMMER*  
Deputy Scientific Director  
Max Delbrück Center for Molecular Medicine (MDC)  

GÜNTER STOCK  
President, ALLEA All European Academies  

TIMO ULRICHs  
Head, Tuberculosis Division  
Koch-Metschnikow-Forum  

SUSANNE WEBER-MOSDORF  
Former Assistant Director-General  
World Health Organization  

SONJA WEINREICH  
Senior Health Advisor  
Bread for the World  

VERA ZYLKA-MENHORN  
Senior Medical Editor  
Deutsches Ärzteblatt  

* = Berlin Chapter
The M8 Alliance’s vision is to harness academic excellence to improve global health.

The M8 Alliance of Academic Health Centres, Universities and National Academies is a collaboration between academic institutions committed to improving global health. Working together with political and economic decision-makers, its primary goal is to develop science-based solutions to health challenges all over the world.

This international network is the outstanding academic foundation upon which the World Health Summit - the pre-eminent annual forum for healthcare dialogue - is built. It functions as a permanent platform for framing the future considerations of global medical developments and health challenges in an equitable fashion.

The M8 Alliance promotes both “bench-to-bedside” translation of research and the transformation of current medical care approaches to treating the ill. It is seeking to accomplish this through the creation of a healthcare system focused on the effective prevention of diseases, as well as the adaptation of health-related solutions to rapidly changing living conditions through research in priority areas like shifting demographics, urbanization and climate.

The M8 Alliance is improving global health through pursuit of five strategic goals:

- Developing a worldwide network of academic health science centers, and bringing together universities and healthcare providers;
- Facilitating dialogue through the World Health Summit across a global network of stakeholders who are engaged with academic health science centers. These stakeholders include (among others) individuals and institutions active in government, industry and commerce, inter-governmental agencies, healthcare providers, academies of medicine and science, professional associations and the media;
- Setting an agenda for global health improvement by addressing issues of interest to academic health science centers, and conveying findings and recommendations based on scientific evidence through the generation of key statements;
- Positioning the M8 Alliance as an authoritative, credible and respected influence when it comes to decision-making in global health; and
- Creating a knowledge base amongst M8 Alliance members, which directly involves the promotion of mutual learning, research collaboration, the enrichment of educational capabilities and enhanced clinical outcomes.
M8 ALLIANCE EXECUTIVE COMMITTEE

ANTOINE FLAHAULT
Acting International President
Director, Institute of Global Health, University of Geneva

DETLEV GANTEN
Founding President
Honorary Chairman of the Board, Charité Foundation, Germany

HÉLÈNE BOISJOLY
Incoming International President
Dean, Faculty of Medicine, University of Montreal, Canada

SHUNICHI FUKUHARA
Past International President
Dean, School of Public Health, Kyoto University

AXEL RADLACH PRIES
Dean of Host Institution
Charité – Universitätsmedizin Berlin

MICHAEL J. KLAG
Strategic Co-operation and Stakeholder Liaison
Dean, Johns Hopkins Bloomberg School of Public Health, Baltimore

BEN CANNY
Governance and Fundraising
Head, School of Medicine, University of Tasmania

JOSÉ OTÁVIO AULER JR.
Officer at large
Dean, University of São Paulo Faculty of Medicine
## M8 ALLIANCE HEADS OF DELEGATION

<table>
<thead>
<tr>
<th>Country</th>
<th>Name</th>
<th>Position and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia</td>
<td>CHRISTINA MITCHELL</td>
<td>Dean, Monash University, Melbourne</td>
</tr>
<tr>
<td>Brazil</td>
<td>JOSÉ OTÁVIO AULER JR.</td>
<td>Dean, University of São Paulo, Faculty of Medicine</td>
</tr>
<tr>
<td></td>
<td>EDUARDO KRIEGER</td>
<td>Former President, Brazilian Academy of Sciences</td>
</tr>
<tr>
<td>Canada</td>
<td>HÉLÈNE BOISJOLY</td>
<td>Dean, Faculty of Medicine, University of Montreal</td>
</tr>
<tr>
<td></td>
<td>TARIK MÖRÖY</td>
<td>President, Clinical Research Institute Montreal</td>
</tr>
<tr>
<td>China</td>
<td>XUETAO CAO</td>
<td>President, Chinese Academy of Medical Sciences &amp; Peking Union Medical College</td>
</tr>
<tr>
<td></td>
<td>DEPEI LI</td>
<td>Chinese Academy of Engineering</td>
</tr>
<tr>
<td>France</td>
<td>FRÉDÉRIC DARDEL</td>
<td>President, Paris Descartes (Paris 5), Sorbonne Paris Cité</td>
</tr>
<tr>
<td></td>
<td>GÉRARD FRIELANDER</td>
<td>Dean, Faculty of Medicine, University of Paris Descartes</td>
</tr>
<tr>
<td></td>
<td>JEAN-YVES MÉRINDOL</td>
<td>President, Sorbonne Paris Cité</td>
</tr>
<tr>
<td>Germany</td>
<td>KARL MAX EINHÄUPL</td>
<td>Chief Executive Officer, Charité - Universitätsmedizin Berlin</td>
</tr>
<tr>
<td></td>
<td>AXEL RADLACH PRIES</td>
<td>Dean, Charité - Universitätsmedizin Berlin</td>
</tr>
<tr>
<td>Italy</td>
<td>LUCIANO SASO</td>
<td>Vice-Rector for European University Networks, Sapienza University</td>
</tr>
<tr>
<td>Japan</td>
<td>SHUNICHI FUKUHARA</td>
<td>Dean, School of Public Health, Kyoto University</td>
</tr>
<tr>
<td>Portugal</td>
<td>JOSÉ MARTINS NUNES</td>
<td>President, Executive Board, Coimbra Academic Clinical Center</td>
</tr>
<tr>
<td></td>
<td>JOÃO GABRIEL SILVA</td>
<td>Rector, University of Coimbra</td>
</tr>
<tr>
<td>Russian Federation</td>
<td>IVAN DEDOV</td>
<td>President, Russian Academy of Medical Sciences</td>
</tr>
<tr>
<td></td>
<td>EVGENY SIDORENKO</td>
<td>Vice-President, Russian Academy of Medical Sciences</td>
</tr>
<tr>
<td>Singapore</td>
<td>JOHN EU LI WONG</td>
<td>Chief Executive Officer, National University Health System</td>
</tr>
<tr>
<td></td>
<td>KHAY GUAN YEOH</td>
<td>Dean, Yong Loo Lin School of Medicine, National University of Singapore</td>
</tr>
<tr>
<td>Switzerland</td>
<td>United Kingdom</td>
<td>Individual Members</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>----------------------------------------</td>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td><strong>HENRI BOUNAMEAUX</strong></td>
<td><strong>PETER PIOT</strong></td>
<td><strong>RIFAT ATUN</strong></td>
</tr>
<tr>
<td>Dean, Faculty of Medicine,</td>
<td>Director, London School of Hygiene</td>
<td>Director, Global Health Systems Cluster,</td>
</tr>
<tr>
<td>University of Geneva</td>
<td>&amp; Tropical Medicine</td>
<td>Harvard T.H. Chan School of Public Health</td>
</tr>
<tr>
<td><strong>ANTOINE FLAHAULT</strong></td>
<td><strong>ELIO RIBOLI</strong></td>
<td><strong>BEN CANNY</strong></td>
</tr>
<tr>
<td>Professor for Public Health,</td>
<td>Director, School of Public Health,</td>
<td>Head, School of Medicine,</td>
</tr>
<tr>
<td>University of Geneva and</td>
<td>Imperial College London</td>
<td>University of Tasmania</td>
</tr>
<tr>
<td>Descartes, University Sorbonne</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paris Cité</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ILONA KICKBUSCH</strong></td>
<td><strong>MICHAEL J. KLAG</strong></td>
<td><strong>LAIMENG LOOI</strong></td>
</tr>
<tr>
<td>Director, Global Health Programme</td>
<td>Dean, Johns Hopkins</td>
<td>Co-Chair, InterAcademy Partnership (IAP) for</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Health</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>LEONEL VALDIVIA</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>President, World Federation of Academic</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Institutions for Global Health (WFAIGH)</td>
</tr>
<tr>
<td><strong>BERTRAND LEVRAT</strong></td>
<td><strong>STEVEN A. WARTMAN</strong></td>
<td></td>
</tr>
<tr>
<td>Chief Executive Officer,</td>
<td></td>
<td>President &amp; Chief Executive Officer,</td>
</tr>
<tr>
<td>Geneva University Hospitals</td>
<td></td>
<td>Association of Academic Health Centers (AAHC),</td>
</tr>
<tr>
<td><strong>CLAUDINE MATHIEU-THIÉBAUD</strong></td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>Director, National and</td>
<td><strong>LEONEL VALDIVIA</strong></td>
<td></td>
</tr>
<tr>
<td>International Affairs, the</td>
<td></td>
<td>President, World Federation of Academic</td>
</tr>
<tr>
<td>Geneva University Hospitals</td>
<td></td>
<td>Institutions for Global Health (WFAIGH)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>LAIMENG LOOI</strong></td>
</tr>
<tr>
<td><strong>Taiwan</strong></td>
<td></td>
<td>Co-Chair, InterAcademy Partnership (IAP) for</td>
</tr>
<tr>
<td><strong>CHANG-CHUAN CHAN</strong></td>
<td></td>
<td>Health</td>
</tr>
<tr>
<td>Associate Dean,</td>
<td></td>
<td><strong>RIFAT ATUN</strong></td>
</tr>
<tr>
<td>National Taiwan University (NTU)</td>
<td></td>
<td>Director, Global Health Systems Cluster,</td>
</tr>
<tr>
<td><strong>Uganda</strong></td>
<td></td>
<td>Harvard T.H. Chan School of Public Health</td>
</tr>
<tr>
<td><strong>NELSON K. SEWANKAMBO</strong></td>
<td></td>
<td><strong>BEN CANNY</strong></td>
</tr>
<tr>
<td>Principal, Makerere University</td>
<td></td>
<td>Head, School of Medicine,</td>
</tr>
<tr>
<td><strong>United Kingdom</strong></td>
<td></td>
<td>University of Tasmania</td>
</tr>
<tr>
<td><strong>International</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LAIMENG LOOI</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LEONEL VALDIVIA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>STEVEN A. WARTMAN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Individual Members</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>RIFAT ATUN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>BEN CANNY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LAIMENG LOOI</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
WELCOME TO THE
WORLD HEALTH SUMMIT
BERLIN 2016
The WHS Startup Track highlights and showcases outstanding ideas and innovative business concepts that have the potential to revolutionize healthcare and improve Global Health. Attending the WHS offers young entrepreneurs three days of access to world leaders in science, industry and politics. The event gives them the chance to exchange ideas with leading minds in the global healthcare sector and the Global Health community, set up future collaborations, and get to know potential mentors, investors and advisory board members.

80 applications from 22 countries were assessed by the jury to select the 25 shortlisted organizations, which were subsequently invited to the World Health Summit 2016.

Of these, 10 finalists will pitch their ideas in front of the audience and jury on Monday, October 10. The Winner of the WHS Startup Track 2016 will be awarded by German Federal Minister of Health Hermann Gröhe at the WHS Night (see page 38 for details).

**Pitch & Award**

Finalists will pitch their ideas on Monday, October 10, at 13:00 in the “Europasaal”. The winner will be awarded by Minister of Health Hermann Gröhe at the “WHS Night” on the evening of the same day.

**Benefits**

The ten finalists will receive their certificates from German Federal Minister of Health Hermann Gröhe during the WHS Night on October 10.

The winner will be given special access to the WHS and M8 Alliance network and receive an exclusive coaching from FLYING HEALTH. The best international startup will be invited for the Berlin Partner “Start Alliance Program Berlin 2017”.

The “WHS Startup Track” offers participants the chance to display their business ideas and to network with the world’s leading minds in the healthcare sector. They will establish strategic partnerships to improve their visibility and credibility with potential investors, industry, political decision makers, doctors, and patients.

Further information on the WHS Startup Track, the shortlisted companies and the finalists is available at:

[www.worldhealthsummit.org/the-summit/startup-track.html](http://www.worldhealthsummit.org/the-summit/startup-track.html)
THE 10 FINALISTS

Care Across | Greece
Business Area: Cancer
www.careacross.com

Cold Plasmatech | Germany
Business Area: Medical Devices/Plasma Wound Therapy
www.coldplasmatech.de

evivecare | Germany
Business Area: Digital Health
www.evivecare.com

Glasschair | Germany
Business Area: Smart Medical Technology
www.glasschair.de

iFeel Healthy | Israel
Business Area: Respiratory Digital Therapy
www.ifeellabs.com

midge medical UG | Germany
Business Area:
Pain free, safe and easy blood extraction
www.midgemedical.com

OneWorldDoctors | Germany
Business Area:
Médecins Sans Frontières (MSF) from home
https://oneworlddoctors.org

Pelvify | Poland
Business Area: Telemedicine, E-Health
www.pelvify.com

Symptoma | Austria
Business Area:
Diagnostic Decision Support System
www.symptoma.com

WinSenga | Uganda
Business Area:
mHealth/Prenatal Care
www.winsenga.org

THE JURY

Kai Uwe Bindseil
(Berlin Partner for Business and Technology GmbH)

Andreas Gebhard
(re:publica GmbH)

Jutta Klauer
(Pfizer Deutschland GmbH)

Karin Knufmann-Happe
(German Federal Ministry of Health)

Jörn Krupa
(Helmholtz Association)

Shari Langemak
(Medscape Germany)

Markus Müschenich
(Bundesverband Internetmedizin – BiM)

Klaus Stöckemann
(Peppermint Venture Partners GmbH)
The New Voices in Global Health (NVGH) initiative promotes the active participation of young scientists in the World Health Summit. It is supported by the M8 Alliance of Academic Health Centers, Universities and National Academies. The NVGH is aimed at empowering research, policy and advocacy initiatives among future leaders in global health, who are invited to send in abstracts of their scientific work and ideas.

The M8 Alliance Executive Committee (see page 29) identified the best applications based on international academic standards. The selected candidates will be able to display their work in a special poster exhibition, thus playing an active role in the World Health Summit.

The selected “New Voices” are:

**Skyler Jayden Dembe**  
Green World I Uganda  
The Influence of Male Circumcision on the Threat of HIV Infection in Uganda

**Christian Akem Dimala**  
London School of Hygiene and Tropical Medicine I UK  
The Association between Highly Active Antiretroviraltherapy (HAART), Hypertension and Diabetes Risk

**Andrea Gelemanovic**  
University of Split I Croatia  
Can Existing Knowledge Help Us Prepare in Case of an Epidemic Crisis? Emergency Exercise on Zika Virus

**Sandra Goldlust**  
Princeton University I USA  
Malaria Control in the Greater Mekong Subregion: Immune Dynamics and Artemisinin Resistance
Kirstin Grosse Frie  
Martin-Luther University Halle (Saale) I Germany  
Tackling Late-Stage Diagnosis and Treatment of Breast Cancer in Africa – a Case Study from Mali, Western Africa

Mohammad Mainul Islam  
University of Dhaka I Bangladesh  
Effects of Remittances on Health Expenditure and Types of Treatment of International Migrants’ Households in Bangladesh

Roxanne Keynejad  
King’s College London I UK  
Building the Capacity of Policy-Makers and Planners to Strengthen Mental Health Systems in Low- and Middle-Income Countries: A Systematic Review

Jessica Snyder  
Massachusetts Institute of Technology I USA  
Health Census Method using a Wastewater-derived Microbiome

Masresha Soressa  
Southern Nations Nationalities and Peoples Region I Ethiopia  
Integrating Youth-Friendly Sexual and Reproductive Health Services (YFS) in Public Health Facilities: Achievements/Succesess, Challenges and Lessons Learned in Southern Region, Ethiopia

Lukas Winter  
Max Delbrück Center for Molecular Medicine I Germany  
Open Source Imaging Initiative (OSI²): Bringing Affordable Magnetic Resonance Imaging (MRI) to the World
After two days of intense work with fellow World Health Summit participants from all over the world, take an evening to relax at the WHS Night - at a venue right next to the Brandenburg Gate.

The highlight of this event will be the WHS Startup Track Award Ceremony, when German Federal Minister of Health Hermann Gröhe will announce the competition’s finalists and winner.

Afterwards, snacks and drinks will be served, and a DJ will be on hand to provide musical entertainment for those who want to dance. A shuttle service from the WHS venue will be available.

Please note that you must register separately (www.registration-whs.com) to attend the WHS Night. There is a €39 entrance fee.
**WHS COMMUNITY**

The World Health Summit provides an ideal framework for networking with like-minded experts from all over the world. The WHS Community has been designed to ease the way for participants to get in touch prior to, during, and after the Summit.

This networking tool offers contact details, CV, pictures, and presentations of many speakers and attendants. Reserve your admission to this exclusive part of the WHS and optimize your WHS experience:

- Enhance your networking opportunities prior to the Summit
- Gain access to profiles of other registered participants
- Promote your presence by publishing your personalized profile
- Register for following WHS easily via your World Health Summits Community profile

Simply click on the “Community” button at the top-right corner of our homepage’s navigation bar and log in or sign up.

www.worldhealthsummit.org/community

---

**SOCIAL MEDIA**

The vision of the World Health Summit is improved health worldwide - catalyzed through collaboration and open dialogue. This dialogue already starts before the meeting and does not end when participants leave Berlin after three days of intense and fruitful discussions.

Stay in touch with fellow participants and the World Health Summit team via our social media outlets and be informed 365 days a year. We are looking forward to exchanging opinions and insights before, during, and after the World Health Summit via:

www.facebook.com/worldhealthsummit
www.twitter.com/WorldHealthSmt
www.linkedin.com/company/whs-foundation-gmbh

This year’s Twitter handle is: 
#WHS2016

To access the complimentary Wi-Fi within the venue, please use:
W-LAN: WorldHealthSummit
Password: #WHS2016
SUMMIT PROGRAM

SUNDAY, OCTOBER 09
PANEL DISCUSSION

GOVERNANCE FOR HEALTH
TACKLING CORRUPTION IN THE HEALTHCARE SECTOR

HOST
Transparency International

CHAIR
Cobus de Swardt
Transparency International | Managing Director | Germany

SPEAKERS

Agnès Couffinhal
Tackling Integrity Violations in Health: Experience from OECD Countries
Organisation for Economic Cooperation and Development (OECD) | Senior Economist, Health Division | France

Andrew Daniels
The Corruption Challenge, a View for Industry
GlaxoSmithKline Pharmaceuticals Europe | Director, Global Integrity Enhancement | United Kingdom

Suzanne Hill
Good Governance for Medicines and Access 2030
World Health Organization (WHO) | Director, Essential Medicines and Health Products | Switzerland

Tewodros Melesse
Social Accountability: Core to Achieving Sexual and Reproductive Health and Rights
The International Planned Parenthood Federation (IPPF) | Director-General | United Kingdom
Corruption is defined as the abuse of entrusted power for private gain. Its presence in society causes public funds to be wasted and trust in government to be lost.

In the healthcare sector corruption can take many forms and actors in the sector experience it in different ways. However, regardless of the type, corruption in the healthcare sector has a direct impact on its victims. From falsified medicines entering the supply chain to doctors demanding bribes from patients, the various types of corruption in the healthcare sectors puts lives at risk.

The session will begin by hearing the experiences of the panelists in dealing with corruption and anti-corruption in the health sector. The Chair will then take questions for the panel from the audience with an emphasis on this being an interactive session.
WORKSHOP

WS00
ROOM 5 | RATHENAU
08:45 – 10:15
OVERFLOW SCREEN 5

CHRONIC KIDNEY DISEASE IN SRI LANKA
A PUBLIC HEALTH CRISIS OF UNKNOWN AETIOLOGY

HOSTS

Government of Sri Lanka
German Federal Foreign Office

CHAIR

Asela Iddawela

SPEAKERS

Kai-Uwe Eckardt
CKD of Unknown Origin – A Global Phenomenon?
University Hospital Erlangen | Director, Nephrology and Hypertension | Germany

Sachie Panawela
Recommendations of the WHO Expert Consultation Conference Held in Colombo in April 2016
The Coordinating Secretariat for Science, Technology and Innovation (COSTI) | Minister of Science Technology and Research | Sri Lanka

Asanga Ranasinghe
Introduction/Present Status of CKDu in Sri Lanka
Anuradhapura General Hospital | Director, Renal Disease Prevention Unit | Sri Lanka
There is a mystery kidney disease that for years has been killing thousands of farmers in Sri Lanka’s rice basket – and as it spreads, locals are becoming increasingly fearful. In 20 years the disease has killed up to 20,000 people and sickened up to 400,000 more; some villages report it causes as many as 10 deaths a month.

As the disease progresses and kidneys fail, sufferers become unable to pass liquids on their own and are prohibited from drinking more than just a bottle of water a day – their extremities retain water and become fat with fluid. Its cause is not yet known, though there are long-held suspicions that agrochemicals are to blame, and Sri Lanka is lacking in the dialysis required to effectively treat the many sufferers.

Though no cases have been reported outside of the North Central province’s dry zone, where farming was transformed in the 1960’s and 70’s following the introduction of modern techniques, the disease has slowly spread from two districts to seven. A report published by the World Health Organisation two years ago could not find a clear cause for the disease, though it pointed to cadmium, pesticides and other factors, such as arsenic, as possibilities.

This Workshop will bring together experts in order to discuss the growing problem and figure out possible avenues for finding solutions.
PANEL DISCUSSION

NONCOMMUNICABLE DISEASES
ACCESSIBILITY AND AFFORDABILITY OF CARDIOVASCULAR SERVICES

HOSTS
M8 Alliance:
Charité – Universitätsmedizin Berlin

CHAIRS
Volkmar Falk
German Heart Institute Berlin (DHZB) | Medical Director | Germany

Charles Yankah
African Cultural Institute (ACI) | President | Germany

SPEAKERS
Fiona Adshead
The Role of Workplaces in NCDs
BUPA | Chief Officer, Wellbeing and Public Health | United Kingdom

Ann Aerts
Cardiovascular Diseases in Low-Income Settings Demand Innovation in Healthcare Delivery more than Delivering Innovations in Healthcare
Novartis Foundation | Director | Switzerland

Oleg Chestnov
Access to NCD Management: An Essential Element of the WHO Global NCD Action Plan
World Health Organization (WHO) | Assistant Director-General, Noncommunicable Diseases and Mental Health | Switzerland

Jayasree Iyer
Engaging the Pharmaceutical Industry to Improve Access to NCD Medicine
Access to Medicine Foundation | Executive Director | Netherlands

Francis E. Smit
Accessibility and Affordability of Cardiac Services in Africa
University of the Free State (UOFS) | Head, Cardiothoracic Surgery | South Africa
All age groups and all regions are affected by NCDs. NCDs are often associated with older age groups, but evidence shows that 16 million of all deaths attributed to noncommunicable diseases (NCDs) occur before the age of 70. Of these “premature” deaths, 82% occurred in low- and middle-income countries. Children, adults and the elderly are all vulnerable to the risk factors that contribute to noncommunicable diseases, whether from unhealthy diets, physical inactivity, exposure to tobacco smoke or the effects of the harmful use of alcohol.

These diseases are driven by forces that include ageing, rapid unplanned urbanization, and the globalization of unhealthy lifestyles. NCDs threaten progress towards the UN Millennium Development Goals and post-2015 development agenda. Poverty is closely linked with NCDs. The rapid rise in NCDs is predicted to impede poverty reduction initiatives in low-income countries, particularly by increasing household costs associated with health care.

Cardiovascular diseases and accessibility and affordability to cardiovascular services have become a global concern. Due to prohibitively high costs and limited access to medical and surgical services, easily treatable cardiovascular conditions often develop to become chronic and deadly diseases.
WORKSHOP

MEDICAL EDUCATION
GLOBAL HEALTH CURRICULUM – STUDENT-LED INITIATIVES

HOSTS
M8 Alliance: Charité – Universitätsmedizin Berlin
M8 Alliance: Monash University
M8 Alliance: National University of Singapore (NUS)
M8 Alliance: University of Geneva
M8 Alliance: University of Montreal

CHAIRS
Ben Canny
University of Tasmania | Head, School of Medicine | Tasmania
Axel Radlach Pries
Charité – Universitätsmedizin Berlin | Dean | Germany

SPEAKERS
Keith Lim
Developments in the M8 Global Health Curriculum
National University of Singapore (NUS) | Assistant Dean (Education), Yong Loo Lin School of Medicine | Singapore

Rafael Ruiz de Castaneda
Development of MOOCs to Inform Global Health Curricula
University of Geneva | Researcher and Lecturer, Institute of Global Health | Switzerland

Amirhossein Takian
Development of a Global Health Curriculum in an Emerging Nation
Tehran University of Medical Sciences | Chair and Professor, Global Health and Public Policy | Iran
There is a growing recognition that the modern health care professional, irrespective of their background and practice intentions, need to have specified competence in Global Health.

This session will outline what learning we can obtain by looking at the achievements of our students in developing their own Global Health Curricula. In addition, updates and perspectives in the development of methods for the delivery of Global Health Curricula will be discussed.
WS02
ROOM 3 | ADENAUER
10:30 – 12:00
OVERFLOW SCREEN 3

WORKSHOP

ENDING THE AIDS EPIDEMIC AS A PUBLIC HEALTH THREAT BY 2030

HOSTS

German Healthcare Partnership (GHP)

UNAIDS

CHAIRS

Roland Göhde
German Healthcare Partnership (GHP) | Chairman of the Board | Germany

Luiz Loures
UNAIDS | Deputy Executive Director | Switzerland

SPEAKERS

Raymonde Goudou Coffie
Ministry of Health and Public Hygiene | Minister of Health and Public Hygiene | Ivory Coast

Ricardo Augustus Guerreiro Baptista Leite
Catholic University Portugal | Head Public Health, Institute of Health Sciences | Portugal

Bernard S. Haufiku
Ministry of Health and Social Services | Minister of Health and Social Services | Namibia

Cleopa Mailu
Ministry of Health | Cabinet Secretary | Kenya

Elisabeth Pott
German AIDS Foundation | Chairman of the Board | Germany

DISCUSSANT

Till Bärnighausen
Harvard T.H. Chan School of Public Health | Associate Professor, Global Health and Population | United States of America
United Nations Member States have declared their political support for the Sustainable Development Goal of ending the AIDS epidemic by 2030. This is based on a Fast-Track approach to meeting ambitious targets by 2020 for HIV prevention, testing, treatment and care and support - and eliminating discrimination. In addition to political leadership, this session will identify other essential factors necessary to meet these targets and review the latest results in HIV diagnostics and treatment, investment and social engagement.

A broad spectrum of private sector, community, scientific and political representatives will draw on their experiences and discuss progress and obstacles in achieving the end of AIDS. How should countries, cities and communities prioritize? What policy frameworks are needed? What innovative and alternative investment sources can be developed and utilized? How can health systems be strengthened to end AIDS and meet other SDGs without leaving behind the people in greatest need?

This Workshop will explore:

- The new targets for ending the AIDS epidemic, arising from the 2016 UN General Assembly Political Declaration on HIV and AIDS.
- The implications of the FastTrack AIDS response, including prevention tools, diagnostics, treatment and care and support services and eliminating discrimination.
- Research results from prevention and treatment trials.
- Latest research on HIV prevention, testing and treatment services, including in West Africa.
DELIVERING MOBILE HEALTH IN REMOTE REGIONS
INSIGHT INTO INTEGRATED CONSERVATION AND DEVELOPMENT STRATEGIES

HOSTS
Protestant Church of the Rheinland (EKIR)
WWF Germany

CHAIR
Yoursen Bosolo
Bolenge Hospital | Coordinator, Medical Service | Congo

SPEAKERS
Yoursen Bosolo
A Boat as the Only Health Service
Access for 70 Villages in the Congo Backwaters in the Ngiri Conservation Area
Bolenge Hospital | Coordinator, Medical Service | Congo

Eva Greitemann
Access to Medicines: Delivering Medical Aid to Remote Regions
action medeor e.V. | Coordinator, Export, Supplies and Partner Development | Germany

Johannes Kirchgatter
Why Does a Conservation Organization Work on Health Service?
WWF Germany | Officer, Africa Projects | Germany

Dorothea Philipps
Successful Civil Society Cooperation to Build Health Support in Weak States
Protestant Church Dortmund | Former Pastor, Partnership Bolenge | Germany
Why would a conservation organization focus on health service in remote regions of the world? Because it would be absurd to discuss sustainability and protection of natural resources when people are dying from easily treatable diseases as a result of the next doctor being 300 km away.

In order to address this evident prioritization, the WWF seeks cooperation with strong partners to develop integrated strategies for health service access and sustainable development alongside WWF’s priority areas.

In this panel, we will discuss with these partners how such strategies can work practically, what we can learn from existing projects, how civil society actors can build strong cooperation in areas where the state is more or less absent and what support is needed from donors and international organizations.

Representatives from field projects, long-term supporters, project developers and global medical supply specialists will give an insight view and discuss the model character of such projects for the least developed areas of the world.
WORKSHOP

NEGLECTED TROPICAL DISEASES
FROM EMERGENCY TO SUSTAINABILITY

HOSTS

German Network against Neglected Tropical Diseases (DNTDs)

M8 Alliance:
University of São Paulo (USP)

CHAIRS

Eduardo Moacyr Krieger
Faculty of Medicina of the University of São Paulo (FMUSP) | Executive Director, International Relations Committee | Brazil

Carsten Köhler
University Hospital Tübingen | Director Center of Competence, Institute for Tropical Medicine | Germany

SPEAKERS

Ayola Akim Adegnika
Know How Transfer: From Germany to Gabun to the Local Population
Centre de Recherches Medicales de Lambarene | Co-Director, Infectious Diseases | Gabon

John Amuasi
Fighting NTDs to Achieve the SDGs – A G lance At From the African Perspective
African Research Network for Neglected Tropical Diseases (ARNTD) | Executive Director | Ghana

Klaus Brill
What Strategies do we Need to Successfully Combat NTDs and Achieve the SDG Goals in Partnership with the WHO
Bayer AG | Vice-President, Corporate Commercial Relations | Germany

Dirk Engels
What is the Main Focus of WHO to Achieve the 2030 Agenda?
World Health Organization (WHO) | Director, Control of Neglected Tropical Diseases | Switzerland

Eva-Maria Schwienhorst-Stich
What are the Challenges in Implementing Interventions Against NTDs?
DAHW German Leprosy and Tuberculosis Relief Association | Medical Councillor, Medical and Social Relief Programs | Germany
More than 1.4 billion people around the world are infected with at least one NTD, but because of their low mortality rate and because mainly poor and marginalized people are affected, these diseases don’t get much attention on the global stage.

But it seems that slowly it is recognized that controlling and eliminating NTDs is critical to ending extreme poverty. NTDs are seen as “indicator diseases” for underdevelopment because their occurrence is a sign of population groups and regions that have been particularly “neglected”. Thus the NTDs are included in the SDGs. But what has to be undertaken to fight NTDs successfully?
PANEL DISCUSSION

INFECTION DISEASES
LESSONS LEARNED FROM EBOLA TO ZIKA

HOSTS
Sabin Vaccine Institute
Sanofi

CHAIR
Peter J. Hotez
Sabin Vaccine Institute | President | United States of America

SPEAKERS
Christian Bréchot
From Ebola to Zika: Areas of Action to Limit the Impact of Future Infectious Disease Outbreaks
Institut Pasteur | President | France

Stefan Kaufmann
New Culprits and Old Foes: How to Combat Both
Max Planck Institute for Infection Biology | Director | Germany

Hon. Suresh Kumar
Access, Innovation and Price are Prerequisites to Preempt Disease, and all Stakeholders Must Play their Parts to Make this Happen
Sanofi | Head, Government Relations US ad interim | United States of America

Joy Phumaphi
Accountability at Community Level
African Leaders Malaria Alliance (ALMA) | Executive Secretary | Tanzania

Rolf Zinkernagel
Why are Vaccines Efficient Against Acute Lethal but not Against Persistent Chronic Infections
University Hospital Zurich | Professor Emeritus, Experimental Immunology | Switzerland
The World Health Organization has declared the Zika virus a global public health emergency. This designation gives the WHO and member states the ability to recommend limits on travel to prevent the potential spread of disease and to call for emergency measures and resources to combat an outbreak. The last time the WHO used this mechanism was during the recent Ebola crisis in West Africa.

The close involvement of the WHO, while there is still a lot of uncertainty about the disease, may tell us two things: that the WHO is seeking to learn from its failure to Ebola, after it was heavily criticized for its slow response; and that BRIC countries, such as Brazil, may be playing an increasingly important role in global health – their health priorities now have a global audience.

Good outbreak control relies on applying a package of interventions, namely case management, surveillance and contact tracing, a good laboratory service, safe burials, and social mobilization. Community engagement is key to successfully controlling outbreaks and to reduce human transmission.

One key lesson from the Ebola response can be applied to Zika – that the success of any intervention will depend on community acceptance. Public health teams must work with community organizations from the start to ensure that prevention and treatment methods are accepted by those who are at risk of the disease and that broader societal concerns are addressed.
WORKSHOP

WS05
ROOM 2 | BRANDT
13:00–14:30
OVERFLOW SCREEN 2

AGING & PRIMARY CARE
HEALTHY AGING AND END OF LIFE ISSUES

HOSTS
M8 Alliance: Coimbra Health
M8 Alliance: Kyoto University
M8 Alliance: National Taiwan University

CHAIRS
Chang-Chuan Chan
National Taiwan University (NTU) | Associate Dean | Taiwan
Shunichi Fukuhara
Kyoto University | Dean, School of Public Health | Japan

SPEAKERS
Ana Abrunhosa
The importance of Ageing @Coimbra to the Center Region of Portugal
European Commission | President, Development Commission CCDRC | Portugal
Chang-Chuan Chan
Overview of the Action Initiative
National Taiwan University (NTU) | Associate Dean | Taiwan
Shunichi Fukuhara
Overview of the Action Initiative
Kyoto University | Dean, School of Public Health | Japan
Rei Goto
Longterm Care Policy in Japan
Keio University | Associate Professor | Japan
Sheng-Jean Huang
Comfort Care in the End of Life Project in Taipei City
Taipei City Hospital | Superintendent | Taiwan
Catarina Resende de Oliveira
Growing Old in Portugal - A Translational Perspective on Coping with Cognitive Changes
Hospital and University Center Coimbra | Member, Executive Board | Portugal
The need to promote and maintain health will intensify with larger numbers of older adults seeking not just a long life but a healthy life as well. With a shift from a model of illness and cure to a model of wellness and care, the advanced practice nurse is the ideal health professional to implement a model of health care shaped by a philosophy of both primary and long-term care for the older population.

This model must include thoroughly integrated strategies for health promotion and disease prevention, interdisciplinary, comprehensive geriatric assessment, care management for integration and coordination of services, and an emphasis on function and quality of life as outcomes of treatment.
WORKSHOP

THE SCIENCE OF ADDICTION
DRUGS, BRAINS AND BEHAVIOR

HOSTS

M8 Alliance: Charité – Universitätsmedizin Berlin
M8 Alliance: Imperial College London
M8 Alliance: Monash University

CHAIR

Antonio Verdejo-Garcia
Monash University | Associate Professor, School of Psychological Sciences | Australia

SPEAKERS

Adrian Carter
Ethics and Policy
Monash University | Senior Research Fellow, School of Psychological Sciences | Australia

Andreas Heinz
Neurobiology and Treatment
Charité – Universitätsmedizin Berlin | Director, Clinic for Psychiatry and Psychotherapy | Germany

Michael T. Lynskey
Addiction and Adolescence
King’s College London | Professor, National Addictions Centre | United Kingdom

David Nutt
Neuropsychopharmacology
Imperial College London | Director, Neuropsychopharmacology Unit | United Kingdom

DISCUSSANT

Karsten Lunze
Boston University | Assistant Professor, School of Medicine | United States of America
Substance use and behavioural addictive disorders are major health problems with high personal impact and societal costs. These addictive disorders involve changes in the brain of those affected. Individual differences in brain networks relevant to reward/punishment learning and executive functions predict vulnerability to addiction, and continued exposure to drugs and other powerful incentives weakens the function of these systems.

This workshop features a panel of experts on the neurobiological and neuropharmacological underpinnings of drugs and drug addiction, and social policy concerning addictive disorders, to discuss a range of issues such as new trends in diagnosis, treatment and recovery and the need to apply new thinking to how society can best deal with the growing problem of addiction.
WS07
ROOM 4 | STRESEMANN
13:00 - 14:30
OVERFLOW SCREEN 4

WORKSHOP

FROM ARCHEOLOGY AND GENOMES TO EVOLUTIONARY MEDICINE

HOSTS
Humboldt Forum Berlin
World Health Summit

CHAIRS
Detlev Ganten
World Health Summit President
Charité Foundation | Honorary Chairman of the Board | Germany

Hermann Parzinger
Prussian Cultural Heritage Foundation | President | Germany

SPEAKERS
Johannes Krause
Genomes in the Evolution of Homo Sapiens in Health and Disease
Max Planck Institute for the Science of Human History | Director | Germany

Albert Zink
Ötzi – An Example of Detailed Medical Analysis of Mummies
EURAC – Institute for Mummies and the Iceman | Scientific Director | Italy

DISCUSSANTS
Frank Rühli
University Zurich | Director, Institute of Evolutionary Medicine | Switzerland

Johannes Vogel
Museum für Naturkunde | Director-General | Germany

Christina Warinner
Laboratories of Molecular Anthropology and Microbiome Research (LMAMR) | Co-Director | United States of America
The application of genomics in archaeology has allowed for unexpected insights into the anthropology, cultural history as well as health and diseases of homo sapiens. Genetic analysis on a population-basis also provides vital information about how homo sapiens migrated and settled, developing from hunter-gatherer societies to sedentary cultures. With the help of biological material from e.g. bones or stomach, it is possible to make statements about the nutritional habits of early humans and thus aid us in understanding their way of life. Dentures newly allow us to find the traces of pathogens such as plague or tuberculosis, which in the future should allow us to reconstruct the evolutionary history of diseases.

The progression in the scientific methods of archaeology, genomics, genetics and molecular-biological analysis will allow for further questions to be answered in this area. The field is developing into a new concept of darwinian evolutionary medicine. This revolutionary approach is driving important advances not only in the history of health and disease, but also in the evolutionary causes of susceptibility, risk factors, and in the long term, new approaches to preventive medicine. This will be based on an interdisciplinary holistic approach of health as a function of our evolutionary understanding of biology and the complex interactions of the individual with the environment determined by culture and lifestyle. The dissociation and gap of modern lifestyles and our old biology is leading to diseases of civilization.

The workshop serves the purpose of bringing together experts in archaeology, biology, genomics, medicine and global health, for a professional exchange to discuss the latest interdisciplinary findings and common ground between these diverse fields.
WORKSHOP

WS08
ROOM 5 | RATHENAU
13:00 - 14:30
OVERFLOW SCREEN 5

CONFLICT AND HEALTH
THE COSTS TO HEALTH AND HEALTH SERVICES IN CONFLICT ZONES

HOSTS
British Medical Journal (BMJ)
Case Reports

International Committee
of the Red Cross (ICRC)

International Institute for
Strategic Studies (IISS)

CHAIRS
Seema Biswas
BMJ Case Reports | Editor-in-Chief | United Kingdom

Esperanza Martinez
International Committee of the
Red Cross (ICRC) | Head, Health
Assistance Division | Switzerland

SPEAKERS
Katri Bertram
Children on the Move: How Conflict and the Refugee Crisis are Affecting the Health and Well-Being of Vulnerable Populations
Save the Children Deutschland e.V. | Head, Advocacy and Policy | Germany

Virginia Comolli
Patterns in Conflict Across the World
International Institute for Strategic Studies (IISS) | Senior Fellow, Security and Development | United Kingdom

Anke Hoeffler
What are the Costs of Conflict?
Oxford University | Research Officer, Centre for the Study of African Economies | United Kingdom

Ahmad Tarakji
The Challenges of Meeting Health Needs of Individuals in Conflict Zones
Syrian American Medical Society | President | United States of America
The increase in civil (intrastate) conflicts across the world has resulted in unprecedented numbers of people displaced from their homes, injured and unsupported as infrastructure around them is destroyed.

Meeting the health needs of these populations involves improvising health care in the face of the flight of health care personnel and the destruction of local health services, humanitarian assistance provided by local and international organisations, and the care of refugees in neighbouring countries.

Health needs include acute care of the injured, medication and follow up for chronic disease, the treatment and prevention of communicable diseases and vaccination, and the delivery of essential health services for women and children.
PANEL DISCUSSION

GLOBAL HEALTH SECURITY
PREPAREDNESS AND RESPONSE

HOSTS
Munich Security Conference Foundation (MSC)
National Academy of Medicine (NAM)

CHAIR
Ambassador Wolfgang Ischinger
Munich Security Conference Foundation (MSC) | Chairman of the Board | Germany

SPEAKERS
Sarbani Chakraborty
Merck Group | Head of Global Health Policy, Government Affairs and Policy | Germany

Tedros Adhanom Ghebreyesus
Ministry of Foreign Affairs | Minister of Foreign Affairs | Ethiopia

Victor J. Dzau
National Academy of Medicine | President | United States of America
Global Health Security has become a priority for world leaders. The Ebola outbreak brought attention to the weaknesses in the systems of preparedness and response at the national, regional and global level. In response the UN, the WHO, the G7 and G20 as well as regional organizations such as the EU and the African Union have increased their resolve to address the global health security challenge at all levels of governance.

In order to deal with the gaps a number of significant steps have been taken: WHO has been reformed to have better emergency capacity, the Global Health Security Agenda has been strengthened and now works as a partnership of over 60 countries to implement the International Health Regulations and meet measurable targets.

A joint assessment tool has been developed with the WHO to enable external assessments of a country’s capacity to prevent, detect and respond. The commitment to Universal Health coverage has been reaffirmed. Private stakeholders – be it the International Aviation Association or the pharmaceutical industry - have become active to define their role and the research community is galvanized to strengthen the commitment to new vaccines, diagnostics and treatments. Especially other sectors – like security, agriculture, travel and tourism - need to become a part of the global effort.

The challenge now is to create synergies between nation-states, international organizations and public & private stakeholders to accelerate progress toward a world that is safe from threats posed by infectious disease, and to promote global health security as an international security priority.
WORKSHOP

ACCESS TO MEDICINES AND INTELLECTUAL PROPERTY RIGHTS
A DISCUSSION ON NEW APPROACHES & REMAINING CHALLENGES

HOST
World Health Organization (WHO)

CHAIR
Peter Beyer
World Health Organization (WHO) | Senior Advisor, Essential Medicines & Health Products | Switzerland

SPEAKERS
Danny Edwards
Encouraging Access-Oriented IP Management in the Industry
Access to Medicine Foundation | Research Programme Manager | The Netherlands

Lorraine Misquith
Access to and Prices of Hepatitis C Treatment in Asia
United Nations | Senior Legal and Advocacy Officer, Lawyers Collective | India

Jayashree Watal
The Economics of Innovation: Trends in Management of IP in Pharmaceutical Innovation
World Trade Organization | Counselor, Intellectual Property | Switzerland
The protection of intellectual property is the essential concept underlying the current innovation model in the pharmaceutical field. Where this model leads to dominant market positions and high prices, this can pose a number of ethical challenges.

This conflict became very apparent with the HIV/AIDS crisis some 20 years ago that led to intense debates and negotiations around this issue in a number of international organizations, including WTO, WIPO and WHO.

In the past years, a lot of progress has been made: there is international funding, prices came down, treatment guidelines were issued, procurement systems streamlined, supply chain management improved to mention just a few. Companies also changed their policies and have started to pay more attention on to facilitate access to treatment in low- and middle income countries where HIV is endemic. The rise of the new cures for hepatitis and their high prices have been compared with the HIV pandemic.

This workshop will shed light on the current situation and how all players have learned from their experience in HIV using different instruments to increase access to life saving medicines.
WORKSHOP

PATIENT SAFETY
PREVENTING HEALTHCARE ASSOCIATED INFECTIONS

HOSTS
M8 Alliance:  
National University of Singapore (NUS)  
VAMED AG

CHAIRS
Frances A. Hughes  
International Council of Nurses | Chief Executive Officer | Switzerland  
Swee Chye Quek  
National University Hospital Singapore (NUHS) | Head of Cardiology, Paediatrics | Singapore

SPEAKERS
Dale Fisher  
National University Hospital Singapore (NUHS) | Head and Senior Consultant, Infectious Diseases | Singapore

Judith Heepe  
Charité – Universitätsmedizin Berlin | Director, Medical and Health Care | Germany

Swee Chye Quek  
National University Hospital Singapore (NUHS) | Head of Cardiology, Paediatrics | Singapore

Silvia Türk  
Federal Ministry of Health | Head, Health Systems Research | Austria

DISCUSSANT
Bernd W. Böttiger  
University Hospital Köln | Director, Anaesthesiology and Intensive Care Medicine | Germany
Healthcare associated infections (HAIs) are a natural phenomenon occurring by way of institutionalizing vulnerable patients. A number of pathogens particularly multidrug resistant organisms are well adapted to healthcare settings, surviving in the environment and transmitting often via the hands of our staff.

The prevention of HAIs is the single largest challenge compromising patient safety and requires an organizational structure from senior government leaders to staff at the bedside.

This session will describe the scale of this problem, the necessary commitment and leadership for an adequate response the flow on effects of that leadership to the bedside.
WORKSHOP

PERSONALIZED HEALTHCARE VISION IN ONCOLOGY

HOSTS
F. Hoffmann-La Roche Ltd.
M8 Alliance:
Charité–Universitätsmedizin Berlin

CHAIR
Manfred Dietel
Charité–Universitätsmedizin Berlin | Director, Institute of Pathology | Germany

SPEAKERS
Dietmar P. Berger
Major Advances in Health Technology and Cancer Treatment and the Impact on Public Health
F. Hoffmann-La Roche Ltd. | Senior Vice-President / Global Head, Clinical Hematology / Oncology Product Development | United States of America

Andreas Jenne
NEO New Oncology | Chief Executive Officer | Germany

Daniel H. Schmutz
Consequences for National and Worldwide Healthcare Systems
Helsana-Gruppe | Chief Executive Officer | Switzerland

Reuben Shaw
Precision Medicine (Targeted Therapy, Immune-Oncology etc.) – An Overview
Salk Institute for Biological Studies | Director, National Cancer Institute | United States of America
In the very near future, a patient’s cancer will be extensively characterized for mutations and other molecular abnormalities, and his or her treatment will be based on the identified molecular changes instead of where the cancer originated in the body. This approach is part of what is called precision (or personalized) medicine.

The greater molecular and mechanistic understanding of cancer that we are gaining - and applying toward the development of new therapies - is also directly applicable to cancer prevention and screening. Precision medicine uses the genetics of disease to identify effective therapies, and, thanks in large part to NCI-supported research, we know that cancer is a disease of the genome.
KEYNOTE

OPENING CEREMONY

HOSTS

German Federal Foreign Office
German Federal Ministry of Health (BMG)
World Health Organization (WHO)
M8 Alliance

CHAIRS

Antoine Flahault
World Health Summit President
University of Geneva | Director, Institute of Global Health | Switzerland

Detlev Ganten
World Health Summit President
Charité Foundation | Honorary Chairman of the Board | Germany

SPEAKERS

Hermann Gröhe
Federal Ministry of Health (Bundesministerium für Gesundheit) | Federal Minister of Health | Germany

Alain Berset
Swiss Confederation | Federal Councillor and Head, Federal Department of Home Affairs FDHA | Switzerland

Ren Minghui
World Health Organization (WHO) | Assistant Director-General, HIV/AIDS, Tuberculosis, Malaria and Neglected Tropical Diseases | Switzerland

Erwin Paul Böttinger
Berlin Institute for Health (BIH) | Chairman of the Board | Germany

Emmanuelle Charpentier
Max Planck Institute for Infection Biology | Director | Germany

STATEMENTS OF YOUNG LEADERS IN HEALTH
SUMMIT PROGRAM

MONDAY, OCTOBER 10
PANEL DISCUSSION

UNIVERSAL HEALTH COVERAGE
ASSURING ACCESS AND SUSTAINABILITY

HOSTS
German Healthcare Partnership (GHP)
M8 Alliance:
The Graduate Institute Geneva –
Global Health Center
Rabin Martin

CHAIRS
Ilona Kickbusch
The Graduate Institute of International
and Development Studies |
Director, Global Health Center |
Switzerland

Michael Rabbow
E&P Focus Africa Consulting GmbH |
Senior Advisor | Germany

SPEAKERS
Rosalinda Baldoz
The Role of the Private Sector in Health
Workforce Development Towards
Universal Health Care, Decent Work
and Fair Migration
Government of the Philippines |
Former Secretary, Labor and
Employment (DOLE) | Philippines

Adalberto Campos Fernandes
The Portuguese NHS Experience:
Scaling Up and Access
Ministry of Health | Minister of Health |
Portugal

Ali Jafarian
Iran’s National Health Network
System and the Private Sector Pillar –
A Model for Mixed Health Systems?
Tehran University of Medical Sciences |
Chancellor | Iran

Justin P. McCarthy
What Role do Private Sector Actors Play
in Achieving UHC as Part of the 2030
Sustainable Development Agenda?
Pfizer Inc. | Senior Vice-President, Global
Policy and International Public Affairs |
United States of America
The role for the private sector in health remains subject to much debate, especially within the context of achieving universal health coverage (UHC). Another reason for this debate stems from the multiple and complex processes implicated in achieving UHC. While the overarching aim of UHC is to ensure that everyone has access to affordable and quality health products and services regardless of background, in practice this requires strengthening health financing for and service provision of, an agreed package of basic health services across a broad population. Yet there remains no blueprint for how this might be accomplished.

This session will focus on the new economy of health and the existing and future contributions of the private sector toward the achievement of UHC in mixed health systems. It is the third session in a progressive series hosted by the World Health Summit exploring UHC and the dimensions of innovation, equity, and the new economy of health.
WORKSHOP

IMPROVING PROCESSES FOR ACCESS TO MEDICINES
DEVELOPING STRONGER COLLABORATION AND DIALOGUE

HOSTS
European Federation of Pharmaceutical Industries and Associations (EFPIA)
Sanofi

CHAIRS
Richard Bergström
European Federation of Pharmaceutical Industries and Associations (EFPIA) | Director-General | Belgium

Ricardo Augustus Guerreiro Baptista Leite
Catholic University Portugal | Head of Public Health, Institute of Health Sciences | Portugal

SPEAKERS
Chantal Belorgey
French National Authority for Health (HAS) | Director, Medical, Economic and Public Health Evaluation | France

Niklas Hedberg
TLV, The Dental and Pharmaceutical Benefits Agency | Chief Pharmacist | Sweden

Thomas Muller
How to Improve Drug Research Output and Patient Access by Early HTA/Industry Communication
Federal Joint Committee | Head, Pharmaceuticals | Germany

Pieter Stolk
The WHO Priority Medicines Report: A Public Health Based Medicines Development Agenda
Exon Consultancy | Director | Netherlands
This session seeks to explore to what extent and under what conditions new and more structured approaches to collaboration and dialogue between the R&D based pharmaceutical industry and governments, regulators and civil society in Europe could make a positive contribution to improving medicines access processes in an environment characterized by economic uncertainty and budgetary pressures.

Debates on pharmaceutical pricing have reached a political and global dimension, often with an adversarial and acrimonious stance. At the same time, we have seen emerge a stronger interest from various stakeholders in developing more structured approaches to collaboration and dialogue aimed at better predictability for both the public authorities involved in making funding decisions and for the R&D based pharmaceutical companies that have to make important investment decisions. This session seeks to take a closer look at two areas in particular, both of which are based on the underlying idea of starting a dialogue well before the marketing authorization of a medicine:

So-called “Horizon-scans” or “pipeline scans” can help identify upcoming breakthrough innovations with high outcomes impact and initiate discussions on health system implications and funding.

The EU is currently exploring permanent models for joint ‘early dialogue’ which refers to the process of advice by HTA bodies (HTABs) and regulatory authorities sought at the initiative of a manufacturer on the appropriateness of study design during the development phase of a medicine. It helps companies address areas of uncertainty by better anticipating evidentiary needs for coverage decision-making by national authorities while bridging the evidentiary requirements for HTABs and regulatory approval.

What role can pipeline scans have in increasing budgetary predictability and planning in the pharmaceuticals sector? How can capabilities for pipeline scans be increased at national or even European level? What model for a permanent joint early dialogue would best meet the needs of all involved? Can joint dialogue accelerate a more harmonised approach to value assessment in Europe? Will any of this matter for an improved dialogue and ultimately for improved access to innovation for patients?
WS13
ROOM 3 | ADENAUER
09.00 - 10.30
OVERFLOW SCREEN 3

WORKSHOP

COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS
R&D PREPAREDNESS AND RESPONSE FOR EPIDEMIC OUTBREAKS

HOSTS
Coalition for Epidemic Preparedness Innovations (CEPI)
Government of Norway
Department of Biotechnology, Government of India

CHAIRS
Gagandeep Kang
Christian Medical College | Professor, Gastrointestinal Sciences | India
John-Arne Røttingen
University of Oslo | Director, Norwegian Institute of Public Health, Infectious Disease Control | Norway

SPEAKERS
Mark Feinberg
International AIDS Vaccine Initiative (IAVI) | President and Chief Executive Officer | United States of America

Yves Levy
The National Institute for Health and Medical Research (INSERM) | Director-General | France

Line Matthiessen-Guyader
European Commission | Head of Fighting Infectious Diseases and Global Epidemics, Research and Innovation | Belgium

Gerd Sutter
Ludwig Maximilians University Munich | Professor and Chair for Virology, Veterinary Sciences | Germany

DISCUSSANT
Michel Chrétien
University of Montréal | Professor Emeritus | Canada
The Ebola outbreak made obvious the need for a global mechanism to ensure development of biomedical countermeasures in situations of market failure. The way forward for such a mechanism will be explored in this session, including ties to the WHO R&D Blueprint and the existing ecosystem of organisations and mechanisms in global health, as well as financing requirements. There is an ongoing process aiming to establish a global initiative called the Coalition for Epidemic Preparedness Innovations, better known as CEPI.

The session will explore the proposed plans for this coalition. John-Arne Røttingen and Gagandeep Kang will give an introduction to the topic and to CEPI. Mark Feinberg, Gagandeep Kang, Line Matthiessen, Yves Levy and Gerd Sutter will form an interactive panel, with Michel Chrétien joining as an expert discussant.
WORKSHOP

TUBERCULOSIS AND MIGRATION
HOW TO CONTAIN TB IN TIMES OF WAR AND NATURAL DISASTER

HOSTS

Friends of the Global Fund
Koch-Metschnikow-Forum (KMF) e.V.

CHAIR

Timo Ulrichs
Koch-Metschnikov-Forum | Founder | Germany
Akkon University for Human Sciences | Head, Emergency Relief and Disaster | Germany

SPEAKERS

Zaza Avaliani
Tuberculosis and Migration in Georgia
National Center for Tuberculosis and Lung Diseases | Director | Georgia

Holger Bartz
Tuberculosis and Migration: Challenges and Impact for the Healthcare Industry
Janssen-Cilag GmbH | Director, Infectiology & Immunology | Germany

Sam Loewenberg
Who is Accountable? Lessons from the Ground on how Refugee Camps became Incubators for Disease
Harvard University I Nieman Global Health Reporting Fellow | United States of America

Andris Piebalgs
Resistancies and Increased Migration: How do we Eliminate TB now?
Government of the Republic of Latvia | Special Advisor to the President of the Republic | Latvia
Member of the Board | Friends of the Global Fund Europe

Martin van den Boom
Key Facts about TB in the WHO European Region
World Health Organization (WHO) | Regional Office for Europe | Technical Officer, Joint TB, HIV/AIDS and Viral Hepatitis Programme | Denmark
Together with malaria and HIV/AIDS, tuberculosis belongs to the most threatening and killing infectious diseases. In our present times, the spread of tuberculosis is accelerated by migration of vulnerable groups and TB patients. Refugees, IDPs and other migrating groups are at special risk to develop and to transmit tuberculosis.

The already existing problems of multidrug resistance and HIV-TB comorbidity are aggravated by migration, insecure containment structures and inadequate health care in refugee facilities. The workshop addresses these current challenges from different perspectives.
WS15
ROOM 5 | RATHENAU
09:00 – 10:30
OVERFLOW SCREEN 5

WORKSHOP

MIGRATION, CULTURES AND HEALTH

HOSTS

All European Academies (ALLEA)

M8 Alliance

World Health Summit

CHAIRS

Ambassador Reinhard Schäfers
World Health Summit - WHS Foundation GmbH | WHS Ambassador | Germany
Former German Ambassador

Günter Stock
All European Academies (ALLEA) | President | Germany

Jean-Yves K. Tano
World Health Summit Foundation GmbH | Scientific Advisor | Germany

SPEAKERS

Aydan Özoğuz
Federal Republic of Germany | Commissioner for Immigration, Refugees and Integration, Federal German Government | Germany

Nils Fietje
Cultural Mediators in Refugee and Migrant Encounters: The Role of the WHO in Promoting Training and Guidelines
World Health Organization (WHO) Regional Office for Europe | Research Officer, Information, Evidence, Research and Innovation | Denmark

İlhan İlkılıç
Interculturality and Ethics in the Health Care System
Istanbul University | Chair, History of Medicine and Ethics | Turkey

Anja Krumeich
Dutch Health Care Practice and its Impact on the Perception of Migrants as a Problematic Category
Maastricht University - Faculty of Health, Medicine and Life Sciences | Associate Professor, Health, Ethics & Society | Netherlands

David Napier
Cultural Competency and Why it Matters
University College London | Director, Anthropology | United Kingdom
Cultural diversity is defined as the differences that exist in the world, a society or an institution. This concept is important to understand and take into account when trying to bring about transformative ideas to a society, especially concerning the healthcare of the public.

The influx of immigrants, fleeing war, poverty and desolation, towards Europe has caused a great stir in 2015 with no end in sight thus far. These immigrants pose a challenge to the healthcare system in their countries of arrival as the differences in the cultures leads to different understandings and expectations for both doctors and the immigrants as patients.

Recent catastrophic events such as the 2011 Earthquake and Tsunami in Japan, or the 2014 and continuing Ebola crisis in West Africa have highlighted the need for healthcare workers to be properly trained in respect to the cultural diversity in these countries in order to provide adequate help.

In the current climate of expansion of noncommunicable diseases in the world, it is very important for all the stakeholders to be aware and properly informed about this topic when developing.
KEYNOTE

MIGRATION AND REFUGEE HEALTH
FROM CARE TO POLICY

HOSTS
International Committee of the Red Cross (ICRC)
International Organization for Migration (IOM)
M8 Alliance:
Johns Hopkins Bloomberg School of Public Health

CHAIR
Michael J. Klag
Johns Hopkins Bloomberg School of Public Health | Dean | United States of America

SPEAKERS
Yves Daccord
See The Person: Ensuring Continuity of Care in Fragile Environments
International Committee of the Red Cross (ICRC) | Director-General | Switzerland

Ambassador William Lacey Swing
The Place of Health in the Migrant and Refugee Global Compacts: A Multisector Partnership Agenda
International Organization for Migration (IOM) | Director-General | Switzerland

Helle Thorning-Schmidt
Migration and Refugee Health: Reaching Every Last Child
Save the Children International | Chief Executive Officer | United Kingdom

Florian Westphal
A Journey from Hell to the Unknown – The Human Cost of Policy Decisions
Médecins Sans Frontières (MSF) Germany | Managing Director | Germany

Aydan Özoğuz
Health Policy in the Immigrant Society
Federal Republic of Germany | Commissioner for Immigration, Refugees and Integration, Federal German Government | Germany
The current migration wave to Europe is unmatched in the history of the continent, and therefore issues pertaining to migrant health have risen high on the agenda of many European countries in response. The current situation is a sign and symptom of the recent globalization process and the increasing political unrest in different parts of the world. This migration is massive, unprecedented, extremely diverse and mostly unregulated. In the future migration into Europe will become a routine for which Germany and other European countries ought to be prepared.

There are multiple driving forces like civil wars and political instability as well as environmental degradation due to extreme weather events and climate change in countries of origin. On the other hand these forces include better life and economic prospects for migrants and their families in countries of destination.

Established migration concepts like pull and push factors and the so-called healthy migrant effect are not sufficient to explain and understand the impacts on health and society of this global phenomenon. Simple care will no longer suffice, new concepts are needed to adapt health policy strategies that take into account the social transformation processes in sending and receiving regions.
PANEL DISCUSSION

PLANETARY HEALTH
SAFEGUARDING BOTH HUMAN HEALTH AND THE NATURAL SYSTEMS THAT UNDERPIN IT

HOSTS
Leopoldina –
German National Academy of Science

M8 Alliance:
London School of Hygiene & Tropical Medicine

CHAIR
Sir Andrew Haines
London School of Hygiene & Tropical Medicine | Professor, Public Health and Primary Care | United Kingdom

SPEAKERS
Anthony Capon
The Future Earth Knowledge Action Network
United Nations University | Director, International Institute for Global Health | Malaysia

Samuel S. Myers
The Case for Planetary Health: Why Accelerating Change to Earth’s Natural Systems may be a Primary Driver of Future Burden of Disease Globally
Harvard T.H. Chan School of Public Health | Director, Planetary Health Alliance | United States of America

Montira Pongsiri
Applying Planetary Health Science to Policy and Decision-Making
Wildlife Conservation Society | HEAL Director | United States of America

Robert Sebbag
Consequences on Health of Climate Change
Sanofi Aventis | Vice-President, Access to Medicines | France
Despite health gains over recent decades, there is growing evidence that the planet’s capacity to sustain the growing human population is declining. Climate change, biodiversity loss, freshwater depletion, overexploitation of fisheries and air, water and soil pollution threaten to halt and reverse these advances in health.

The concept of “Planetary health” recognises the interdependencies of human and natural systems, and that the integrity of natural systems is an essential precondition for human health, survival, and prosperity.

This session will discuss the potential health implications of environmental changes for example through their effects on food and agriculture, emerging diseases, disasters and displacement of populations, exposure to pollution and increased poverty.

The session will also debate potential policies that could promote environmental sustainability and safeguard health across a range of sectors such as energy, transport, urban planning, agriculture and food as well as health care.

Finally it will discuss the challenges of implementing such policies and how these can be addressed with a particular emphasis on the role of health professionals in researching, educating and advocating for policies to sustain Planetary Health.
WORKSHOP

WS16
ROOM 2 | BRANDT
14:00–15:30
OVERFLOW SCREEN 2

GLOBAL MENTAL HEALTH
THE QUESTION OF CULTURE

HOSTS
Max Planck Institute for Psychiatry
University Hospital Tübingen

CHAIRS
Niall Boyce
The Lancet Psychiatry | Editor-in Chief | United Kingdom
Stephan Zipfel
University Hospital Tübingen | Head, Psychosomatic Medicine | Germany

SPEAKERS
Elisabeth Binder
Max Planck Institute of Psychiatry | Director | Germany
Dixon Chibanda
The Friendship Bench Project – A Mental Health Intervention Delivered by Community Health Workers in Zimbabwe
University of Zimbabwe | Consultant, Psychiatry | Zimbabwe
Erminia Colucci
Breaking the Chains – Ethnographic Film-Making in Mental Health
Queen Mary University of London | Lecturer and Leader, Transcultural Mental Healthcare | United Kingdom
Valentina Iemmi
Global Mental Health Policy and Mental Disabilities, Both in Developed and Developing Countries
London School of Economics and Political Sciences | Research Fellow, Personal Social Services Research Unit (PSSRU) | United Kingdom
Jan Ilhan Kizilhan
Help for Yazidi Survivors of Sexual Violence in Northern Iraq
Cooperative State University Baden-Württemberg | Head, Faculty of Social Studies | Germany
Ulrich Schnyder
Trauma is a Global Issue
University Hospital Zurich | Head, Psychiatry and Psychotherapy | Switzerland
The Workshop will focus on the issue of culture - the extent to which concepts of mental health care can translate and be implemented in different social, economic, and cultural settings around the world. Might the “friendship bench” concept in Zimbabwe translate to provide sustainable, effective mental health interventions in Europe?

And how do European concepts of trauma management work when applied to traumatized refugee populations from different cultures (eg, the Yezidi people from northern Iraq)?

Finally, by presenting an excerpt from the film project “Breaking the Chains”, we will give a brief insight into the use of physical restraint and confinement of people with mental illness in Indonesia, which has recently come to international attention.

With this workshop, we would like to discuss cultural entities such as “trauma” as a global issue rather than simply a psychological phenomenon. In our view, global mental health might be best understood using an interdisciplinary, multi-professional, biopsychosocial approach.
WS17
ROOM 3 | ADENAUER
14:00 – 15:30
OVERFLOW SCREEN 3

WORKSHOP

ONE HEALTH
TACKLING EMERGING INFECTIONS AT THE SOURCE

HOSTS
M8 Alliance: InterAcademy Partnership for Health (IAP)
One Health Platform

CHAIRS
Peter McGrath
InterAcademy Partnership for Health (IAP) | Program Officer | Italy

Albert Osterhaus
University of Veterinary Medicine Hannover | Professor, Wildlife Virology and Virus Discovery | Germany

SPEAKERS

Anthony Capon
One Health and Planetary Health: What is the Difference?
United Nations University | Director, International Institute for Global Health | Malaysia

Rajae El Aouad
The Challenge of Implementing One Health in Developing Countries and the Way Forward
Hassan II Academy of Science and Technology | Resident Member, National Institute of Hygiene | Morocco

Fabian Leendertz
One Health at the Human-Wildlife Interface
Robert Koch Institute | Research Leader, Epidemiology of Highly Pathogenic Microorganisms | Germany

Balakrishna Pisupati
The Deja Vu Moment in Promoting One Health
United Nations Environment Programme (UNEP) | Head, Environmental Law and Conventions Programme | Kenya
The concept of ‘One Health’ has been defined as “the collaborative effort of multiple disciplines – working locally, nationally and globally – to attain optimal health for people, animals and the environment.”

This session not only aims to link across disciplines, but also across continents and events – from the United Nations Environment Assembly held in Nairobi, Kenya, in May 2016 (web.unep.org/unea), to the One Health EcoHealth congress scheduled for Melbourne, Australia, this coming December (oheh2016.org).

Indeed, we hope the outputs of this session will feed into a satellite symposium in Melbourne on ‘Combating emerging infections at the source: from early detection to effective intervention strategies’.
WORKSHOP

WS18
ROOM 4 | STRESEMANN
14:00 – 15:30
OVERFLOW SCREEN 4

FOSTERING OPEN SCIENCE IN GLOBAL HEALTH
THE CASE OF PUBLIC HEALTH EMERGENCIES

HOSTS
Centre Virchow-Villermé for Public Health
M8 Alliance: Charité – Universitätsmedizin Berlin

CHAIRS
Antoine Flahault
World Health Summit President
University of Geneva | Director, Institute of Global Health | Switzerland

Tobias Kurth
Charité – Universitätsmedizin Berlin | Director, Institute of Public Health | Germany
Centre Virchow-Villermé (CVV) | Co-Director | Germany

SPEAKERS
Michael Baffi
The Role of Open Detection Platforms and Analytics in Outbreak Mitigation
Thermo Fisher Scientific Inc. | Global Director, Public Health | United States of America

Alpha Ahmadou Diallo
Why Both Public and the Scientific Community Benefits From Sharing.
Ministry of Health | Head of Department | Guinea

Katherine Littler
Funders’ Strategies to Foster Collaboration in Global Health
Wellcome Trust | Senior Policy Adviser | United Kingdom

Ben Meghreblian
OpenTrials: An Open, Linked Database of Information About the World’s Clinical Trials
Open Knowledge International | Community Manager, OpenTrials | United Kingdom

Ali Sié
Researcher’s Perspective: The Importance of Open Science in a Global Health
Research Center for Health of Nouna | Director | Burkina Faso
This Workshop aims to address collaboration and open dialogue in Global Health related research using the example of data and results sharing during public health emergencies. In February 2016, the World Health Organization has declared that the clusters of brain-damaged babies born in Brazil - linked to but not yet proven to be caused by the Zika virus - constitute a public health emergency of international concern.

This became the first test to the proposed WHO global norm of transparent sharing of data and results during public health emergencies - only weeks after publishing the results of this consultation.

Key questions to be discussed:

- What can we learn from past public health emergencies?
- How can open research approaches improve the management of global health crisis?
- What is the role of each actor in this area of open science/research?
WORKSHOP

NEXT GENERATION MEDICAL LOGISTICS
THE ROLE OF UAVS IN OVERCOMING SUPPLY CHAIN CHALLENGES

HOST
KfW Development Bank

CHAIRS
Annika Calov
KfW Development Bank | Head, Health Education & Social Protection | Germany

Ambassador Hinrich Thölken
Permanent Representation of the Federal Republic of Germany to the International Organisations in Rome | Ambassador | Italy

SPEAKERS
Andreas Bicking
Technical Possibilities/Requirements of UAVs – Role of Commercial Providers
DHL Parcel | Vice-President, DHL Product Development | Germany

Wolfgang Herbinger
Logistics for a Sustainable Development in Global Health
UN World Food Programme WFP | Senior Advisor, Pandemic Supply Chain | Italy

Jonathan Ledgard
Bridging the Middle Mile in Health Supply Chains With UAVs
Afrotech-EPFL | Director | Switzerland

Oriol Lopez
Sustainable Operation of UAVs on the Last Mile of Health Supply Chains
Médecins Sans Frontières (MSF) | Field Logistician | Spain

DISCUSSANTS
Gregory Rockson
mPharma Data Inc. | Chief Executive Officer | Ghana

Daniel Shoukimas
mPharma Data Inc. | Chief Product Officer, Co-Founder | Israel
Worldwide, at least 400 million people do not have access to essential health services, many of them in rural hard-to-reach regions. This is a major impediment to achieving Universal Health Coverage (UHC). Amongst others, overcoming it requires reliable transport links between remote health centers and provincial/central hospitals. Technologically, this is now realistic.

Unmanned Aerial Vehicles (UAVs) can contribute to solving the existing supply chain challenges by making deliveries of urgently needed, lifesaving supplies to off-grid communities faster and cheaper while allowing for better tracking. Initial pilot payload delivery projects utilizing UAVs were launched in e.g. Rwanda, Papua New Guinea and Germany. The planned session aims at bringing experts (e.g. innovators, developers, industry, governments, NGOs) with practical experience together to share lessons learned for future cargo UAV medical applications.

Besides the technical and regulatory aspects, ways of embedding the technology into the existing health infrastructure, as well as locally sustainable business models will be discussed.
KEYNOTE

TECHNOLOGICAL INNOVATION FOR HEALTH
IMPROVING HEALTHCARE DIAGNOSTICS AND DELIVERY

HOSTS
M8 Alliance:
Clinical Research Institute Montreal (IRCM)
Royal Philips NV

CHAIR
Tarik Möröy
Clinical Research Institute Montreal (IRCM) | President and Scientific Director | Canada

SPEAKERS
Jutta Allmendinger
The World We Live to See. How People Picture Futures of Health Technology
Berlin Social Science Center (WZB) | President | Germany

Yukiya Amano
The Role of Nuclear Technology and the IAEA Contribution to Expanding Access to Quality Health Care in Developing Countries
International Atomic Energy Agency | Director-General | Austria

Pascale Ehrenfreund
Space Research for Health Applications
German Aerospace Center (DLR) | Chairman of the Board | Germany

Lloyd B. Minor
The Precision Health Revolution: From Silicon Valley to the World
Stanford University | Dean, School of Medicine | United States of America

Steve Singh
The Power of the Network: Lessons from the World of Modern Business Applications
SAP SE | President, Business Networks and Applications | United States of America

Frans van Houten
Creating Healthcare Systems for All
Royal Philips NV | Chief Executive Officer | Netherlands
Successful health care delivery requires effective medical devices as tools for prevention, diagnosis, treatment and rehabilitation. As the digital and genetics revolutions converge with healthcare we are increasingly able to track, manage, and improve both our own health and that of our loved ones. Technological innovation in the field of health is also helping to reduce inefficiencies in healthcare delivery, while at the same time streamlining access, reducing costs, improving quality and making medicine more personalized and precise.

The essential elements that are making this development a reality include wireless devices, hardware sensors and software sensing technologies, micro-processors and integrated circuits, the Internet, social networking, mobile and body area networks, health information technology, genomics, and personal genetic information.

Despite the exponential growth of scientific and technological development, low- and middle-income countries are still largely excluded from access to appropriate and affordable health technologies. Therefore novel technological devices need to be developed that can address health problems and improve quality of life. Of particular interest are technologies that have the ability to enhance the access to essential health products and services leading to improved health for the population most in need.
PANEL DISCUSSION

THE CONTRIBUTION OF BIOLOGIC MEDICINES TO PUBLIC HEALTH

HOSTS

F. Hoffmann-La Roche Ltd.
World Health Summit

SPEAKERS

Paul Declerck
Focus on the Biologics' Story
KU Leuven University | Dean, Faculty of Pharmaceutical Sciences | Belgium

Axel C. Mühlbacher
Focus on the Health Economics
Hochschule Neubrandenburg | Professor, Health Economics and Healthcare Management | Germany

Brendan Shaw
Focus on the Value to Public Health
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Assistant Director General | Switzerland

Durhane Wong-Rieger
Focus on the Patient Perspective
International Alliance of Patients’ Organizations | Past Chair | United States of America

CHAIRS

Janis Bernat
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Associate Director, Biotherapeutics & Scientific Affairs | Switzerland

Matthias Wienold
International Alliance of Patients Organizations | Board Treasurer | United Kingdom

KEYNOTE

Georg Marckmann
Current and Future Role of Biologics
Ludwig Maximilians University Munich | President, Institute for Ethic, History and Theory in Practice | Germany
This Session will feature panel presentations and facilitated discussion to discuss stakeholders perspectives, roles and responsibilities in ensuring sustainability of innovation. Listen to perspectives from: the clinic, the patient community, industry, and health economics:

- The role of biologics in addressing complex and hard to treat diseases such as cancer and the overall value offered by this class of medicines to patients, their caregivers, and their healthcare providers.
- The special characteristics of biologics that hold implications for decisions regarding R&D, approval and use
- What is being done to expand appropriate patient access to needed biologic medicines in a financially sustainable way and what more can be done.
- How stakeholders can work together to ensure that the appropriate use of biologics deliver maximum benefit and value to patients and societies and preserve incentives for continued innovation.
SOCIAL EVENT

WHN NIGH AT THE
ALLIANZ FOU RM BERLIN

HOST

M8 Alliance

SPEAKER

Hermann Gröhe
Federal Ministry of Health
(Bundesministerium für Gesundheit BMG) |
Federal Ministry of Health | Germany
After two days of intense work with fellow World Health Summit participants from all over the world, take an evening to relax at the WHS Night, right next to Brandenburg Gate.

Highlight of this event will be the WHS Startup Track Award Ceremony: German Federal Minister of Health Hermann Gröhe will award the winner and finalists.

Snacks and drinks will be served, whilst a DJ will satisfy the needs of those who wish to dance. A shuttle service will be available for transportation between the Summit venue and the AllianzForum, where the WHS Night will be hosted.

Please note that you must register separately (www.registration-whs.com/) to attend the WHS Night, taking place at the Allianz Forum Berlin (Pariser Platz 6). There is a €39 entrance fee.
SUMMIT PROGRAM

TUESDAY, OCTOBER 11
PANEL DISCUSSION

VALUE IN HEALTHCARE

DRIVERS OF SYSTEM REFORM

HOSTS

The Boston Consulting Group (BCG) | World Economic Forum

CHAIRS

Stefan Larsson
The Boston Consulting Group (BCG) | Senior Partner & Managing Director | Sweden

Olivier Oullier
World Economic Forum | Head, Strategy, Global Health and Healthcare | Switzerland

SPEAKERS

Eric Hans Eddes
The Dutch Acceleration to Value-Based Healthcare – Establishing a National Platform
Dutch Institute for Clinical Auditing (DICA) | Director | Netherlands

Norbert Hauser
Challenges in Emerging Markets and Opportunities for Leapfrogging
The Global Fund to Fight AIDS, Tuberculosis and Malaria | Chairman of the Board of the Board | Switzerland

Paul Hudson
Rethinking the Role of Pharma in Improving Healthcare Value
Novartis Pharmaceuticals | Chief Executive Officer | Switzerland

Jan Kimpen
Digital Innovation to Address Barriers in Both Emerging and Developed Markets
Royal Philips NV | Chief Medical Officer | Netherlands

Christina Rångemark Åkerman
Outcomes Measurement is the Foundation – From Standardization to Implementation
ICHOM International Consortium for Health Outcomes Measurement | President | United States of America
What is the issue?
Global healthcare spending has reached an estimated USD 7–8 trillion, a third of which is reported to be “wasted”. The misalignments of incentives, interests, strategies and behaviours of parties engaged in healthcare delivery (i.e. policy makers, regulators, private sector, R&D, providers, suppliers and individuals) are at the core of this inefficiency. Healthcare – in countries where people can benefit from it – is therefore imprecise and inequitable. The misalignments amongst healthcare stakeholders have led to dead ends at the financial (unsustainable costs), human (outcomes far from delivering the expected quality of care) and systemic levels (high degrees of variability between delivery systems).

How can this issue be addressed?
What is known as value-based healthcare (VBHC) has aimed to redefine how care is organized, measured, and reimbursed. Today, the concept is pushed further with the massive spread of technology, systems and devices allowing for almost real-time evidence-informed strategies and decision-making in healthcare that, in principle, could allow tailoring of care to the needs and differences of each individual and ecosystem.

What is the role of the World Economic Forum?
The World Economic Forum is The International Organization for Public-Private Cooperation. In this capacity, the Forum has initiated a project “Value in Healthcare,” in collaboration with the Boston Consulting Group. The project’s goal is to develop global roadmaps toward value-based healthcare while initiating transformative pilots to accelerate system-level change. To date, the team has identified 5 core building blocks of a value-based healthcare system

1. Focus on defined populations segments
2. Measurement of value: both outcomes and costs
3. Population interventions along the fully cycle of care
4. Payments and incentives aligned to value
5. Continuous improvement

While these building blocks are now well defined, the question remains as to how public-private cooperation can most effectively drive system reform toward achieving these critical building blocks.
WORKSHOP

WS20
ROOM 2 | BRANDT
09:00 – 10:30
OVERFLOW SCREEN 2

BETTER LEADERSHIP: IMPROVED HEALTHCARE
YOUNG PHYSICIAN LEADERS: “THE LEADERSHIP WE WANT”

HOSTS
European School of Management and Technology (ESMT)
InterAcademy Partnership for Health (IAP)
M8 Alliance
Young Physician Leaders (YPL)

CHAIRS
Jo Ivey Boufford
New York Academy of Medicine | President | United States of America

Thomas Zeltner
Swiss Academy of Medical Sciences | Head, International Affairs | Switzerland

SPEAKER
Nora Ilona Grasselli
ESMT–European School of Management and Technology GmbH | Program Director | Germany

SELECTED
YOUNG PHYSICIAN LEADERS
Successful institutions need good leaders. And whether they are in high income countries or poorer countries, institutions providing healthcare, educating future physicians or promoting the public’s health are no different. Yet decision-makers in such institutions are often appointed from among people trained in medicine, not leadership.

The Inter-Academy Partnership (IAP for Health) Young Physician Leaders (YPL) programme aims to bridge this gap. Launched in 2011, to date some 107 young physicians from more than 30 countries have participated in 5 international and one regional edition of this personalized leadership training programme (a dedicated IAMP YPL Directory is available here: www.iamp-online.org/iamp-young-physician-leaders-directory). In addition, a group of alumni were introduced to the recent World Health Assembly in Geneva.

IAP for Health YPL training events take place immediately prior to WHS meetings. This session will be designed by the 20 participants of the 2016 event taking place on 7–9 October. Discussions will likely focus on leadership challenges for young physicians and their solutions in countries with different socio-economic conditions. The session is open to everyone – students, young medical personnel at the start of their careers, as well as delegates holding more senior positions.
WORKSHOP

STRENGTHENING HEALTH SYSTEMS FOR EDUCATION AND TRAINING
CAPACITY BUILDING THROUGH MULTI-STAKEHOLDER PARTNERSHIPS

HOSTS
Association of Research-Based Pharmaceutical Companies (vfa)
Joint Conference Church and Development (GKKE)

CHAIRS
Gertrud Casel
Joint Conference Church and Development (GKKE) | Director-General, Catholic Division | Germany

George M. Kuria
Boehringer Ingelheim Kenya | Key Account Manager | Kenya

SPEAKERS
Karim Bendhaou
Education and Training to Fight Counterfeit Drugs in Resource-poor Settings
Merck S.A.R.L | Managing Director, North West Africa Group Merck KGaA | Tunisia

Maria Kipele
The Education of a Neuro Surgeon in Tanzania – Perspectives and “Brain Gain”
University Würzburg | Scholar KAAD | Germany

Bernhard Köhler
The Importance of Trilateral Multi-Stakeholder Dialogue in Development Policy
Medical Mission Institute Würzburg | Medical Consultant | Germany

Wilson Mlaki
PPPs in Education & Training of Non-Academic Pharmaceutical Staff
Saint Luke Foundation | Executive Director | Tanzania

Elisabeth Shekhalage
Challenges in the Education, Training and Employment of Non-Academic Pharma Staff
Government of Tanzania | Registrar, Pharmacy Council | Tanzania
The session aims at highlighting the contribution of a cross-sector cooperation of different stakeholders in education and training in several areas of the healthcare sector with the aim of strengthening the health sector. The organizers are representatives of faith-based organizations and the research-based pharmaceutical industry.

There is a focus on the education of skilled non-academic pharmaceutical staff in pharmaceutical distribution in Tanzania (pharmaceutical dispensers, assistants and technicians). Dr. Kipele is an example of a young Tanzanian physician who is a candidate to work everywhere in the world. What are the challenges in her education and work, what are her perspectives? The specific challenges of fighting counterfeit drugs in resource-poor settings is the third area that this session highlights.

In all the addressed issues the cross-sectoral cooperation of multi-stakeholder partnerships (government, civil society and private sector) is the underlying principle. The needs, opportunities and challenges of such cooperations for development policy may be part of the discussion in this session.
WORKSHOP

POLIO ERADICATION

HOSTS

M8 Alliance: The Graduate Institute Geneva – Global Health Center

CHAIR

Stephen Matlin
The Graduate Institute of International and Development Studies | Senior Fellow, Global Health Center | Switzerland
Imperial College London | Adjunct Professor | United Kingdom

SPEAKERS

Nellie Bristol
Center for Strategic & International Studies (CSIS) | Senior Fellow, Global Health Policy Center | United States of America

Ambassador Suraya Dalil
Permanent Mission of Afghanistan to the United Nations Office | Ambassador | Switzerland

Ilona Kickbusch
The Graduate Institute of International and Development Studies | Director, Global Health Center | Switzerland

Matshidiso Rebecca Moeti
World Health Organization (WHO) | Regional Office for Africa | Regional Director | Botswana
The endgame of polio eradication (final interruption of wild poliovirus transmission is targeted by the end of 2016) has presented technical and financial challenges and also the need to overcome social, political, religious and cultural hurdles in the last disease-endemic countries (Afghanistan and Pakistan).

There are critical issues to be tackled in learning the lessons of this 30-year effort and ensuring that the legacy of polio eradication is captured at both national and global levels.

This session will present the results of a one-year study of the polio endgame lessons and legacy and will provide the opportunity following the presentation of research findings to comment and debate how these can best be used for the benefit of national health systems and global health and the implications for health governance.

The session will include a brief presentation summarising the key study findings and reactions from a distinguished panel (45 min); and a dialogue with the audience (45 min).
WORKSHOP

CARdiovascular Diseases
THE HYPERTENSION Paradigm

HOSTS
M8 Alliance:
Charité – Universitätsmedizin Berlin
European Society of Cardiology
German Heart Institute Berlin

CHAIR
Axel Radlach Pries
Charité – Universitätsmedizin Berlin | Dean | Germany

SPEAKERS
Ann Aerts
Novartis Foundation | Director | Switzerland

Daniel T. Lackland
World Hypertension League | President | United States of America

Stefan M. Schulz
University Würzburg | Post-Doc, Psychology | Germany
Hypertension is quantitatively the most important risk factor for premature cardiovascular disease, being more common than cigarette smoking, dyslipidemia, and diabetes, which are other major risk factors. Hypertension accounts for an estimated 54 percent of all strokes and 47 percent of all ischemic heart disease events globally. Since hypertension does not evoke direct symptoms and may thus remain unnoticed by the individual patient it has been named the 'silent killer'. Hypertension increases the risk for a variety of cardiovascular diseases, including stroke, coronary artery disease, heart failure, atrial fibrillation, and peripheral vascular disease with coronary disease in men and stroke in women being typical first cardiovascular events noted after hypertension onset. In view of the evidence that the hypertension incidence and hypertension related mortality rates are rising even in younger people, greater attention must be given to prevention, diagnosis and treatment of this disease.
KEYNOTE

TRANSLATIONAL RESEARCH
ADVANCING INNOVATIVE TREATMENT

HOSTS
Berlin Institute of Health (BIH)
M8 Alliance:
Monash University
M8 Alliance:
National University of Singapore (NUS)

CHAIR
Christina Mitchell
Monash University | Academic Vice-President & Dean, Faculty of Medicine Nursing & Health Sciences | Australia

SPEAKERS
Elizabeth Blackburn
It is really a Two-Way Street
Salk Institute for Biological Studies | President | United States of America

Dario Campana
Cell Therapy of Cancer
National University Cancer Institute | Director, Immunopathology and Cell Therapy | Singapore

Angelika Eggert
Personalized Medicine Approaches in Pediatric Oncology
Charité - Universitätsmedizin Berlin | Director, Department of Pediatrics, Division of Oncology and Hematology | Germany

Stephen M. Jane
Novel Therapies for the Hemoglobinopathies
Monash University | Head, Central Clinical School | Australia
Translational research helps turn early-stage innovations into new health products, advancing the innovation to the point where it becomes attractive for further development by the medical industry or healthcare agencies. Although research in academia and in companies produces many new discoveries and inventions that have the potential to improve health, turning those ideas into deliverable products can prove extremely difficult.

This calls for an additional strategy in translational research, securing the translation of results from clinical studies into everyday clinical practice and health decision making, while ensuring that new treatments and research knowledge actually reach the patients or populations for whom they are intended. This development is a two-way street; basic scientists therefore have to provide clinicians with new tools for use in patients and for assessment of their impact, and clinical researchers need to make novel observations about the nature and progression of disease that often stimulate basic investigations.

Central for this is the effective translation of the new knowledge, mechanisms, and techniques generated by advances in basic science research into new approaches for prevention, diagnosis, and treatment of disease, so that the essential goal of improving health from bench to bedside can be reached.
WORKSHOP

WS28
ROOM 5 | RATHENA U
12:45 - 13:45
OVERFLOW SCREEN 5

ACTION: SDG – ALL FOR HEALTH EQUITY
INTERSECTORAL ACTIONS TOWARDS SDGS

HOST
World Health Organization (WHO)

CHAIR
Nicole Valentine
World Health Organization (WHO) I Senior Technical Officer, Department of Public Health, Environmental and Social Determinants of Health, Switzerland

SPEAKERS
Julian Fisher
THEnet Training for Health Equity | Director, Advocacy and Networks | Germany

Ilona Kickbusch
The Graduate Institute of International and Development Studies | Director, Global Health Center | Switzerland

Charlotte Marchandise
City of Rennes | Deputy Mayor for Health | France

Martina Merten
Ärzte Zeitung Verlags GmbH | Healthcare Journalist | Germany

Viktoria Sargsyan
World Vision International | Health Learning Hub Lead, Regional Health and HIV Unit | United Kingdom

Michaela Told
The Graduate Institute of International and Development Studies | Executive Director, Global Health Programme | Switzerland
The World Health Organization (WHO) Social Determinants of Health (SDH) unit is seeking to scale-up globally available e-based information services on the SDH. It is therefore supporting coordination between different e-platform and SDH information services providers, considered as leaders in the field of SDH. Numerous tools developed in previous years by these providers (including WHO) share the principles of the 2030 Sustainable Development Agenda and therefore can be helpful for the accomplishment.

For that purpose Action:SDG SharePoint platform has been under development, able to provide all these and advance (where needed) action-oriented information services on the social determinants of health framed into the context of the Sustainable Development Goals. It is user-oriented platform, offering a common logic model for action on the SDH to key stakeholders with an influence to people’s health and health equity.

The World Health Summit, as a multi-stakeholder conference, is recognized as a great opportunity to present this valuable platform to broader audiences, gain their interest in further collaboration for the action on the SDGs, as well as receiving suggestions for the platform’s improvement. With this idea, WHO/SDH Unit is organizing a panel with academic, government and private sector representatives, elaborating their experiences, views and potential contributions framed into the logic model of the Action:SDG platform.
PANEL DISCUSSION

ANTIMICROBIAL RESISTANCE

INNOVATIONS IN ANTIMICROBIAL RESEARCH AND DRUG DEVELOPMENT

HOST

German Federal Ministry of Health (BMG)

CHAIR

Lothar Wieler
Robert Koch Institute | President | Germany

SPEAKERS

Helge Braun
Federal Chancellery | Minister of State | Germany

Peter Hammann
Sanofi-Aventis Deutschland | Head, Therapeutic Area Infectious Diseases (TA ID) | Germany

Line Matthiessen-Guyader
European Commission | Head of Fighting Infectious Diseases and Global Epidemics, Research and Innovation | Belgium

Jim O’Neill
The Review on Antimicrobial Resistance | Chairman of the Board | United Kingdom

Jaqueline Shea
Aeras | Chief Executive Officer | United States of America

Marc Sprenger
World Health Organization (WHO) | Director, Antimicrobial Resistance Secretariat | Switzerland

Bernd-Alois Tenhagen
Federal Institute for Risk Assessment (BfR) | Private Lecturer, Biological Safety | Germany
The increasing development of resistance of pathogenic microorganisms is one of the major challenges in medical care for the next decade. The intensified exchange of knowledge strongly supports the research of pathogens, resistance mechanisms and new drug target and is therefore one prerequisite for developing innovative approaches for antimicrobial treatments.

In this respect, the German Ministry of Health will host an international network conference as a back-to-back event to the World Health Summit 2016 to expand existing networks between international experts. The primary goal of the event is to provide a sustainable basis for a multilateral knowledge transfer between related players, complementing already existing networks.

Focusing on the “one health approach”, to which the G7 Health Ministers have committed to in 2015, interdisciplinary experts will discuss the context of uprising resistances, the availability of antibiotics and the use of antimicrobial drugs in human and veterinary medicine, the role improved tuberculosis vaccines can play in the fight against antimicrobial resistance. Health care scientists from academia and drug industry, agriculture and veterinary experts and scientists as well as regulatory authorities and international organisations will aim for promising approaches and possibilities to overcome hurdles to foster efficiency and transparency in health care, science and the veterinary use of antibiotics. Exchange about the current state of science, e.g. of new diagnostics and vaccines and their impact for veterinary and human medicine, shall result in tangible outcomes e.g. a list of the most threatening microorganisms.

This session will consist of an open discussion following the outcome of the Global Expert Network Conference on innovations in antimicrobial drug research and development, Berlin, 10 October. Active participation of the audience is very welcome.
WORKSHOP

STRATEGIC PRIORITIES IN R&D FOR GLOBAL HEALTH

HOSTS
European Commission and the Horizon 2020 Scientific Panel for Health
KU Leuven University

CHAIR
Karin R. Sipido
University Leuven | Head, Experimental Cardiology | Belgium

SPEAKERS
Bernhard Fleckenstein
Friedrich Alexander University Erlangen-Nürnberg | Professor Emeritus, Virology | Germany

Ildiko Horvath
National Koranyi Institute for Pulmonology | Strategic Director | Hungary

Michael J. Klag
Johns Hopkins Bloomberg School of Public Health | Dean | United States of America

Tana Wuliji
World Health Organization (WHO) | Technical Officer, Health Workforce | Switzerland
The European Commission’s Scientific Panel for Health (SPH) is a science-led expert group based on the provisions of the Horizon 2020 Specific Programme that has been tasked with helping to achieve better health and wellbeing for all. The changing parameters in health and disease prevention (chronic diseases, infectious diseases, mental disorders and an aging population) are expected to decrease the labor force and raise healthcare costs around the globe.

Therefore international discussions on health research priorities are warranted because of the concern about loss of competitiveness and a reduced drive towards innovation. Efforts for setting strategic priorities in R&D for Global Health have to be made because of the transnational dimension of research, with distributed expertise and human resources, infrastructure, and the need to reach critical mass. To address these concerns, strong input from the international scientific and stakeholders community is needed.

In 2015 the SPH set out its vision on the future of health and biomedical research in a working document that described future challenges and proposed a way forward through intensified cross-border collaboration.

To further build on these recommendations the SPH wishes to connect more directly to the stakeholders in health research through an interactive workshop taking place at the World Health Summit, discussing strategic priorities with representatives from international research organizations.
WORKSHOP

DATA WAREHOUSE SYSTEMS
AS A BASIS FOR PRECISION MEDICINE

HOST

German Centers for Health Research (DZG)

CHAIR

Werner Seeger
German Center for Lung Research (DZL) | Chairman of the Board | Germany
University Hospital Giessen | Medical Director | Germany

SPEAKERS

Erwin Paul Böttinger
Berlin Health Data Platform for Systems Medicine and Digital Health
Berlin Institute of Health (BIH) | Chairman of the Board | Germany

Roland Eils
Data Warehouse Systems at the German Centers for Health Research (DZG)
German Cancer Research Center DKFZ | Head, Theoretical Bioinformatics | Germany

Hans-Ulrich Prokosch
Reforming Medical Informatics in Germany – Basis for Precision Medicine
University Hospital Erlangen | Chief Information Officer | Germany
FAU Erlangen-Nürnberg | Chair of Medical Informatics | Germany

Fabian Theis
From Data Storage to Data Mining in Biomedicine
Helmholtz Zentrum Munich | Director, Institute of Computational Biology | Germany
TU Munich | Associate Professor, Mathematical Modelling of Biological Systems | Germany

DISCUSSANTS

Thomas Eschenhagen
University Hospital Hamburg-Eppendorf | Director, Experimental Pharmacology and Toxicology | Germany

Martin Hrabé de Angelis
Helmholtz Zentrum Munich | Director, German Center for Diabetes Research | Germany
Quantity and quality of health data is growing rapidly. In order to utilize data warehouses for biomedical research and patient care, open access and interchange of data are mandatory. This is particularly true for the German Centers for Health Research (DZG), devoted to translational research with the common goal to combat the leading diseases causing modern era morbidity and mortality.

Distinguished keynote speakers will introduce the audience to the hot topics of the field: volume/velocity/variety challenges, quality management and reproducibility of data in the field of data warehouses. Conclusively, implications for cooperative research initiatives will be discussed in order to achieve important progress towards precision medicine.

The six DZG (German Centers for Cardiovascular Research, Diabetes Research, Infection Research, Lung Research, Neurodegenerative Diseases, and German Consortium for Translational Cancer Research) are funded by the German Federal Ministry of Education and Research (BMBF) and the ministries of the German Federal States of the partner sites. The DZG are structured as long-term partnerships between universities with university hospitals and non-university research institutions and throughout Germany, focusing on the prevention, diagnosis and treatment of widespread diseases.
WORKSHOP

WS26
ROOM 4 | STRESEMANN
14:00–15:30
OVERFLOW SCREEN 4

GENDER RESPONSIVE GOVERNANCE
A KEY PILLAR FOR WOMEN’S HEALTH AND EMPOWERMENT

HOSTS

Women in Global Health
USAID

CHAIRS

Roopa Dhatt
Women in Global Health | Co-Founder and Director | United States of America

Sally Theobald
Liverpool School of Tropical Medicine | Chair, Social Science and International Health | United Kingdom

SPEAKERS

Lourdes de la Peza
How Can Women’s Leadership Capacity be Developed?
Management Science for Health (MSH) | Principal Technical Advisor, Management and Leadership | United States of America

Temitayo Ifafore-Calfee
(Wo)man in the Mirror: 5 Strategies to Educate Yourself About Reducing Gender Discrimination and Promoting Gender Equality in the Health Workplace
USAID/PHI | Technical Advisor, Health Workforce | United States of America

Désirée Lichtenstein
How do we Work Gender Equally for Gender Equality
Women in Global Health | Co-Founder | Sweden

Niyati Shah
HOW Do We Integrate Gender into Programming: Operationalizing = Getting to Equal
USAID | Senior Gender Advisor, Global Health Bureau | United States of America
Women play a vital role in the advancement of global health, yet men still remain the majority holders of leadership positions. Leadership is key for improving performance, strengthening workforce capacity, enhancing connections with target populations, and increasing the ability to respond effectively to change and thus key to achieving sustainable development goals (SDGs) targets.

The Women Leaders in Global Health Initiative, a joint initiative of Women in Global Health and the Global Health Council, envisions a world where women are represented in equal numbers to men at the highest levels of decision making and visibility.

The initiative strives to address the individual, institutional and political challenges that impede women’s positioning as leaders in global health through strategic advocacy, networking, mentorship and capacity building.
WORKSHOP

IMPLEMENTING THE HEALTH-RELATED SDGS
BRIDGING THE GLOBAL-NATIONAL GAP

HOSTS
M8 Alliance: The Graduate Institute Geneva – Global Health Center
Think Tank Initiative Canada (TTI)

CHAIRS
Ilona Kickbusch
The Graduate Institute of International and Development Studies | Director, Global Health Center | Switzerland

Peter Taylor
International Development Research Centre (IDRC) | Associate Director, Think Tank Initiatives | Canada

SPEAKERS
Johanna Hanefeld
Ensuring Intersectoral Action to Achieve the SDGs, the Trade and Health Agenda – What Role for Think Tanks and Universities?
London School of Hygiene & Tropical Medicine | Head of Anthropology, Politics and Policy Group, Global Health and Development | United Kingdom

Ashish K. Jha
Translating the Global to the National: What Accountability Frameworks Does the Global Community Have or Need to Create to Accelerate SDG implementation?
Harvard T.H. Chan School of Public Health | Director, Harvard Global Health Institute | United States of America

Christian Kroll
The SDG Index and Major Regional Challenges to SDG Implementation – How can Think Tanks and Academic Institutions Help Fill these Gaps?
Bertelsmann Foundation and SDSN | Scientific Director, SDG Index | Germany

Joy Phumaphi
Setting Priorities and Ensuring Accountability for SDG Implementation at the National Level – What Role for Civil Society?
African Leaders Malaria Alliance (ALMA) | Executive Secretary | Tanzania
The Sustainable Development Goals (SDGs) set a global agenda for development but what is the added value of such an agenda for each country? How can a commitment be gained at national level to implement the SDGs, especially those related to health, and what are the means available at global level to exercise accountability? What is the role think tanks and academic institutions can play to bridge the gap between global and national?

This workshop will frame the debate around the available accountability mechanisms which could and should accelerate the implementation of the health-related SDGs. Given the great number of goals and targets which impact on health, accountability may work better at national level once priorities are set and may be far more challenging at global level: the implementation of the health-related SDGs requires to recognize them as a global responsibility and requires the application of a global public goods lens.
KEYNOTE

WOMEN, EMPOWERMENT AND HEALTH: EQUITY AND AGENCY
CLOSING CEREMONY

HOSTS

M8 Alliance: Clinical Research Institute Montreal (IRCM)
M8 Alliance: The Graduate Institute Geneva - Global Health Center
M8 Alliance: University Hospital Geneva
M8 Alliance: University of Geneva
M8 Alliance: University of Montreal

SPEAKERS

Karen Linehan
Sanofi | Executive Vice-President, Legal Affairs and General Counsel | France

Matshidiso Rebecca Moeti
WHO Regional Office for Africa | Regional Director | Botswana

Heidemarie Wieczorek-Zeul
Friends of the Global Fund Europe | Vice-President | France

CHAIR

Hélène Boisjoly
University of Montreal | Dean, Faculty of Medicine, | Canada
In recent decades, women’s empowerment and equity have been increasingly recognized as crucial components of efforts to achieve a myriad of health and development objectives. The empowerment and autonomy of women, and improvements in their political, social, economic and health status, are therefore becoming accepted as highly important ends in themselves.

Disparities in educational access, limited economic opportunities, and low relative status of women all shape women’s ability to control their health and their futures. Improving women’s agency is therefore essential not only for successful family planning and reproductive health, but also for improving development, and global organizations are increasingly taking note.

In addition, they are seen as essential for the achievement of sustainable development. Greater equality for girls in regard to health, nutrition and education is the first step in ensuring that women realize their full potential and become equal partners in development. Access to health and education is one of the most important means of empowering women with the knowledge, skills and self-confidence necessary to participate fully in the development process.
GENERAL INFORMATION
The World Health Summit will be taking place at the Federal Foreign Office. Please be advised that due to security reasons, all delegates will be subject to a security check including a passport identification confirmation.

Please be aware: You will not be able to enter the Summit venue, if you are not able to present your passport or ID-card. Unfortunately, this procedure may produce a slight delay for entrance into the building. We therefore kindly ask you to refrain from bringing your luggage to the Summit venue, as this will slow down the security check process.
HOW TO GET TO THE SUMMIT VENUE

Federal Foreign Office (Auswärtiges Amt)
Entrance: Unterwasserstraße 10

Arriving by public transportation:
• From the underground station “Spittelmarkt” (Line U2): Walk along the left side of the water canal. Shortly after the antique draw bridge, the Summit entrance will be on your left.
• From the underground station “Hausvogteiplatz” (Line U2): Turn into “Oberwallstraße”, turn right onto Werderscher Markt, go past the Auswärtiges Amt and turn right again directly afterwards. Continue along the side of the building to the Summit entrance.

Arriving by air:
• From Tegel Airport: Take the bus line X9 to “Ernst-Reuter-Platz”, connect to the underground line U2 in the direction of Pankow and exit at “Spittelmarkt”.
• From Schönefeld Airport: Take the S-Bahn (train) to “Friedrichstraße”, connect to bus line 147 in the direction of Ostbahnhof and exit at “Spittelmarkt”. Alternatively take the S-Bahn line S9 to “Schönhauser Allee”, connect to the line U2 (underground train) in the direction of Ruhleben and exit at “Spittelmarkt”.
• Transfer time by taxi is approximately 25 minutes from Tegel Airport and 50–60 minutes from Schönefeld Airport.

Arriving by train:
From Berlin Hauptbahnhof (main station): Take bus line 147 in the direction of U Märkisches Museum and exit at “Spittelmarkt”. Please check the area-map on page 123 for further orientation.
<table>
<thead>
<tr>
<th>Hotel Name</th>
<th>Address</th>
<th>Distance to Summit Venue</th>
<th>Category</th>
<th>Single Room</th>
<th>Double Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Westin Grand Berlin</td>
<td>Friedrichstraße 158–164</td>
<td>0.8 km</td>
<td>5*</td>
<td>€ 189.00</td>
<td>€ 209.00</td>
</tr>
<tr>
<td>2 Sofitel Berlin</td>
<td>Charlottenstraße 50</td>
<td>0.6 km</td>
<td>5*</td>
<td>€ 215.00</td>
<td></td>
</tr>
<tr>
<td>3 Arcotel John F.</td>
<td>Werderscher Markt 11</td>
<td>0.2 km</td>
<td>4*</td>
<td>€ 129.00</td>
<td>€ 159.00</td>
</tr>
<tr>
<td>4 Cosmo Hotel Berlin Mitte</td>
<td>Spittelmarkt 13</td>
<td>0.4 km</td>
<td>4*</td>
<td>€ 114.00</td>
<td>€ 124.00</td>
</tr>
<tr>
<td>5 Courtyard by Marriott Berlin</td>
<td>Axel-Springer-Straße 55</td>
<td>0.6 km</td>
<td>4*</td>
<td>€ 135.00</td>
<td>€ 145.00</td>
</tr>
<tr>
<td>6 Motel One Spittelmarkt</td>
<td>Leipziger Straße 50</td>
<td>0.4 km</td>
<td>2*</td>
<td>€ 76.50</td>
<td>€ 99.00</td>
</tr>
<tr>
<td>7 Radisson Blu</td>
<td>Karl-Liebknecht-Straße 3</td>
<td>0.9 km</td>
<td>5*</td>
<td>€ 149.00</td>
<td>€ 199.00</td>
</tr>
</tbody>
</table>

**VENUE:**
Federal Foreign Office
Werderscher Markt 1
10117 Berlin

**ENTRANCE:**
Unterwasserstraße 10

**CONTACT:**
Email: contact@worldhealthsummit.org
BERLIN -
A METROPOLIS FOR SCIENCE

Today, Berlin is not only Germany’s largest location for science and IT start-ups; the city can also look back at a 300-year tradition in medical research. More than a dozen Nobel Prize winners have worked here, including Rudolf Virchow and Robert Koch. One of its most famous medical institutions is the renowned Charité, Europe’s largest university hospital and one of Germany’s leading hospitals. The doctors and scientists at the Charité are well recognised in international medicine, and co-operate with foreign research institutes like the Johns Hopkins Bloomberg School of Public Health in Baltimore, USA.

Berlin has become one of Europe’s centres for start-ups and even major international players like Google are setting up in Berlin. The scene is well-linked with other cities like New York, Washington and San Francisco and also maintains strong links with Tel Aviv, the IT centre of Israel.

This environment makes Berlin a popular international destination for meetings and conventions: With 195 events hosted last year, the city is the top location choice for gatherings of international associations, as revealed in latest statistics by the “International Congress & Convention Association” (ICCA). It is the first time that Berlin is at the top of the list. In the last years, the German capital has also positioned itself as a location for events in science and medicine: fourteen per cent of the approximately 63,000 meetings, conventions and events held in the first half of 2016 were in the fields of medicine, science and research. International conferences such as the World Health Summit show that the German capital has been able to consolidate its strong position as a destination for medical events.

For more information about Berlin, go to convention.visitBerlin.com
Along with scientific conferences, Berlin also provides varied cultural experiences. From ancient art by the Old Masters to avant-garde design, from classical opera to musicals to pop concerts, Berlin’s cultural calendar leaves nothing to be desired. Visitors to the capital can choose from around 1,500 events a day.

Culture and art enthusiasts can also admire new styles and prominent works from all eras every day in Berlin’s over 180 museums and approximately 440 galleries. The city’s best known museums include the five buildings at Museum Island (Museumsinsel), which is in the historic centre. All buildings display valuable artistic treasures from 3000 years of human history, e.g. the famous bust of Nefertiti in the New Museum, while the New National Gallery and Martin-Gropius-Bau present contemporary art.

Berlin is the world’s only city to have three opera houses: the Berlin State Opera (Berliner Staatsoper), the Deutsche Oper and the Komische Oper. Classical music lovers can choose from a repertoire of famous works, such as Mozart’s Don Giovanni, or new and experimental operas. Apart from these opera houses, the city’s eight large orchestras, including the world famous Berlin Philharmonic conducted by Sir Simon Rattle, also make for high-class musical enjoyment.

Among the cultural highlights this year is “El Siglo de Oro: Spanish Painting and Sculpture of the 17th Century” at the Gemäldegalerie. The exhibition is an opportunity to become familiar with one of the most important periods of European cultural history.

Every autumn, two lighting festivals “Berlin leuchtet” and the “Festival of Lights” let the German capital shine in new, brighter colours. For more than two weeks, well-known landmarks such as the Brandenburg Gate, the TV Tower, and Berlin Cathedral become impressive canvases for the lighting artists.

For more events, visit events.visitBerlin.com
THE HOUSE ON WERDERSCHER MARKT

Since its return to Berlin in 1999, the Federal Foreign Office has been located in the “Haus am Werderscher Markt” (House on Werderscher Markt). After the former Tempelhof airport terminal, this is the second largest building in Berlin with its 550,000 m³ of enclosed space. Like many other buildings in Germany’s capital, the building and surrounding area is a Berlin icon which has witnessed Germany’s eventful and turbulent history.

**1690**
A court building was constructed to the southwest of Werderscher Markt.

**1765**
The “Royal Savings and Loan Bank”, (Königliche Giro- und Lehnbank) founded by Frederick the Great, moved into the building. Thanks to considerable economic growth and development in Prussia the following decades saw a number of modifications and extensions to the building.

**1846**
First as the “Prussian Bank” (Preußische Bank) and then starting in 1876 as the “Reichsbank” (Reichsbank) the building continued to grow until 1903 when it took up the entire block between Jäger-, Kur-, Oberwall- and Kleiner Jägerstraße.

**In 1913**
Even before the First World War, the premises of the “Reichsbank” were too small. In 1913 the bank began to buy land in the surrounding area.

**1932**
Plans were formulated for a new building close by, and two years later the foundation stone was laid.

**1940**
After six years of construction, the building was completed and the “Reichsbank” moved in, at which time its main task had changed to primarily funding the war. The new bank building was located on the opposite side of the road from Werderscher Markt, but a bridge was built between the two which provided access to the first floor of each building.
1945
During the Second World War the “Reichsbank” extension suffered severe damage. After the initial repairs were carried out, the “Berlin City Office” (Stadtkontor) took over several rooms in the house.

1949
In autumn, the Ministry of Finance of the newly-founded German Democratic Republic (GDR) took over the building.

1959
In summer, the Central Committee of the SED (Socialist Unity Party) moved in. With this move, the building on Werderscher Markt came to be at the center of political power in the GDR.

1989
In the course of the political demise of the GDR, the central committee of the SED was dissolved on December 8.

1990
In the first few weeks of the year, the house on Werderscher Market was vacated. A little later the building was renamed the “House of Parliamentarians” (Haus der Parlamentarier). This new name came about on March 18 when the members had a free election to select their new “People’s Chamber” (Volkskammer), which would now occupy the space.

1999
Thanks in part to the design by Berlin architects Thomas Müller and Ivan Reimann, a new building was added on Werderscher Markt to accommodate the Federal Foreign Office (Auswärtiges Amt). The two buildings are connected by a shared courtyard. A photovoltaic system on the roof of the older building with a connection to the newer building’s heating network provides an environmentally-friendly energy supply.

INTERIOR VIEWS – THE FEDERAL FOREIGN OFFICE

The old and new buildings of the Federal Foreign Office provide 62,500 m² office space for more than 2,000 employees. In addition, the two buildings house several conference halls, the political archives, medical and social services, a canteen, as well as the library.

The nerve center of the Federal Foreign Office is the old building erected in 1934, which served as the Reichsbank from 1934 to 1938. In 1959, the building became the headquarters of the Socialist Unity Party of Germany, the ruling party in the GDR. The Central Committee and the Politbüro met there. In 1995 it was decided to locate the Federal Foreign Office in this building and to add a new building on Werderscher Markt.
The new building was designed by the architects Thomas Müller and Ivan Reimann and constructed from 1997 to 1999. The transparent facade of glass and travertine stone invites visitors to enter the atrium and its visitor center, which is open to the public. All in all, the new building with its three partially open inner courts recalls the link between the old building and the Spree Canal, Schlossplatz and Werderscher Markt.

The architect commissioned to refurbish and alter the old building, Hans Kollhoff, faced a three-fold task. Firstly, he had to make it evident that Germany’s new foreign policy had nothing to do with the policies pursued in this building during the two German dictatorships. On the other hand, however, he could not simply wipe out all traces of the past. What is more, the building had to be redesigned to meet the Federal Foreign Office’s spatial and functional requirements.

To this end, Hans Kollhoff developed the three-layer concept. The first layer highlights the modern aspects of the old building, which should not be transformed solely as an embodiment of National Socialist architecture. The second layer preserves in an exemplary fashion the building’s design during the GDR era. For the third layer, a color concept which developed in collaboration with the artist Gerhard Merz whose large monochrome surfaces lend the building a modern flair.

**THE WELTSAAL (WORLD HALL)**

At the heart of the old building on the first floor lies a large conference center, almost 900m² in size. The former Reichbank Hall 1 was considerably altered for use by the SED leadership as a conference hall. During this process the luminous ceiling was covered over. When the Federal Foreign Office was refurbished, however, it was uncovered, as was the original wood paneling in the central part of the ceiling.

The entire room can be divided by a 9 meter high and 16 meter wide mobile partition. It was designed by Gerhard Merz as part of the three layer concept. The surface consists of numerous small squares in various colors. This deviation here in the Weltsaal from the monochrome surface principle applied in the rest of the Old Building was intended to highlight the world’s cultural diversity.

The lower part of the walls and the doors to the lounges are clad in German cherrywood. The interpretation booths, screened off from the hall, are situated on top. This screen is divided into three monochrome sections, each of which has a slim aluminum frame. The lower sections consist of black glass, the larger middle sections of a white screen, while the upper sections are mirrors.
ACCESS TO THE VENUE/SECURITY

To enter the World Health Summit venue (Federal Foreign Office), participants are required to present a valid identity card/passport or a similar personal identification document (photo included). Please be advised that due to security reasons, all participants will be subject to a security check including a passport identification confirmation. This procedure may cause a slight delay for entrance into the building. We therefore kindly ask you to refrain from bringing your luggage to the venue, as this will slow down the security check process.

AVAILABILITY

Please note that the capacity of the venue and of single session rooms is limited. If the maximum number of participants is reached, the organizers reserve the right to refuse access.

BERLIN WELCOME CARD

The Berlin WelcomeCard enables free travelling with all public transport services, discounts of at least 25% and up to 50% at around 200 participating partners, and a travel guide with various tour suggestions and insider tips. You can order your ticket at www.berlin-welcomecard.de/en

CLOAKROOM

A cloakroom will be open in the back of the venue (next to the “Weltsaal”) during the registration opening times.

COFFEE BREAKS

Refreshments will be served during the coffee breaks.

CURRENCY

The currency used in Berlin is the Euro (€ or EUR). Automated teller machines (ATMs), are located everywhere in Berlin and they accept most main credit cards such as Visa, Mastercard and American Express.

CASH POINT/ATM

BBBank eG Berlin
Hausvogteiplatz 3–4
10117 Berlin

EMERGENCY NUMBERS

Fire: 112
Ambulance: 112
Police: 110
FILMING AND TAKING PICTURES
The organizer will provide a broad spectrum of pictures and other graphical material for the representation of all World Health Summit events. These files will be made available at www.worldhealthsummit.org.

HOMEPAGE
For up-to-date information regarding the World Health Summit, please visit www.worldhealthsummit.org.

INSURANCE AND LIABILITY
The organizers cannot accept liability for personal injury, loss of or damage to belongings of participants, either during or as a result of the Summit. Please check the validity of your own insurance. Attendees are advised to arrange their own adequate travel and medical insurance for medical treatment, accidents, cancellation of bookings etc. No responsibility will be accepted by the World Health Summit organizers.

INTERNET/WIRELESS LAN
Complimentary Wi-Fi will be available within the venue:
Name: WorldHealthSummit
Password: #WHS2016

LANGUAGE
The official World Health Summit language is English. There will be no simultaneous translation.

LUNCHES
Lunches will be available during the lunch breaks.

MEDIA
Media representatives have access to all official sessions of the World Health Summit. Prior accreditation is required via www.worldhealthsummit.org/press-media/accreditation.

MOBILE PHONES
As a courtesy to speakers and other attendees, we kindly request that all mobile phones and similar devices will be turned to silent mode before entering a session.

NAME BADGE
A badge is required for admittance to all World Health Summit sessions and events. Each participant is asked to present the badge in order to gain access to the Summit.
PEOPLE WITH DISABILITIES

The venue is accessible to participants with disabilities. Please contact the Secretariat for assistance: Phone: +49 30 49855031 or contact@worldhealthsummit.org

LOST AND FOUND

Lost items can be collected at the registration desk during the Summit. Any objects found during the event and not claimed will remain at the venue.

LIVE-STREAM/WEBCASTS

All sessions in the “Weltsaal” and “Europasaal” will be available as live-stream at www.worldhealthsummit.org. Recorded webcasts will be available online after the event.

OVERFLOW

To serve the interests of all participants, Panel Discussions and Workshops will be available as live broadcasts on-site. Room 1 (“Europasaal”) will be broadcasted on screens in the “Europa-Foyer”, Workshop rooms 2–5 to screens 2–5 inside the “Weltsaal”.

PARKING

Please note that there are no public parking facilities at the venue.

PROGRAM CHANGES

The organizers cannot assume liability for any changes in the program due to external or unforeseen circumstances. Please check the website for regular updates. The organizers reserve the right to cancel, postpone, relocate or change any of the sessions.

POSTERS

A poster exhibition will be located at the poster area in front of Workshop rooms 2–5.

PUBLIC TRANSPORTATION

Berlin’s public transport provides safe and comfortable rides to almost all destinations in the city. Tickets can be purchased directly at most train stations and in all busses.

Fees:
Short Trip 1,70 € (max. 3 stations, one way only)
Single Trip AB 2,70 € (one way only)
Single Trip BC 3,00 € (one way only)
Single Trip ABC 3,30 € (one way only)
Day Ticket ABC 7,60 € (all directions)
(AB, BC, ABC are indicating the travel zone.) Detailed information regarding public transportation is available at www.bvg.de
### REGISTRATION

The registration desk is open during the following times:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, October 09, 2016</td>
<td>08:00 – 22:00</td>
</tr>
<tr>
<td>Monday, October 10, 2016</td>
<td>08:00 – 19:00</td>
</tr>
<tr>
<td>Tuesday, October 11, 2016</td>
<td>08:00 – 19:00</td>
</tr>
</tbody>
</table>

### SMOKING POLICY

It is forbidden to smoke in any part of the World Health Summit venue.

### SPEAKER CENTER

All speakers and presenters must report to the Speaker Center, located at the “Europasaal”, at least two hours prior to their presentation in order to check and upload their presentation. Please provide the data on a USB Memory Stick or a CD-ROM. Please note that you cannot run the presentation from your personal laptop in the session room. Video support is at the sole responsibility of the speaker.

The Speaker Center is open during the following times:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, October 09, 2016</td>
<td>08:00 – 18:00</td>
</tr>
<tr>
<td>Monday, October 10, 2016</td>
<td>08:00 – 18:00</td>
</tr>
<tr>
<td>Tuesday, October 11, 2016</td>
<td>08:00 – 18:00</td>
</tr>
</tbody>
</table>

### TAXIS

All official taxis are colored off-white with a yellow taxi sign on the roof. The meter starts at a set minimum price.

Major Taxi Hotlines:
- Taxi Berlin  +49 30 202020
- Taxi Würzelfunk  +49 30 210101
- Taxi Funk  +49 30 443322

If there is no taxi available, please ask the registration desk staff for assistance.

### TAXIS

All official taxis are colored off-white with a yellow taxi sign on the roof. The meter starts at a set minimum price.

Major Taxi Hotlines:
- Taxi Berlin  +49 30 202020
- Taxi Würzelfunk  +49 30 210101
- Taxi Funk  +49 30 443322

If there is no taxi available, please ask the registration desk staff for assistance.
**Media Registrations**

Media Registrations are available free of charge to journalists (pending proof of affiliation). Prior to the Summit, please establish your accreditation online via www.worldhealthsummit.org/press-media/accreditation.

During the Summit, please contact the media accreditation counter at the registration desk.

**Media Access**

Media has access to all official sessions of the World Health Summit.

**Media Office**

Location: Room “Europasaal”

Sunday, October 09, 2016 09:00 – 20:00
Monday, October 10, 2016 08:30 – 17:30
Tuesday, October 11, 2016 08:30 – 17:30

It is possible to arrange interviews with our speakers in a designated interview-area.

**PRESS CONTACT**

Tobias Gerber, Daniela Levy
tobias.gerber@charite.de
daniela.levy@charite.de
Tel.: +49 30 450 572 114

**PRESS CONFERENCE**

Date: Sunday, October 9, 15:15 – 16:00
Room: Brandt
WHS Foundation GmbH  
c/o Charité-  
Universitätsmedizin Berlin  
Charitéplatz 1  
10117 Berlin, Germany

WHS Presidents  
Antoine Flahault  
Detlev Ganten

Managing Directors  
Jörg Heldmann  
joerg.heldmann@charite.de  
Tel.: +49 30 450 572 118  
Fax: +49 30 450 517 911

Alexander Hewer  
alexander.hewer@charite.de

Program Director  
Julian Kickbusch  
julian.kickbusch@charite.de  
Tel.: +49 30 450 572 102  
Fax: +49 30 450 517 911

Press & Public Relations Director  
Tobias Gerber  
tobias.gerber@charite.de  
Tel.: +49 30 450 572 114  
Fax: +49 30 450 517 911

Strategic Communications  
Daniela Levy  
daniela.levy@charite.de  
Tel.: +49 30 450 572 114  
Fax: +49 30 450 517 911

Strategic Development  
Cara Pries  
cara.pries@charite.de

Secretariat  
Pascale Schulte  
pascale.schulte@charite.de

Conference Manager/Office Assistant  
Sarah-Maria Riedel  
sarah-maria.riedel@charite.de  
Tel: +49 30 450 572 219  
Fax: +49 30 450 517 911

PA to the Managing Director  
Petra Neitzel  
petra.neitzel@charite.de  
Tel: +49 30 450 572 219  
Fax: +49 30 450 517 911

Organizing Secretariat  
Agentur WOK GmbH  
Palisadenstraße 48  
10243 Berlin

Project Manager  
Julia Egloff

Registration Department  
Felix Heller, Anna Blattner
Dr. Adhanom Ghebreyesus was appointed Minister of Foreign Affairs in 2012. He is an internationally renowned malaria researcher who joined the Ministry of Health in 1986. As Minister of Health, he initiated health reforms that improved access to health services especially for women and children.

Dr. Fiona Adshead is Bupa’s Chief Wellbeing and Public Health Officer, and is responsible for the clinical leadership of partnerships, prevention and health promotion. She previously was Director of Chronic Disease and Health Promotion at the World Health Organization.

Dr. Ann Aerts has been Head of the Novartis Foundation since January 2013, where she has played a key role in devising new policy recommendations. In July 2014, she was nominated by PharmaVOICE as one of the 100 Most Inspiring People in the life science industry.

Dr. Christina Rångemark Åkerman is President of the International Consortium for Health Outcomes Measurement (ICHOM), a non-profit organization with the purpose to transform health care systems worldwide by measuring and reporting patient outcomes in a standardized way.

Prof. Jutta Allmendinger is President of the Berlin Social Science Center (WZB) and Professor of educational sociology and labor market research at Humboldt University Berlin. She has held both positions since 2007.

Dr. Yukiya Amano is Director-General of the International Atomic Energy Agency (IAEA), assuming office in 2009. He was endorsed by the IAEA General Conference for a second term as Director-General on 16 September 2013.
**Rosalinda Dimapilis-Baldoz**
Rosalinda Dimapilis-Baldoz is the former Secretary of Labor and Employment and a Commissioned Officer in the Reserved Force of the Philippine Army with the rank of Lieutenant Colonel. A Lawyer by training and holder of the Master Degree on National Security Administration.

**Janis Bernat**
Janis Bernat is currently Associate Director for the policy and technical work in the area of biotherapeutic and biosimilar medicines and leads the organization’s regulatory team. Prior to joining IFPMA, she worked for a US-based multi-national food company in quality assurance and regulatory compliance.

**Dr. Alain Berset**
Dr. Alain Berset is Federal Councillor and Head of the Federal Department of Home Affairs FDHA since 2012. He was President of the Council of States from 2008–2009 and Vice-President of the parliamentary Social Democratic Group from 2005–2011.

**Prof. Elizabeth H. Blackburn**
Prof. Elizabeth H. Blackburn, President of Salk Institute for Biological Studies, is a leader in the area of telomere and telomerase research. She won the Nobel Prize in Physiology or Medicine in 2009 for discovering the molecular nature of telomeres.

**Prof. Hélène Boisjoly**
Prof. Hélène Boisjoly is appointed Dean of Medicine at University of Montreal since June 2011. She is the first woman to hold the position of Dean of a Faculty of Medicine at both the University of Montreal (UdeM) and in the province of Québec.

**Prof. Erwin P. Böttinger**
Prof. Erwin P. Böttinger currently serves as Chief Executive Officer of the Berlin Institute of Health and Professor for Personalized Medicine at Charité – Universitätsmedizin Berlin. He is the PI of Mount Sinai’s landmark BioMe hospital-based Biobank where electronic health records for over 30,000+ patients can be linked with their genomic and molecular marker datasets.

**Dr. Helge Braun**
Dr. Helge Braun is Minister of State for the German Chancellor since December 2013. Prior to this appointment, he was parliamentary Minister of State for the Federal Ministry of Education and Research (2009–2013). He is Member of the German Bundestag since 2009.

**Prof. Christian Bréchot**
Prof. Christian Bréchot has been appointed President of Institut Pasteur in 2013. From 2001 to 2007 Christian Bréchot was General-Director of Inserm.
DARIO CAMPANA
Prof. Dario Campana is Director of the Immunopathology and Cell Therapy Unit at National University Cancer Institute Singapore. A hematologist with laboratory training in immunology, his translational research aims at developing more effective and less toxic cancer therapies.

ADALBERTO CAMPOS FERNANDES
Dr. Campos Fernandes is the current Minister of Health in Portugal. He is also Professor at the National School of Public Health, at Universidade Nova de Lisboa, where he teaches and coordinates several university institutions in management and health administration.

ANTHONY CAPON
Prof. Capon is the Director for the International Institute for Global Health at the United Nations University. He is a public health physician and an authority on environmental health and health promotion. He was the founding convener of the Climate Change Adaptation Research Network for Human Health in Australia.

SARBANI CHAKRABORTY
Dr. Sarbani Chakraborty is Head of Global Health Policy in the Department of Government Affairs and Policy. She works closely with the general medicine section of Merck that focuses on health solutions for diabetes, CVD and thyroid disorders. She lectures on Global Health at the Center for International Health, Munich University.

EMMANUELLE CHARPENTIER
Prof. Emmanuelle Charpentier currently holds position as Director at the Max Planck Institute for Infection Biology in Berlin. Following research positions in New York, at The Rockefeller University, and in New York and Memphis, she returned to Europe in 2002 and established a research group at the Max F. Perutz Laboratories, University of Vienna.

OLEG CHESTNOV
Dr. Oleg Chestnov was appointed Assistant Director-General for Noncommunicable Diseases and Mental Health at WHO in February 2012. Prior to that, Dr. Chestnov was Deputy-Director for International Relations at the Ministry of Health and Social Development of the Russian Federation, a post he occupied from 2005.

AGNÈS COUFFINHAL
Dr. Agnès Couffinhal is a Senior Economist at the OECD, specialized in the analysis of health systems and policies. Her current work focuses on ineffective care and waste though the preparation of a background report to a 2017 meeting of OECD Health Ministers.

YVES DACCORD
Dr. Yves Daccord holds position as Director-General of the ICRC since 2010, with a prior appointment as Director of Communications since 2002. As a former journalist, he joined the ICRC in 1992 and worked in Israel and the occupied and autonomous territories, Sudan, Yemen, the northern Caucasus and Georgia.
ANDREW DANIELS
Andrew Daniels is currently Head of the Anti-Bribery and Corruption Centre of Excellence at GlaxoSmithKline PLC, a science-led global healthcare company. He started his career at the aerospace, defence and security company BAE Systems.

PAUL DECLERCK
Prof. Declerck is Dean of the Faculty of Pharmaceutical Sciences of the KU Leuven and President of the International Society for Fibrinolysis and Proteolysis. He is Research Director of the Laboratory for Therapeutic and Diagnostic Antibodies at the Department of Pharmaceutical and Pharmacological Sciences (KU Leuven).

COBUS DE SWARDT
Cobus de Swardt joined Transparency International in 2004 and was appointed Managing Director in 2007. He is also a member and former Chair of the World Economic Forum (WEF) Global Agenda Council on Transparency & Anti-Corruption. In addition, he serves on the Board of the WEF Partnering against Corruption Initiative (PACI).

VICTOR J. DZAU
Prof. Victor J. Dzau is President of The Institute of Medicine at National Academy of Sciences, USA. He is also Chancellor of Health Affairs, Director of Molecular and Genomic Vascular Biology and President and Chief Executive Officer at Health System of Duke University Medical Center.

ERIC HANS EDDES
Dr. Eric Hans Eddes is GastroIntestinal Surgeon at the Deventer Hospital, a teaching hospital in the Netherlands and Director of the Dutch Institute for Clinical Auditing, an organization facilitating 23 clinical registries with a nationwide coverage in the Netherlands.

ANGELIKA EGGERT
Prof. Angelika Eggert is Director at Charité Center for Gynecology, Perinatal, Pediatric & Adolescent Medicine with Perinatal Center & Human Genetics. She started her scientific career 1977 at the Children's Hospital of Philadelphia, University of Pennsylvania. Her main interest is the molecular biology and genetics of neuroblastoma, a common solid tumor of childhood.

PASCALE EHRENFREUND
Prof. Pascale Ehrenfreund has been Chair of the DLR Executive Board since August 2015. Since 2008, she has been Professor of Space Policy and International Affairs at the Elliott School of International Affairs, George Washington University and Lead Investigator at the NASA Astrobiology Institute.

VOLKMAR FALK
Prof. Volkmar Falk is Medical Director and Director of the DHZB Department of Cardiothoracic and Vascular Surgery of the Deutsches Herzzentrum Berlin and Chair of the Division of Cardiovascular Surgery at Charité Berlin.
**Prof. Antoine Flahault**

Prof. Antoine Flahault is Professor of Public Health at University Descartes, Sorbonne Paris Cité. He was appointed Chair of the Centre Virchow Villermé de Santé Publique Paris-Berlin (CVV) and is Founding Director of the Institute of Global Health, University of Geneva.

**Prof. Detlev Ganten**

Prof. Detlev Ganten is Founding President of the World Health Summit since 2009. From 1991 to 2004 he was Founding Director and President of Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch. He currently is Honorary Chairman of the Board at Charité Foundation.

**Hermann Gröhe**

Hermann Gröhe is Minister of Health of the Federal German Republic. From 2005 to 2008, he acted as legal counsel to the CDU/CSU parliamentary group and, from 2006–2008 he was the spokesperson of the CDU/CSU parliamentary group in the First Committee of Inquiry.

**Sir Andrew Haines**

Sir Andrew Haines is Professor of Public Health and Primary Care. He formerly held position as Director of LSHTM (2001-2010) as well as Professor of Primary Health Care and Head of the Department of Primary Care and Population Sciences at University College London.

**Prof. Peter Hammann**

Prof. Peter Hammann is Member of the Management Board of the Therapeutic Area Infectious Diseases, responsible for the German research activities in this area at Sanofi-Aventis. In 2005 after Sanofi was created he was one of the key leaders to rebuild infectious disease research within the company.

**Norbert Hauser**

Norbert Hauser is Chair of the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria. As a former Member of Parliament and international Auditor from Germany Mr. Hauser previously served as interim Inspector-General at the Global Fund (2012-13) and as a Member of the High-Level Panel. Until 2011, he served as Vice-President of Germany’s Supreme Audit Institution.

**Dr. Suzanne Hill**

Dr. Suzanne Hill, the Director of Essential Medicines and Health Products Department at WHO, is a clinical pharmacologist and public health physician, trained at the University of Newcastle, Australia. Prior to this appointment, she was Chair of the Australian Pharmaceutical Benefits Committee as well as Visiting Professor at the University of Melbourne Medical School.

**Dr. Peter J. Hotez**

Dr. Peter J. Hotez is Dean of the National School of Tropical Medicine and Professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine where he is also the Texas Children’s Hospital Endowed Chair of Tropical Pediatrics. He is President of the Sabin Vaccine Institute.
**Paul Hudson**
Paul Hudson has been Chief Executive Officer at Novartis Pharmaceuticals since July 2016. He is a Member of the Executive Committee of Novartis. He began his career at GlaxoSmithKline UK and Sanofi-Synthelabo UK with roles in sales and marketing.

**Wolfgang Ischinger**
H.E. Prof. Wolfgang Ischinger is Chairman of the Munich Security Conference. He has been appointed ambassador to the United States of America and to the United Kingdom. As a Political Director he was Head of the German Delegation during the Bosnian Peace negotiations in Dayton/Ohio in 1995, the negotiations on the NATO-Russia Founding Act in 1996/97, and during the Kosovo crisis in 1998.

**Jayasree K. Iyer**
Dr. Jayasree K. Iyer is a specialist in global health and neglected tropical diseases. She is the Executive Director at the Access to Medicine Foundation. She has a career in malaria and neglected tropical disease research and development and in public-private partnerships strategy.

**Ali Jafarian**
Prof. Jafarian was appointed Chancellor of Tehran University of Medical Sciences in 2013. He is also a member of Supreme council for Science, Research and Technology and National Council of Evaluation of State Education. He was Executive Advisor for the chancellor of TUMS in 2005–2008, Dean of Medical School in 2008–2009 and Vice-Chancellor in 2009–2011.

**Stephen M. Jane**
Prof. Stephen M. Jane was appointed Head of Central Clinical School, Professor of Medicine, Monash University and Director of Research of Alfred Hospital in 2011. He also is Member of the Clinical Hematology Department.

**Stefan H. E. Kaufmann**
Prof. Stefan H. E. Kaufmann is Founding Director and Member of Max Planck Institute for Infection Biology in Berlin, where he heads the Department of Immunology. He is Professor of Microbiology and Immunology at Charité University Clinics in Berlin.

**Ilona Kickbusch**
Prof. Ilona Kickbusch is Director of the Global Health Center at the Graduate Institute of International and Development Studies, Geneva. She is a leading contributor to academic and political debates on governance for health on national and global level.

**Jan Kimpen**
Prof. Kimpen joined Philips from the University Medical Center Utrecht (UMC Utrecht) in the Netherlands, where he was Chairman of the Executive Board. He has been the driving force behind partnerships with Philips and Eindhoven University of Technology, where he is a Member of the strategic advisory board health.
MICHAEL J. KLAG
Prof. Michael J. Klag is Dean of the Johns Hopkins Bloomberg School of Public Health. He is an internist and epidemiologist. Prof. Klag is a world-renowned kidney disease epidemiologist whose scientific contributions have been in the prevention and epidemiology of kidney disease, hypertension and cardiovascular disease.

HON. SURESH KUMAR
Hon. Suresh Kumar currently serves as Member of the Executive Committee and the Global Leadership Team as well as Head of Government Relations US ad interim. He has more than 30 years of experience in the healthcare industry beginning in 1978 in India with Johnson and Johnson.

STEFAN LARSSON
Dr. Stefan Larsson joined BCG in 1996 and is Senior Partner and Managing Director. He is the Global Leader of BCG's Health Care Payor and Provider sector and Member of the Global Health Care leadership team. Mr. Larsson has worked across all aspects of the Health Care industry.

YVES LEVY
Prof. Yves Levy is Chief Executive Officer and Chairman of INSERM, the National Institute of Health and Medical Research, since June 2014. He also leads since July 2014 Aviesan, the French Alliance for Health and Life Sciences. He is Professor of Clinical Immunology at Henri Mondor Hospital/Université Paris Est. Créteil since 1996.

KAREN LINEHAN
Dr. Karen Linehan is Executive Vice-President, Legal Affairs and General Counsel at Sanofi since 2007. Ms. Linehan leads Sanofi’s Legal, Ethics & Business Integrity departments and sits on the Executive Committee. She has been instrumental in inciting the diversity conversation within Sanofi and was one of the Founding Members of the Diversity Council in 2009.

LINE MATTHIESSEN-GYADER
Dr. Line Matthiessen leads the Unit responsible for Fighting Infectious Diseases and Advancing Public Health in the Directorate-General for Research and Innovation. The unit promotes and supports EU research and innovation activities in the area of global health issues.

JUSTIN P. MCCARTHY
Justin McCarthy is the Senior Vice-President of Global Policy and International Public Affairs at Pfizer Inc. He serves on the Boards of the Business Council for International Understanding, The Global Intellectual Property Center (GIPC), and the United States Council for International Business.

TEWODROS MELESSE
As IPPF Regional Director for Africa, Tewodros Melesse played a pivotal role in providing technical and management support to the African Union in the development and adoption of the Continental Sexual and Reproductive Health Policy Framework and the Maputo Plan of Action.
**REN MINGHUI**  
Dr. Ren Minghui was appointed WHO Assistant Director-General for HIV/AIDS, Tuberculosis, Malaria and Neglected Tropical Diseases on January 2016. Prior to that, he was Director-General for International Cooperation in the National Health and Family Planning Commission of the People’s Republic of China.

**LLOYD B. MINOR**  
Prof. Lloyd B. Minor is a scientist, surgeon, and academic leader. He is the Carl and Elizabeth Naumann Dean of Stanford University School of Medicine, a position he has held since December 2012. He is also Professor of Otolaryngology - Head and Neck Surgery and Professor of Bioengineering and of Neurobiology at Stanford University.

**CHRISTINA MITCHELL**  
In 2006 Prof. Mitchell became Head of School of Biomedical Sciences at Monash University, which is the largest of the Schools within the Faculty of Medicine. In 2011 she was promoted to the position of Dean of Medicine, Nursing and Health Sciences.

**MATSHIDISO REBECCA MOETI**  
Dr. Matshidiso Moeti from Botswana is the first female WHO Regional Director for Africa. Dr. Moeti is a public health veteran, with more than 35 years of national and international experience. She joined WHO’s Africa Regional Office in 1999 and has served as Deputy Regional Director and Assistant Regional Director.

**TARIK MÖRÖY**  
Prof. Tarik Möröy is current President and Scientific Director of the Clinical Research Institute Montreal (IRCM), a position he holds since March 2006. He is also Director of the Hematopoiesis and Cancer Research Unit at the IRCM.

**SAMUEL S. MYERS**  
Prof. Samuel Myers is Senior Research Scientist for Environmental Health at Harvard School of Public Health as well as Director, Planetary Health Alliance at Harvard Center for the Environment. He won the Prince Albert II of Monaco - Institut Pasteur 2015 Award: For “outstanding work and publications in the field of the impact of environmental and climatic changes on human health.”

**JIM O’NEILL**  
Dr. Jim O’Neill is Chairman of the Board at The Review on Antimicrobial Resistance. Lord O’Neill is currently the Commercial Secretary of the Treasury and his duties include leading the work for the Government on the Northern Powerhouse, city devolution and infrastructure. In May 2015 he was also made Life Peer to the House of Lords.

**OLIVIER OULLIER**  
Dr. Olivier Oullier is Professor of Behavioural and Brain Sciences at Aix-Marseille University in France. As a consultant for public and private organizations, he designs and implements evidence-informed behaviour change and engagement strategies.
AYDAN ÖZOĞUZ
Aydan Özoğuz is Minister of State to the Federal Chancellor and Federal Government Commissioner for Migrants, Refugees and Integration since December 2013. She holds a MA in English Language and Literature, Spanish Language and Literature, and Personnel Management.

JOY PHUMAPHI
Joy Phumaphi is the Executive Secretary of the African Leaders Malaria Alliance. She served as Member of the UNSG’s High-Level Panel on the Global Response to Health Crises and Chair of the Global Leaders Council for Reproductive Health. She has served on a number of commissions and expert groups and sits on the Board of several international non-profit organizations.

MONTIRA PONGSIRI
Dr. Montira Pongsiri is HEAL Director and Health Science Policy Advisor. She has worked before as Environmental Health Scientist at the U.S. Environmental Protection Agency as well as Science Advisor at the U.S. Mission to the Association of Southeast Asian Nations (ASEAN).

AXEL RADLACH PRIES
Prof. Axel Radlach Pries is Dean of Charité–Universitätsmedizin Berlin since 2005. He is Head of the Charité Institute for Physiology since 2001. In the European Society of Cardiology (ESC), he was Chair of the Working Group for Coronary Pathophysiology and Microcirculation and of the Council for Basic Cardiovascular Science (CBCS).

MICHAEL RABBOW
Dr. Michael Rabbow is Chairman at the Privat Sector Advisory Board at GIZ (Deutsche Gesellschaft für Internationale Zusammenarbeit) and holds position as Senior Advisor at E&P Focus Africa Consulting.

ROBERT SEBBAG
Dr. Robert Sebbag is Vice-President for Access to Medicines at Sanofi. Dr. Sebbag is also teaching public health courses within the Paris hospital system, focusing on tropical parasitic diseases. He is active within the French Red Cross and has participated in numerous health missions in the Southern Hemisphere.

BRENDAN SHAW
Dr. Brendan Shaw is Assistant Director General at IFPMA since 2014. He assists the Director General in leading on a range of policy and representational functions particularly in innovation policy, intellectual property, trade, health technology assessment, ethics, compliance and vaccines.

JAQUELINE SHEA
Dr. Shea is Chief Executive Officer at Aeras. She is well known and widely respected in the TB vaccine development community, where she plays a leading role for Aeras in advancing new TB vaccines for the world.
### Keynote Speakers and Chairs

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Position</th>
<th>Background</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Steve Singh</strong></td>
<td>Member of the Executive Board of SAP SE and President, Business Networks and Applications</td>
<td>Nominated seven times as one of the 25 Most Influential People of the Year by Business Travel News. Began career with Apple Computer.</td>
</tr>
<tr>
<td><strong>Francis E. Smit</strong></td>
<td>Head of the Department of Cardiothoracic Surgery at the University of the Free State</td>
<td>Specializes in adult and paediatric cardiac surgery.</td>
</tr>
<tr>
<td><strong>Marc Sprenger</strong></td>
<td>Director of the World Health Organization (WHO) Secretariat for Antimicrobial Resistance</td>
<td>Director of the European Centre for Disease Prevention and Control (ECDC) in Stockholm, Sweden.</td>
</tr>
<tr>
<td><strong>William Lacey Swing</strong></td>
<td>Director-General of the International Organization for Migration (IOM)</td>
<td>Formerly diplomat, managed largest diplomatic missions and foreign development and humanitarian aid programs.</td>
</tr>
<tr>
<td><strong>Bernd-Alois Tenhagen</strong></td>
<td>Senior Researcher at the Group for Epidemiology, Zoonoses and Antimicrobial Resistance</td>
<td>European Veterinary Specialist in Bovine Health Management.</td>
</tr>
<tr>
<td><strong>Helle Thorning-Schmidt</strong></td>
<td>Head of Division for Health, Social Security and Population Policy</td>
<td>Led coalition government from 2011 until 2015; Member of Parliament and Leader of Social Democratic Party for 10 years.</td>
</tr>
<tr>
<td><strong>Frans van Houten</strong></td>
<td>Chief Executive Officer and Chairman of the Executive Committee and the Board of Management of Royal Philips</td>
<td>Strengthened Philips activities in health technology through acquisition of Volcano and emerging businesses such as Digital Pathology and Health informatics.</td>
</tr>
<tr>
<td><strong>Heiko Warnken</strong></td>
<td>Head of Division for Health, Social Security and Population Policy</td>
<td>Has served in multiple positions in the German Federal Ministry for Economic Cooperation and Development (BMZ) since 1991.</td>
</tr>
</tbody>
</table>
**FLORIAN WESTPHAL**  
Florian Westphal currently works as Managing Director at Médecins Sans Frontières Germany. He worked for 15 years as a Member of the International Committee of the Red Cross (ICRC) in various countries such as Democratic Republic of Congo, Sierra Leone and Kenya and subsequently served as the ICRC’s Head of Media.

**HEIDEMARIE WIECZOREK-ZEUL**  
Heidemarie Wieczorek-Zeul is Vice-President of Friends of the Global Fund Europe. She also serves on the Board of Directors of the International Partnership for Microbicides (IPM). She was Germany’s Minister for Economic Cooperation and Development and Governor of the World Bank from 1998 to 2009.

**LOTHAR H. WIeler**  
Prof. Lothar H. Wieler is President of Robert Koch Institute, the central institution responsible for disease control and prevention in Germany. He is also Professor at the Centre for Infection Medicine, Institute of Microbiology and Epizootics at Freie Universität (FU) in Berlin.

**MATTHIAS WIENOLD**  
Dr. Matthias Wienold (MD, MPH) is a physician from Germany who engages in patient orientation and patients’ rights. He has been a patient advocate since 1986. He is a Founding Member of the European AIDS Treatment Group (EATG).

**DURHANE WONG-RIEGER**  
Dr. Wong-Rieger is immediate Past-Chair of the International Alliance of Patient Organizations and President & Chief Executive Officer of the Canadian Organization for Rare Disorders, the umbrella organization of patients and patient groups, and chair of the Consumer Advocate Network, a national network for patient engagement in healthcare policy and advocacy.

**CHARLES YANKAH**  
Prof. Charles Yankah is President of African Cultural Institute (ACI) and Pan-African Society for Cardiothoracic Surgery. As a retired pioneer cardiothoracic and vascular surgeon at the Deutsches Herzzentrum Berlin – DHZB (German Heart Institute Berlin) and Professor of Surgery at Charité, he is still active as a global player in the profession as a consultant heart specialist.

**ROLF ZINKERNAGEL**  
Dr. Rolf Zinkernagel is Professor at the University of Zurich, University Hospital Zurich and former Head of Institute of Experimental Immunology, Zurich. He was awarded the Nobel Prize in Physiology or Medicine in 1996 for the discovery of how the immune system recognizes virus-infected cells.
SPEAKER INDEX

ANA ABRUNHOSA
European Commission | Portugal

AYOLA AKIM ADEGNIKA
Centre de Recherches Médicales de Lambaréné | Gabon

TEDROS ADHANOM GHEBREYESUS
Ministry of Foreign Affairs | Ethiopia

FIONA ADSHEAD
BUPA | United Kingdom

ANN AERTS
Novartis Foundation | Switzerland

CHRISTINA RÅNGEMARK ÅKERMAN
ICHOM International Consortium for Health Outcomes Measurement | United States of America

JUTTA ALLMENDINGER
Berlin Social Science Center (WZB) | Germany

YUKIYA AMANO
International Atomic Energy Agency | Austria

JOHN AMUASI
African Research Network for Neglected Tropical Diseases (ARNTD) | Ghana

AZA AVALIANI
National Center for Tuberculosis and Lung Diseases | Georgia

MICHAEL BAFFI
Thermo Fisher Scientific Inc. | United States of America

ROSALINDA BALDOZ
Government of the Philippines | Philippines

HOLGER BARTZ
Janssen-Cilag GmbH | Germany

CHANTAL BELORGEY
French National Authority for Health (HAS) | France

KARIM BENDHDAOU
Merck S.A.R.L | Tunisia

DIETMAR P. BERGER
F. Hoffmann-La Roche Ltd. | United States of America

RICHARD BERGSTROM
European Federation of Pharmaceutical Industries and Associations (EFPIA) | Belgium

JANIS BERNAT
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Switzerland
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alain Berzet</td>
<td>Swiss Confederation</td>
</tr>
<tr>
<td>Katrin Bertram</td>
<td>Save the Children Deutschland e.V.</td>
</tr>
<tr>
<td>Peter Beyer</td>
<td>World Health Organization (WHO)</td>
</tr>
<tr>
<td>Andreas Bicking</td>
<td>DHL Parcel</td>
</tr>
<tr>
<td>Elisabeth Binder</td>
<td>Max Planck Institute of Psychiatry</td>
</tr>
<tr>
<td>Seema Biswas</td>
<td>BMJ Case Reports</td>
</tr>
<tr>
<td>Elizabeth Blackburn</td>
<td>Salk Institute for Biological Studies</td>
</tr>
<tr>
<td>Hélène Boisjoly</td>
<td>University of Montreal</td>
</tr>
<tr>
<td>Yourseen Bosolo</td>
<td>Bolenge Hospital</td>
</tr>
<tr>
<td>Erwin Paul Bottinger</td>
<td>Berlin Institute for Health (BIH)</td>
</tr>
<tr>
<td>Jo Ivey Boufford</td>
<td>New York Academy of Medicine</td>
</tr>
<tr>
<td>Niall Boyce</td>
<td>KfW Development Bank</td>
</tr>
<tr>
<td>Helge Braun</td>
<td>Federal Chancellery</td>
</tr>
<tr>
<td>Christian Bréchot</td>
<td>Institut Pasteur</td>
</tr>
<tr>
<td>Klaus Brill</td>
<td>Bayer AG</td>
</tr>
<tr>
<td>Nellie Bristol</td>
<td>Center for Strategic &amp; International Studies (CSIS)</td>
</tr>
<tr>
<td>Annika Calov</td>
<td>KfW Development Bank</td>
</tr>
<tr>
<td>Dario Campana</td>
<td>National University Cancer Institute</td>
</tr>
</tbody>
</table>
BERNHARD FLECKENSTEIN  
Friedrich Alexander University  
Erlangen-Nürnberg | Germany

SHUNICHI FUKUHARA  
Kyoto University | Japan

DETLEV GANTEN  
World Health Summit President, Charité Foundation | Germany

ROLAND GÖHDE  
German Healthcare Partnership (GHP) | Germany

REI GOTO  
Keio University | Japan

RAYMONDE GOUDOU COFFIE  
Ministry of Health and Public Hygiene | Ivory Coast

NORA ILONA GRASSELLI  
ESMT – European School of Management and Technology GmbH | Germany

EVA GREITEMANN  
action medeor e.V. | Germany

HERMANN GRÖHE  
Federal Ministry of Health | Germany

RICARDO AUGUSTUS GUERREIRO BAPTISTA LEITE  
Catholic University | Portugal

SIR ANDREW HAINES  
London School of Hygiene & Tropical Medicine | United Kingdom

PETER HAMMANN  
Sanofi-Aventis Deutschland | Germany

JOHANNA HANEFELD  
London School of Hygiene & Tropical Medicine | United Kingdom

BERHARD S. HAUFUKU  
Ministry of Health and Social Services | Namibia

NORBERT HAUSER  
The Global Fund to Fight AIDS, Tuberculosis and Malaria | Switzerland

JUDITH HEEPE  
Charité – Universitätsmedizin Berlin | Germany

ANDREAS HEINZ  
Charité – Universitätsmedizin Berlin | Germany

WOLFGANG HERBINGER  
UN World Food Programme WFP | Italy
<table>
<thead>
<tr>
<th>Speaker</th>
<th>Institution/Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUZANNE HILL</td>
<td>World Health Organization (WHO)</td>
</tr>
<tr>
<td>ANKE HOEFFLER</td>
<td>Oxford University</td>
</tr>
<tr>
<td>ILDIKO HORVATH</td>
<td>National Koranyi Institute for Pulmonology</td>
</tr>
<tr>
<td>PETER J. HOTEZ</td>
<td>Sabin Vaccine Institute</td>
</tr>
<tr>
<td>SHENG-JEAN HUANG</td>
<td>Taipei City Hospital</td>
</tr>
<tr>
<td>PAUL HUDSON</td>
<td>Novartis Pharmaceuticals</td>
</tr>
<tr>
<td>FRANCES A. HUGHES</td>
<td>International Council of Nurses</td>
</tr>
<tr>
<td>ASEL A. IDAWELA</td>
<td>Government of the Democratic Socialist Republic of Sri Lanka</td>
</tr>
<tr>
<td>VALENTINA IEIMI</td>
<td>London School of Economics and Political Sciences</td>
</tr>
<tr>
<td>TEMITAYO IFAFORE-CALFEE</td>
<td>USAID/PHI</td>
</tr>
<tr>
<td>ILHAN ILKILIC</td>
<td>Istanbul University</td>
</tr>
<tr>
<td>WOLFGANG ISCHINGER</td>
<td>Munich Security Conference Foundation (MSC)</td>
</tr>
<tr>
<td>JAYASREE IYER</td>
<td>Access to Medicine Foundation</td>
</tr>
<tr>
<td>ALI JAFARIAN</td>
<td>Tehran University of Medical Sciences</td>
</tr>
<tr>
<td>STEPHEN M. JANE</td>
<td>Monash University</td>
</tr>
<tr>
<td>ANDREAS JENNE</td>
<td>NEO New Oncology</td>
</tr>
<tr>
<td>ASHISH K. JHA</td>
<td>Harvard T.H. Chan School of Public Health</td>
</tr>
<tr>
<td>GAGANDEEP KANG</td>
<td>Christian Medical College</td>
</tr>
<tr>
<td>Name</td>
<td>Institution/Company</td>
</tr>
<tr>
<td>-----------------------</td>
<td>---------------------------------------------------------</td>
</tr>
<tr>
<td>Fabian Leendertz</td>
<td>Robert Koch Institute</td>
</tr>
<tr>
<td>Yves Levy</td>
<td>The National Institute for Health and Medical Research (INSERM)</td>
</tr>
<tr>
<td>Desiree Lichtenstein</td>
<td>Women in Global Health</td>
</tr>
<tr>
<td>Keith Lim</td>
<td>National University of Singapore (NUS)</td>
</tr>
<tr>
<td>Karen Linehan</td>
<td>Sanofi</td>
</tr>
<tr>
<td>Katherine Littler</td>
<td>Wellcome Trust</td>
</tr>
<tr>
<td>Sam Loewenberg</td>
<td>Harvard University</td>
</tr>
<tr>
<td>Oriol Lopez</td>
<td>Medicins Sans Frontieres (MSF)</td>
</tr>
<tr>
<td>Luiz Loures</td>
<td>UNAIDS</td>
</tr>
<tr>
<td>Michael T. Lynskey</td>
<td>King’s College London</td>
</tr>
<tr>
<td>Cleopa Mailu</td>
<td>Ministry of Health</td>
</tr>
<tr>
<td>Charlotte Marchandise</td>
<td>City of Rennes</td>
</tr>
<tr>
<td>Georg Marckmann</td>
<td>Ludwig Maximilians University Munich</td>
</tr>
<tr>
<td>Esperanza Martinez</td>
<td>International Committee of the Red Cross (ICRC)</td>
</tr>
<tr>
<td>Stephen Matlin</td>
<td>The Graduate Institute of International and Development Studies</td>
</tr>
<tr>
<td>Line Matthiasen-Guyader</td>
<td>European Commission</td>
</tr>
<tr>
<td>Justin P. McCarthy</td>
<td>Pfizer Inc.</td>
</tr>
<tr>
<td>Peter McGrath</td>
<td>InterAcademy Partnership for Health (IAP)</td>
</tr>
</tbody>
</table>
SACHIE PANAWELA
The Coordinating Secretariat for Science, Technology and Innovation (COSTI) | Sri Lanka

HERMANN PARZINGER
Prussian Cultural Heritage Foundation | Germany

DOROTHEA PHILIPPS
Protestant Church Dortmund | Germany

JOY PHUMAPHI
African Leaders Malaria Alliance (ALMA) | Tanzania

ANDRIS PIEBALGS
Government of the Republic of Latvia | Latvia

BALAKRISHNA PISUPATI
United Nations Environment Programme (UNEP) | Kenya

MONTIRA PONGSIRI
Wildlife Conservation Society | United States of America

ELISABETH POTT
German AIDS Foundation | Germany

AXEL RADLACH PRIES
Charité-Universitätsmedizin Berlin | Germany

HANS-ULRICH PROKOSCH
University Hospital Erlangen | Germany

SWEE CHYE QUEK
National University Hospital Singapore (NUHS) | Singapore

MICHAEL RABBOW
E&P Focus Africa Consulting GmbH | Germany

ASANGA RANASINGHE
Anuradhapura General Hospital | Sri Lanka

CATARINA RESENDE DE OLIVEIRA
Hospital and University Center Coimbra | Portugal

JOHN-ARNE RØTTINGEN
University of Oslo | Norway

RAFAEL RUIZ DE CASTANEDA
University of Geneva | Switzerland

VIKTORIA SARGSYAN
World Vision International | United Kingdom

REINHARD SCHÄFERS
World Health Summit – WHS Foundation GmbH | Germany
<table>
<thead>
<tr>
<th>Speaker</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abrunhosa, Ana</td>
<td>58</td>
</tr>
<tr>
<td>Adegnika, Ayola Akim</td>
<td>54</td>
</tr>
<tr>
<td>Adhanom Ghebreyesus, Tedros</td>
<td>66</td>
</tr>
<tr>
<td>Adshead, Fiona</td>
<td>46</td>
</tr>
<tr>
<td>Aerts, Ann</td>
<td>46, 116</td>
</tr>
<tr>
<td>Åkerman, Christina Rångemark</td>
<td>108</td>
</tr>
<tr>
<td>Allmendinger, Jutta</td>
<td>100</td>
</tr>
<tr>
<td>Amano, Yukiya</td>
<td>100</td>
</tr>
<tr>
<td>Amuasi, John</td>
<td>54</td>
</tr>
<tr>
<td>Avaliani, Zaza</td>
<td>84</td>
</tr>
<tr>
<td>Baffi, Michael</td>
<td>96</td>
</tr>
<tr>
<td>Baldoz, Rosalinda</td>
<td>78</td>
</tr>
<tr>
<td>Bärnighausen, Till</td>
<td>50</td>
</tr>
<tr>
<td>Bartz, Holger</td>
<td>84</td>
</tr>
<tr>
<td>Belorgey, Chantal</td>
<td>80</td>
</tr>
<tr>
<td>Bendhaou, Karim</td>
<td>112</td>
</tr>
<tr>
<td>Berger, Dietmar P.</td>
<td>72</td>
</tr>
<tr>
<td>Bergström, Richard</td>
<td>80</td>
</tr>
<tr>
<td>Bernat, Janis</td>
<td>102</td>
</tr>
<tr>
<td>Berset, Alain</td>
<td>74</td>
</tr>
<tr>
<td>Bertram, Katri</td>
<td>64</td>
</tr>
<tr>
<td>Beyer, Peter</td>
<td>68</td>
</tr>
<tr>
<td>Bicking, Andreas</td>
<td>98</td>
</tr>
<tr>
<td>Binder, Elisabeth</td>
<td>92</td>
</tr>
<tr>
<td>Biswas, Seema</td>
<td>64</td>
</tr>
<tr>
<td>Blackburn, Elizabeth</td>
<td>118</td>
</tr>
<tr>
<td>Boisjoly, Hélène</td>
<td>132</td>
</tr>
<tr>
<td>Bosolo, Yoursen</td>
<td>52</td>
</tr>
<tr>
<td>Böttiger, Bernd W.</td>
<td>64</td>
</tr>
<tr>
<td>Bötttinger, Erwin Paul</td>
<td>74, 126</td>
</tr>
<tr>
<td>Boufford, Jo Ivey</td>
<td>110</td>
</tr>
<tr>
<td>Boyce, Niall</td>
<td>92</td>
</tr>
<tr>
<td>Braun, Helge</td>
<td>122</td>
</tr>
<tr>
<td>Bréchot, Christian</td>
<td>56</td>
</tr>
<tr>
<td>Brill, Klaus</td>
<td>54</td>
</tr>
<tr>
<td>Bristol, Nellie</td>
<td>114</td>
</tr>
<tr>
<td>Calov, Annika</td>
<td>98</td>
</tr>
<tr>
<td>Campana, Dario</td>
<td>118</td>
</tr>
<tr>
<td>Campos Fernandes, Adalberto</td>
<td>78</td>
</tr>
<tr>
<td>Canny, Ben</td>
<td>48</td>
</tr>
<tr>
<td>Capon, Anthony</td>
<td>90, 94</td>
</tr>
<tr>
<td>Carter, Adrian</td>
<td>60</td>
</tr>
<tr>
<td>Casel, Gertrud</td>
<td>112</td>
</tr>
<tr>
<td>Chakraborty, Sarbani</td>
<td>66</td>
</tr>
<tr>
<td>Chan, Chang-Chuan</td>
<td>58</td>
</tr>
<tr>
<td>Charpentier, Emmanuelle</td>
<td>74</td>
</tr>
<tr>
<td>Chestnov, Oleg</td>
<td>46</td>
</tr>
<tr>
<td>Chibanda, Dixon</td>
<td>92</td>
</tr>
<tr>
<td>Chrétien, Michel</td>
<td>82</td>
</tr>
<tr>
<td>Colucci, Erminia</td>
<td>92</td>
</tr>
<tr>
<td>Comolli, Virginia</td>
<td>64</td>
</tr>
<tr>
<td>Couffinhal, Agnès</td>
<td>42</td>
</tr>
<tr>
<td>Daccord, Yves</td>
<td>88</td>
</tr>
<tr>
<td>Dalil, Suraya</td>
<td>114</td>
</tr>
<tr>
<td>Daniels, Andrew</td>
<td>42</td>
</tr>
<tr>
<td>Declerck, Paul</td>
<td>102</td>
</tr>
<tr>
<td>de la Peza, Lourdes</td>
<td>128</td>
</tr>
<tr>
<td>de Swardt, Cobus</td>
<td>42</td>
</tr>
<tr>
<td>Dhatt, Roopa</td>
<td>128</td>
</tr>
<tr>
<td>Diallo, Alpha Ahmadou</td>
<td>96</td>
</tr>
<tr>
<td>Dietel, Manfred</td>
<td>72</td>
</tr>
<tr>
<td>Dzau, Victor J.</td>
<td>66</td>
</tr>
<tr>
<td>Eckardt, Kai-Uwe</td>
<td>44</td>
</tr>
<tr>
<td>Eddes, Eric Hans</td>
<td>108</td>
</tr>
<tr>
<td>Edwards, Danny</td>
<td>68</td>
</tr>
<tr>
<td>Eggert, Angelika</td>
<td>118</td>
</tr>
<tr>
<td>Ehrenfreund, Pascale</td>
<td>100</td>
</tr>
<tr>
<td>Eils, Roland</td>
<td>126</td>
</tr>
<tr>
<td>El Aouad, Rajae</td>
<td>94</td>
</tr>
<tr>
<td>Engels, Dirk</td>
<td>54</td>
</tr>
<tr>
<td>Eschenhagen, Thomas</td>
<td>126</td>
</tr>
<tr>
<td>Falk, Volkmar</td>
<td>46</td>
</tr>
<tr>
<td>Feinberg, Mark</td>
<td>82</td>
</tr>
<tr>
<td>Fietje, Nils</td>
<td>86</td>
</tr>
<tr>
<td>Fisher, Dale</td>
<td>70</td>
</tr>
<tr>
<td>Fisher, Julian</td>
<td>120</td>
</tr>
<tr>
<td>Flahault, Antoine</td>
<td>74, 96</td>
</tr>
<tr>
<td>Fleckenstein, Bernhard</td>
<td>124</td>
</tr>
<tr>
<td>Freund, Paul</td>
<td>49</td>
</tr>
<tr>
<td>Fukuhara, Shunichi</td>
<td>58</td>
</tr>
<tr>
<td>Ganten, Detlev</td>
<td>62, 74</td>
</tr>
<tr>
<td>Göhde, Roland</td>
<td>50</td>
</tr>
<tr>
<td>Goto, Rei</td>
<td>58</td>
</tr>
<tr>
<td>Goudou Coffie, Raymond</td>
<td>50</td>
</tr>
<tr>
<td>Grasselli, Nora Ilona</td>
<td>110</td>
</tr>
<tr>
<td>Greitemann, Eva</td>
<td>52</td>
</tr>
<tr>
<td>Gröhe, Hermann</td>
<td>74, 104</td>
</tr>
<tr>
<td>Guerreiro Baptista Leite, Ricardo Augustus</td>
<td>50, 80</td>
</tr>
<tr>
<td>Haines, Sir Andrew</td>
<td>90</td>
</tr>
<tr>
<td>Hammann, Peter</td>
<td>122</td>
</tr>
<tr>
<td>Hanefeld, Johanna</td>
<td>130</td>
</tr>
<tr>
<td>Haufiku, Bernard S.</td>
<td>50</td>
</tr>
<tr>
<td>Hauser, Norbert</td>
<td>108</td>
</tr>
<tr>
<td>Hedberg, Niklas</td>
<td>80</td>
</tr>
<tr>
<td>Heep, Judith</td>
<td>70</td>
</tr>
<tr>
<td>Heinz, Andreas</td>
<td>60</td>
</tr>
<tr>
<td>Herbinger, Wolfgang</td>
<td>98</td>
</tr>
<tr>
<td>Hill, Suzanne</td>
<td>42</td>
</tr>
<tr>
<td>Hoeffler, Anke</td>
<td>64</td>
</tr>
<tr>
<td>Horvath, Ildiko</td>
<td>124</td>
</tr>
<tr>
<td>Hotez, Peter J.</td>
<td>56</td>
</tr>
<tr>
<td>Hrabé de Angelis, Martin</td>
<td>126</td>
</tr>
<tr>
<td>Huang, Sheng-Jean</td>
<td>58</td>
</tr>
<tr>
<td>Hudson, Paul</td>
<td>108</td>
</tr>
<tr>
<td>Hughes, Frances A.</td>
<td>70</td>
</tr>
<tr>
<td>Iddawela, Asela</td>
<td>44</td>
</tr>
<tr>
<td>Iemmi, Valentina</td>
<td>92</td>
</tr>
<tr>
<td>Ifafore-Calfee, Temitayo</td>
<td>128</td>
</tr>
<tr>
<td>Ilkilic, Ilhan</td>
<td>86</td>
</tr>
<tr>
<td>Ischinger, Wolfgang</td>
<td>66</td>
</tr>
<tr>
<td>Iyer, Jayasree</td>
<td>46</td>
</tr>
<tr>
<td>Jafarian, Ali</td>
<td>78</td>
</tr>
<tr>
<td>Jane, Stephen M.</td>
<td>118</td>
</tr>
<tr>
<td>Jenne, Andreas</td>
<td>72</td>
</tr>
<tr>
<td>Jha, Ashish K.</td>
<td>130</td>
</tr>
<tr>
<td>Kang, Gagandeep</td>
<td>82</td>
</tr>
<tr>
<td>Kaufmann, Stefan</td>
<td>56</td>
</tr>
<tr>
<td>Kickbusch, Ilona</td>
<td>78, 114, 120, 130</td>
</tr>
<tr>
<td>Speaker Name</td>
<td>Page</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Kimpen, Jan</td>
<td>108</td>
</tr>
<tr>
<td>Kipele, Maria</td>
<td>112</td>
</tr>
<tr>
<td>Kirchgatter, Johannes</td>
<td>52</td>
</tr>
<tr>
<td>Kizilhan, Jan Ilhan</td>
<td>92</td>
</tr>
<tr>
<td>Klag, Michael J.</td>
<td>88, 124</td>
</tr>
<tr>
<td>Köhler, Bernhard</td>
<td>112</td>
</tr>
<tr>
<td>Köhler, Carsten</td>
<td>54</td>
</tr>
<tr>
<td>Krause, Johannes</td>
<td>62</td>
</tr>
<tr>
<td>Krieger, Eduardo Moacyr</td>
<td>54</td>
</tr>
<tr>
<td>Krause, Johannes</td>
<td>62</td>
</tr>
<tr>
<td>Kroll, Christian</td>
<td>130</td>
</tr>
<tr>
<td>Krumeich, Anja</td>
<td>86</td>
</tr>
<tr>
<td>Kumar, Hon. Suresh</td>
<td>56</td>
</tr>
<tr>
<td>Kuria, George M.</td>
<td>112</td>
</tr>
<tr>
<td>Kurth, Tobias</td>
<td>96</td>
</tr>
<tr>
<td>Lackland, Daniel T.</td>
<td>116</td>
</tr>
<tr>
<td>Larsson, Stefan</td>
<td>108</td>
</tr>
<tr>
<td>Ledgard, Jonathan</td>
<td>98</td>
</tr>
<tr>
<td>Leendertz, Fabian</td>
<td>94</td>
</tr>
<tr>
<td>Leroux-La Pierre, Maxime</td>
<td>49</td>
</tr>
<tr>
<td>Levy, Yves</td>
<td>82</td>
</tr>
<tr>
<td>Lichtenstein, Désirée</td>
<td>128</td>
</tr>
<tr>
<td>Lim, Keith</td>
<td>48</td>
</tr>
<tr>
<td>Linehan, Karen</td>
<td>132</td>
</tr>
<tr>
<td>Littler, Katherine</td>
<td>96</td>
</tr>
<tr>
<td>Loewenberg, Sam</td>
<td>84</td>
</tr>
<tr>
<td>Lopez, Oriol</td>
<td>98</td>
</tr>
<tr>
<td>Loures, Luiz</td>
<td>50</td>
</tr>
<tr>
<td>Lunze, Karsten</td>
<td>60</td>
</tr>
<tr>
<td>Lynskey, Michael T.</td>
<td>60</td>
</tr>
<tr>
<td>Mailu, Cleopa</td>
<td>50</td>
</tr>
<tr>
<td>Mall, Marcus</td>
<td>127</td>
</tr>
<tr>
<td>Marchandise, Charlotte</td>
<td>120</td>
</tr>
<tr>
<td>Marckmann, Georg</td>
<td>102</td>
</tr>
<tr>
<td>Martinez, Esperanza</td>
<td>64</td>
</tr>
<tr>
<td>Matlin, Stephen</td>
<td>114</td>
</tr>
<tr>
<td>Matthiessen-Guyader, Line</td>
<td>82, 122</td>
</tr>
<tr>
<td>Maumann, Sven</td>
<td>127</td>
</tr>
<tr>
<td>McCarthy, Justin P.</td>
<td>78</td>
</tr>
<tr>
<td>McGrath, Peter</td>
<td>94</td>
</tr>
<tr>
<td>Meghreblian, Ben</td>
<td>96</td>
</tr>
<tr>
<td>Melesse, Tewodros</td>
<td>42</td>
</tr>
<tr>
<td>Merten, Martina</td>
<td>120</td>
</tr>
<tr>
<td>Minghui, Ren</td>
<td>55, 74</td>
</tr>
<tr>
<td>Minor, Lloyd B.</td>
<td>100</td>
</tr>
<tr>
<td>Misquith, Lorraine</td>
<td>68</td>
</tr>
<tr>
<td>Mitchell, Christina</td>
<td>118</td>
</tr>
<tr>
<td>Mlaki, Wilson</td>
<td>112</td>
</tr>
<tr>
<td>Mochly-Rosen, Daria</td>
<td>55</td>
</tr>
<tr>
<td>Moeti, Matshidiso</td>
<td>100</td>
</tr>
<tr>
<td>Montagni, Ilaria</td>
<td>97</td>
</tr>
<tr>
<td>Möröy, Tarik</td>
<td>100</td>
</tr>
<tr>
<td>Mühlbacher, Axel C.</td>
<td>102</td>
</tr>
<tr>
<td>Müller, Thomas</td>
<td>80</td>
</tr>
<tr>
<td>Myers, Samuel S.</td>
<td>90</td>
</tr>
<tr>
<td>Napier, David</td>
<td>86</td>
</tr>
<tr>
<td>Nauck, Matthias</td>
<td>127</td>
</tr>
<tr>
<td>Ng, Shi Hui</td>
<td>49</td>
</tr>
<tr>
<td>Nutt, David</td>
<td>60</td>
</tr>
<tr>
<td>O’Neill, Jim</td>
<td>122</td>
</tr>
<tr>
<td>Osterhaus, Albert</td>
<td>94</td>
</tr>
<tr>
<td>Oullier, Olivier</td>
<td>108</td>
</tr>
<tr>
<td>Özoğuz, Aydan</td>
<td>86, 88</td>
</tr>
<tr>
<td>P</td>
<td></td>
</tr>
<tr>
<td>Panawela, Sachie</td>
<td>44</td>
</tr>
<tr>
<td>Parzinger, Hermann</td>
<td>62</td>
</tr>
<tr>
<td>Philipps, Dorothea</td>
<td>52</td>
</tr>
<tr>
<td>Phumaphi, Joy</td>
<td>56, 130</td>
</tr>
<tr>
<td>Piebalgs, Andris</td>
<td>84</td>
</tr>
<tr>
<td>Pisupati, Balakrishna</td>
<td>94</td>
</tr>
<tr>
<td>Pongsiri, Montira</td>
<td>90</td>
</tr>
<tr>
<td>Pott, Elisabeth</td>
<td>50</td>
</tr>
<tr>
<td>Pries, Axel Radlach</td>
<td>48, 116</td>
</tr>
<tr>
<td>Prokosch, Hans-Ulrich</td>
<td>126</td>
</tr>
<tr>
<td>Q</td>
<td></td>
</tr>
<tr>
<td>Quek, Swee Chye</td>
<td>70</td>
</tr>
<tr>
<td>R</td>
<td></td>
</tr>
<tr>
<td>Rabbow, Michael</td>
<td>78</td>
</tr>
<tr>
<td>Ranasinghe, Asanga</td>
<td>44</td>
</tr>
<tr>
<td>Resende de Oliveira, Catarina</td>
<td>58</td>
</tr>
<tr>
<td>Rockson, Gregory</td>
<td>98</td>
</tr>
<tr>
<td>Røttingen, John-Arne</td>
<td>82</td>
</tr>
<tr>
<td>Rühl, Frank</td>
<td>62</td>
</tr>
<tr>
<td>Ruiz de Castaneda, Rafael</td>
<td>48</td>
</tr>
<tr>
<td>S</td>
<td></td>
</tr>
<tr>
<td>Sargsyan, Viktoria</td>
<td>120</td>
</tr>
<tr>
<td>Saso, Luciano</td>
<td>87</td>
</tr>
<tr>
<td>Schäfers, Reinhard</td>
<td>86</td>
</tr>
<tr>
<td>Schmutz, Daniel H.</td>
<td>72</td>
</tr>
<tr>
<td>Schnyder, Ulrich</td>
<td>92</td>
</tr>
<tr>
<td>Schulz, Stefan M.</td>
<td>116</td>
</tr>
<tr>
<td>Schwienhorst-Stich, Eva-Maria</td>
<td>54</td>
</tr>
<tr>
<td>Sebbag, Robert</td>
<td>90</td>
</tr>
<tr>
<td>Seegar, Werner</td>
<td>126</td>
</tr>
<tr>
<td>Sehouli, Jalid</td>
<td>87</td>
</tr>
<tr>
<td>Shah, Niyati</td>
<td>128</td>
</tr>
<tr>
<td>Shaw, Brendan</td>
<td>102</td>
</tr>
<tr>
<td>Shaw, Reuben</td>
<td>72</td>
</tr>
<tr>
<td>Shea, Jaqueline</td>
<td>122</td>
</tr>
<tr>
<td>Shekhalage, Elisabeth</td>
<td>112</td>
</tr>
<tr>
<td>Shoukimas, Daniel</td>
<td>98</td>
</tr>
<tr>
<td>Sié, Ali</td>
<td>96</td>
</tr>
<tr>
<td>Singh, Steve</td>
<td>100</td>
</tr>
<tr>
<td>Sipido, Karin R.</td>
<td>124</td>
</tr>
<tr>
<td>Smit, Francis E.</td>
<td>46</td>
</tr>
<tr>
<td>Smith, Neal</td>
<td>49</td>
</tr>
<tr>
<td>Sprenger, Marc</td>
<td>122</td>
</tr>
<tr>
<td>Stock, Günter</td>
<td>86</td>
</tr>
<tr>
<td>Stolk, Pieter</td>
<td>80</td>
</tr>
<tr>
<td>Sultana, Victoria</td>
<td>87</td>
</tr>
<tr>
<td>Sutter, Gerd</td>
<td>82</td>
</tr>
<tr>
<td>Swing, William Lacey</td>
<td>88</td>
</tr>
<tr>
<td>T</td>
<td></td>
</tr>
<tr>
<td>Takian, Amirhossein</td>
<td>48</td>
</tr>
<tr>
<td>Tano, Jean-Yves K.</td>
<td>86</td>
</tr>
<tr>
<td>Tarakji, Ahmad</td>
<td>64</td>
</tr>
<tr>
<td>Taylor, Peter</td>
<td>130</td>
</tr>
<tr>
<td>Tenhagen, Bernd-Alois</td>
<td>122</td>
</tr>
<tr>
<td>Theis, Fabian</td>
<td>126</td>
</tr>
<tr>
<td>Theobald, Sally</td>
<td>128</td>
</tr>
<tr>
<td>Thölken, Hinrich</td>
<td>98</td>
</tr>
<tr>
<td>Thorning-Schmidt, Helle</td>
<td>88</td>
</tr>
<tr>
<td>Told, Michaela</td>
<td>120</td>
</tr>
<tr>
<td>Tsi, Sean</td>
<td>49</td>
</tr>
<tr>
<td>Türk, Silvia</td>
<td>70</td>
</tr>
<tr>
<td>U</td>
<td></td>
</tr>
<tr>
<td>Ulrichs, Timo</td>
<td>84</td>
</tr>
</tbody>
</table>
SUPPORTING INSTITUTIONS

SESSION CO-HOSTS

A
All European Academies (ALLEA)
Association of Research-Based Pharmaceutical Companies (vfa)

B
Berlin Institute of Health (BIH)
British Medical Journal (BMJ) Case Reports

C
Centre Virchow-Villermé for Public Health
Charité - Universitätsmedizin Berlin
Clinical Research Institute Montreal (IRCM)
Coalition for Epidemic Preparedness Innovations (CEPI)
Coimbra Health

D
Department of Biotechnology, Government of India

E
European Commission and the Horizon 2020 Scientific Panel for Health
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European School of Management and Technology (ESMT)
European Society of Cardiology

F
F. Hoffmann-La Roche Ltd.
Friends of the Global Fund

G
German Centers for Health Research (DZG)
German Federal Foreign Office
German Federal Ministry of Health (BMG)
German Healthcare Partnership (GHP)
German Heart Institute Berlin
German Network against Neglected Tropical Diseases (DNTDs)
Government of Norway
Government of Sri Lanka

V
Valentine, Nicole 120
van den Boom, Martin 84
van Houten, Frans 100
Vehreschild, Jörg Janne 127
Verdejo-Garcia, Antonio 60
Vogel, Johannes 62

W
Warinner, Christina 62
Warnken, Heiko 79
Watal, Jayashree 68
Westphal, Florian 88
Wieczorek-Zeul, Heidemarie 132
Wieler, Lothar 122
Wienold, Matthias 102
Wong-Rieger, Durhane 102
Wuliji, Tana 124

Y
Yankah, Charles 46

Z
Zeltner, Thomas 110
Zink, Albert 62
Zinkernagel, Rolf 56
Zipfel, Stephan 92
## SPONSORING PARTNERS

### Strategic Partners

- CHARITÉ
- SANOFI

### Major Partners

- BERLIN INSTITUTE OF HEALTH
  - Charité & Max Delbrück Center

### General Partners

- BAYER
- Federal Ministry of Health
- PHILIPS
- SAP
Supporting Partners

AERAS  
Bayer Science & Education Foundation  
DZG Deutsche Zentren der Gesundheitsforschung  
DLR  
Printing Partner:  
KfW  
Laserline  
Leibniz Association  
Leopoldina National Academy of Sciences  
M8 Alliance  
Novartis Foundation  
Pfizer  
Siemens  
Stanford University  
The Global Fund  
Thermo Fisher Scientific  
Transparency International  
VAMED  
Visit Berlin  
World Wide Fund for Nature  

Service Aides

Concept Partner:  
BCG  
eobiont  
Mobility Partner:  
Mercedes-Benz  
Berlin
POLICY MAKERS

Partner & Co-Host:
- Federal Foreign Office
- Federal Ministry of Education and Research
- Federal Ministry for Economic Cooperation and Development
- World Health Organization

ACADEMIA

- Berlin-Brandenburgische Akademie der Wissenschaften
- Centre Virchow-Villermé
- Esc
- Fraunhofer
- DFG Deutsche Forschungsgemeinschaft
- DKFZ German Cancer Consortium
- DZD German Center for Diabetes Research
- DZHK Deutsches Zentrum für Herz-Kreislauf-Forschung e.V.
- DZIF
- DZL Deutsches Zentrum für Lungenforschung
- DZNE Deutsches Zentrum für Neurodegenerative Erkrankungen in der Helmholtz-Gemeinschaft
- GJU German Jordanian University
- GSCN GermanStemCellNetwork
- Global Health Next Generation Network
- HELMHOLTZ ASSOCIATION
- IMI Innovative Medicines Initiative
- IFMSA International Federation of Medical Student Associations
- Koch Metchnikow Forum
- MDC MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE IN THE HELMHOLTZ ASSOCIATION
- NIH
- Robert Koch Institute
- UAEM Union of Allied Health Professionals
CIVIL SOCIETY

ACTION FOR GLOBAL HEALTH

FRIEDRICH EBERT STIFTUNG

GLOBAL NETWORK

GAVI

POLIO

RE:PUBLICA

Robert Bosch Stiftung

TDRO

terre des hommes

welt hunger hilfe

WIKIMEDIA DEUTSCHLAND

ASSOCIATES

AFRIKA-VEREIN

FALLING WALLS

GERMAN ACCELERATOR

GHP

HEALTH WEEK

HUMOR HILFT HEILEN

IIJ

REKLIM

scienceOPEN.com

startupbootcamp

STIFTUNG CHARITÉ

MEDIA PARTNERS

Deutsches Ärzteblatt

DW Deutsche Welle

DIE ZEIT VERLAGSGRUPPE

Handelsblatt GLOBAL EDITION

EUSJA

Pulitzer Center ON CRISIS REPORTING

Medscape

Polish Healthcare Journal OSOZ

academics.de

Molegel Medizin
SAVE THE DATES!

WHS REGIONAL MEETING
NORTH AMERICA, MONTREAL
MAY 8–9, 2017

WORLD HEALTH SUMMIT
BERLIN, GERMANY
OCTOBER 15–17, 2017

www.worldhealthsummit.org
Summit Organizer/Academic Office

WHS Foundation GmbH
World Health Summit
c/o Charité-Universitätsmedizin Berlin
Charitéplatz 1
10117 Berlin
Germany

Tel.: +49 30 450 572102
Fax: +49 30 450 572911

secretariat@worldhealthsummit.org
www.worldhealthsummit.org